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ABSTRACT 
Ovarian cancer (OC) is characterized by late stage discovery and low 
survivability. However, when diagnosed early (Stages I or II) the 5-year survival rate is 
92% up from 29%.5 The extreme dichotomy in survivability is what makes OC a prime 
candidate for early diagnosis techniques. Exosomes, a subtype of extracellular vesicles, 
may bridge the gap between early and late diagnosis, but are lacking consistent isolation 
and detection technologies. Here poly(ethylene terephthalate) (PET) capillary channeled 
polymer (C-CP) fibers employing an HIC protocol are investigated as a novel exosome 
isolation method and a quick, inexpensive, and easy-to-use platform for OC diagnosis. 
The cell model system, immunoaffinity protocols, and biomarker identification tools 
developed here will aid in the refinement of a selective PET C-CP exosome isolation. 
The exosome isolation and diagnostic technique developed as a result of these 
investigations will allow for earlier and routine diagnosis of OC and save many women 
from one of the deadliest cancers. 
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Cell signaling is an encompassing term that covers a variety of complex processes 
in which biological systems, collections of cells, and individual cells communicate 
information, directives, and functions. Most methods of cellular communication involve 
transmission of soluble molecules, neurotransmitters, hormones, or ligands followed by 
signal reception, signal transduction, and cellular response. However, more recently, 
exosomes have emerged as an accompanying and complex means of cell signaling.6 
Exosomes are a class of lipid bilayer membrane vesicles, approximately 30-150 nm in 
diameter, that play a variety of roles in autocrine and paracrine signaling. Prior to 
investigation into exosomes’ role in cellular communication, the vesicles were assumed 
to play a role in dissemination and disposal of intracellular waste.1, 7  
 Over the last several years, exosomes have generated immense excitement within 
the biotech and scientific communities. As such, there has been an explosion of research, 
with exponential growth in the number of articles published over the last 10 years. 
Remarkably, exosomes may be involved in a variety of processes including stem cell 
renewal, cancer metastasis, inflammation, coagulation, and chemotaxis.6-12 As more 
information about the complex role of exosomes is discovered, further potential medical 
and research applications are being examined. Exosome applications may include 
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biomarker disease diagnostics, drug delivery, gene therapy, cancer therapy, and tissue 
regeneration.1, 7, 10, 13-15 
Exosomes contain transmembrane, cytosolic, intracellular proteins, and several 
types of RNA that may be used as biomarkers for cancers and various disease states.13, 16-
18 Furthermore, since exosomes are derived directly from cells, there is little immune 
response associated with inserting autologous exosomes back into the same human 
system.19-22 Remarkably, Alvarez et al.23 have been able to manipulate the lipid bilayer 
membrane content of exosomes to include a peptide that specifically targets neurons, 
microglia, and oligodendrocytes in the brain. The versatility and applications of 
exosomes seem endless and will surely impact the field of medicine in the future. Their 
potential for disease diagnostics could alone eliminate the need for biopsies and more 
invasive procedures. Simply put, with exosome biomarkers, a urine, blood, or 
cerebrospinal sample may be used for early detection of diseases.  
Despite the emerging popularity of exosome research, very little is known about 
what happens to an exosome once it reaches and enters a target cell. There is an extensive 
understanding of how an exosome is manufactured and released in the original cell, but 
the mechanisms of transport in the target cell still remain in the dark.24 In the original 
cell, exosomes do not simply bud off from the plasma membrane. In the 1980s, Harding 
et al.25 and Pan et al.26 revealed a slightly more complex mechanism of exosome 
formation and secretion. They showed that exosomes are formed by inward budding of 
intracellular endosomes. The intracellular endosomes containing the exosomes then fuse 
with the plasma membrane, thus releasing the exosomes outside of the cell. There are a 
3 
 
number of theorized mechanisms for exosome uptake, transport, and dissemination into 
the target cell, none of which have gained widespread backing. In particular, 
understanding of these mechanisms is crucial for developing the proper drugs for 
exosome loading, determining how to manipulate exosome drug vector targeting 
properly, and increasing the efficacy of loaded drugs. For instance, if the exosomes were 
to follow the endocytic pathway and eventually come in contact with a lysosome, the 
loaded drug could become deactivated or degraded. Greater understanding of the 
biochemical makeup, biogenesis, transport, uptake, and dissemination mechanisms will 
enhance our ability to capitalize on the natural properties of exosomes. 
One of the largest problems preventing exosome technology from advancing into 
the clinical setting is the lack of a quick, efficient, and reliable exosome isolation method. 
Current exosome isolation techniques can be crude, often producing small yields and 
damaging the exosomes. Before any potential applications of exosomes can be realized, 
we need to learn how to better isolate exosomes. Furthermore, current methods of 
studying exosomes can be expensive due to the cost of mammalian cells lines, cell media, 
and equipment. The burgeoning amount of research being conducted on exosomes and 
related vesicles calls for the development of new exosome isolation techniques that may 
result in clinical translation. Our research group has proposed using hydrophobic 
interaction chromatography and Polyethylene terephthalate (PET) Capillary-Channeled 
Polymer (C-CP) fibers in order to achieve a lower cost, faster, and more effective 
exosome isolation and ultimately develop an all-in-one exosome isolation and disease 
diagnostic test for ovarian cancer.  However, the testing of such a diagnostic technique 
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will require expensive and time consuming marker detection. In this study, we detail the 
development of two new cell lines, one cancerous and one normal, which express 
fluorescent tags on exosome and extracellular vesicle-enriched proteins and demonstrate 
the ability to differentiate between these two populations of vesicles using antibody 
capture.  
Our research has resulted in three primary outcomes. First, we have developed 
and tested a poly(ethylene terephthalate) (PET) capillary-channeled polymer (C-CP) fiber 
EV isolation method employing a hydrophobic interaction chromatography (HIC) 
protocol. This new method will allow for faster, cheaper, and easier EV isolation for 
diagnostic and therapeutic applications. Second we have developed and tested a model 
system of cell lines, one normal ovarian cell line with green fluorescent protein (GFP)-
tagged CD81 and one ovarian cancer cell line with red fluorescent protein (RFP)-tagged 
CD9. This model system will be used to investigate and refine a selective PET C-CP EV 
isolation method. We have demonstrated that EV populations from these two cell lines 
can be differentiated using antibody capture on nitrocellulose membranes and 
fluorescence microscopy. The ability to differentiate cancerous and non-cancerous 
vesicle populations is an important step in the development of a selective diagnostic test. 
Third, we have shown the importance of sample selection for downstream analysis of 
EVs through comparison of urine and cervical mucus and demonstrated the diagnostic 
potential of miRNA expression patterns to compare ovarian cancer and non-cancerous 
clinical samples. Continued analysis of the miRNA expression data and ongoing 
proteomics will reveal biological pathways and connections that will identify novel 
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biomarkers for OC. These biomarkers can be applied to a PET C-CP EV isolation method 
for further refinement of EV selective capture. The achievements of these investigations 
will ultimately aid in the development of a tool for earlier, routine OC diagnosis that will 
save the lives of many women. 
The following review covers the different topics investigated by this research 
including the current understanding of exosome and extracellular vesicle mechanisms, 
physiological responsibilities, techniques, and medical applications, the potential of 
liquid chromatography to separate and isolate extracellular vesicles, an overview of 
ovarian cancer and exosome involvement in tumorigenesis, and the use of antibody 
capture to identify extracellular vesicles.  
 
Exosome Biogenesis, Sorting, and Release 
 Exosome are a class of extracellular vesicles (EVs), approximately 30-150 nm in 
diameter.8 Typically, the varying categories of extracellular vesicles are classified based 
on size and method of biogenesis. Exosomes are formed by inward budding of 
multivesicular bodies (MVBs, or multivesicular endosomes; MVEs) followed by 
extracellular release by MVB fusion with the cell membrane (see Figure 1.1).2 The 
membrane contents and interior contents are determined by a number of factors unique to 
individual cell types and the function of the exosome being produced. 
6 
Initially, intraluminal vesicles (ILVs) are formed by inward budding of the 
endosomal membrane into MVBs. After maturing from late stage endosomes, MVBs 
then either fuse with a lysosome to degrade any internal contents or fuse with the cell 
membrane to release any contents into the extracellular environment. ILVs are referred to 
as exosomes only after extracellular release. During the formation process, specific 
proteins and RNAs are sorted into the cytosol and membranes of the ILVs.27 The very 
complex protein sorting process, although still not fully understood, is thought to be 
primarily guided by the endosomal sorting protein complexes required for transport 
(ESCRTs).28 As such, most ILV sorting mechanisms are categorized as ESCRT-
dependent or ESCRT-independent mechanisms. During the sorting process, ILVs are 
typically enriched in specific proteins including tetraspanins CD63, CD81, and CD9, 
Figure 1.1. Diagram of exosome and microvesicle biogenesis. Adapted from 
Raposo et al.2  
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cytosolic protein tumor susceptibility gene 101 (TSG101) and programmed cell death 6-
interacting protein (ALIX).28-33 Although not nearly as well understood as the protein 
sorting mechanisms, RNA sorting mechanisms are now being discovered. RNA sorting is 
often thought to be associated with special 4 nucleotide motifs. Specifically, the 
nucleotide sequence GGAG may be involved in the sorting and management of 
miRNA.32, 33 The proteins and RNAs enriched in exosomes are distinctive from the 
original cell membrane and cytosolic RNAs, suggesting an advanced preferential means 
of determining exosome content exists.34 However, despite the knowledge surrounding 
the mechanisms, proteins, and RNAs involved in ILV formation and sorting, the means 
of determining vesicle content and production are still shrouded in mystery.  
 
 Exosome release into the extracellular environment is mediated by fusion of 
MVBs with the plasma membrane of the cell. However, depending on the cell type and 
physiological state of the cell, the mechanisms by which the MVB fuses with the plasma 
membrane can vary. Much like other endosomal and endocytic vesicles, the mechanisms 
of MVB plasma membrane fusion are facilitated by a variety of membrane-trafficking 
Rab GTPase or SNARE proteins including RAB7, RAB11, RAB27a, RAB31, RAB35, 
YKT6, and VAMP7.1, 11, 28, 35-37 Often, each mechanism of MVB plasma membrane 




Exosome Uptake and Dissemination 
 
There are several known mechanisms that are likely involved in exosome target 
cell uptake including clathrin-mediated endocytosis, caveolin-dependent endocytosis, 
micropinocytosis, phagocytosis, lipid rafts, and cell surface membrane fusion.3, 38, 39 
Mulcahy et al.3 describe the range of possibilities for each of these uptake mechanisms 
Figure 1.2. Possible mechanisms of extracellular vesicle uptake in the recipient 
cell. Adapted from Mulcahy et al.3 
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and suggest that certain mechanisms have greater involvement in extracellular vesicle 
uptake than others depending on the cell type.  
 Exosomes are initially taken into the target cell by either plasma membrane fusion 
or endocytosis. If the exosome fuses directly with the plasma membrane of the target cell, 
then its contents are presumably delivered directly into the cytoplasm, but very little is 
known of the whereabouts of the contents after entry into the cell. If the exosome is taken 
up by endocytosis, the exosome would likely fuse with the endosomal plasma membrane 
and release its contents into the cytoplasm (see Figure 1.2). However, it is unknown 
where along the endocytic pathway the exosomes may fuse with the endosome. As the 
endocytic pathway is designed to digest incoming material, there is the potential that 
incoming exosomes will be destroyed by lysosome fusion as well. As exosomes are, by 
nature, vehicles of transportation, it is important to understand the mode of transport and 
location of delivery. Knowledge of the uptake and dissemination mechanisms of 
exosomes could have large impacts on the development of many medical applications. 
 
Division of Extracellular Vesicles 
Exosomes 
 Exosomes are one of several types of EVs. There is some debate regarding the 
actual divisions of EVs based on size, but by defining the vesicles based on size, 
function, content, and mode of biogenesis, general divisions can be created.40, 41 
However, when the vesicles cannot be identified as a specific division of extracellular 
10 
 
vesicle, it is more appropriate to label samples as small EVs (sEVs), large EVs (lEVs), 
or, more generally, EVs, based on the isolation method. Exosomes are generally accepted 
to be approximately 30-150 nm in diameter, with wide ranging functions within cell 
signaling including inflammation mediation, antigen presentation, coagulation, and 
angiogenesis among others.14, 18, 42, 43 Furthermore, exosomes are formed through inward 
budding of the endosomal membrane of MVBs and released into the extracellular 
environment (see Figure 1.1).27  
Microvesicles 
Perhaps most often confused for exosomes, microvesicles are a distinct class of 
EVs with vastly different size, function, content, and biogenesis than exosomes. With a 
size range of 100-1000 nm 24, 34, microvesicles can be easily confused as exosomes when 
solely looking at vesicle diameter, especially if larger microvesicles have been 
eliminated. When defining and characterizing vesicles after EV isolation, it is important 
to distinguish between these two EVs. Furthermore, when microvesicle roles are 
compared to exosome roles, the functions look very similar. Microvesicles are involved 
in a variety of processes including inflammation, coagulation, and stem cell renewal, but 
are capable of carrying much larger cargo like circular DNA and loaded reporter 
molecules.34, 44 The biogenesis of microvesicles involves outward budding and fission 
from the plasma membrane of the cell (see Figure 1.1). Therefore, the membrane and 




Lastly, apoptotic bodies, EVs approximately 500-4000 nm in diameter, only 
appear when a cell begins undergoing apoptosis.24 Apoptotic bodies are not usually 
confused with exosomes or microvesicles since their diameter, functions, content, and 
biogenesis are distinct from smaller EVs. The formation of apoptotic bodies is likely a 
means for dividing cell components for easier digestion by phagocytes. 
Characteristically, apoptotic bodies will contain organelles, large cell components, and 
genetic information. Most findings suggest that apoptotic bodies are used for cell 
disposal, but some studies have found that they may be able to pass genetic information 
upon uptake.45, 46 
Physiological Roles of Exosomes 
Exosomes are released by many cells in vivo and in vitro and have been found in 
every biological fluid tested thus far, including urine, blood, saliva, breast milk, cervical 
mucus, amniotic fluid, cerebrospinal fluid, and ascitic fluid.13, 27, 47 With such a large 
presence in biological fluids, it makes sense that exosomes would have a variety of 
important physiological roles. As carriers for cell communication, exosomes may play a 
diverse regulatory role depending on the vesicle contents including, but not limited to, 
immunomodulation and antigen presentation, wound healing and angiogenesis, 
inflammation, drug resistance, disease propagation, regulation of the central nervous 
system, synaptic plasticity, reproduction and embryonic development, and homeostasis.1, 
7, 8, 14, 43, 48 
 Several aspects of exosomes have been extensively studied, but perhaps the most 
well-characterized is their role in immunomodulation and antigen presentation. The 
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adaptive immune response is an incredibly complex system in which exosomes may play 
a regulatory role. In particular, exosomes derived from immune cells have demonstrated 
antitumor effects and have been found to display class I and II major histocompatibility 
complex (MHC) molecules involved in antigen presentation.49 However, tumor cells have 
benefited from the same immunomodulatory properties of exosomes. Tumor cell-derived 
exosomes have been shown to promote tumor development through a variety of 
mechanisms.43, 50 These contradictory functions further demonstrate the versatility of 
exosome communication and function under both normal and pathological physiological 
conditions. 
Immunomodulation and Antigen Presentation 
 Exosomes that contain MHC class I and II molecules play an important antigen 
presentation role in the adaptive immune system.51 Dendritic cells and macrophages, two 
types of antigen presenting cells, release exosomes with these MHC-peptide complexes, 
which can have both stimulatory and suppressive effects on the immune system.52-54 
Exosomes released by these cells can form an antigen-MHC complex which can be used 
to directly present the antigen to T-cells, thereby leading to T-cell activation. 
Additionally, exosomes containing this antigen-MHC complex can present the antigen to 
other antigen presenting cells resulting in processing of the antigen and cross-
presentation to T-cells.43, 54, 55  Pregnancy immune regulation presents a unique 
immunomodulatory situation in which the fetus must be protected from the allogenic 
immune response of the mother. The immunomodulatory effects of exosomes released by 
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the placenta may play a role in this regulation.11, 56 In fact, exosome concentration in the 
amniotic fluid increases over each pregnancy trimester.56 
Wound Healing and Angiogenesis 
 Wound healing is a remarkable process that is regulated and controlled by a 
complex network and cascade of growth factors, cytokines, and proteins. Through 
homeostasis, inflammation, proliferation, and remodeling, damaged tissue is repaired and 
reconstructed to restore tissue function.57-59 Exosomes may play a significant role in 
regulating the intricate interactions of chronic and acute would healing developments. By 
carrying gene influencing material, exosomes can initiate wound healing pathways 
(PI3K/Akt, ERK, STAT3)57, 60, promote expression of growth factors (hepatocyte growth 
factor, insulin-like growth factor-1, nerve growth factor, stromal-derived growth factor-
1), heat shock proteins, and other signaling molecules.57, 61, 62 Specifically, mesenchymal 
stem cells (MSCs) and adipose tissue-derived stem cells (ADSCs) play an important role 
in modifying and controlling wound healing. Likewise, exosomes derived from MSCs 
and ADSCs play a significant role in communicating to fibroblasts, promoting cell 
migration and proliferation, and promoting angiogenesis.60, 61 Exosomes may allow for 
further paracrine signaling to aid in faster wound healing and angiogenesis. Furthermore, 
several cell types have been revealed to release pro-angiogenic exosomes, including 
endothelial cells, tumor-derived cells, hematopoietic stem cells, mesenchymal stem cells, 





Inflammation is a normal physiological process that is used to defend against 
generic foreign material and infection and to remove damaged tissue. It is characterized 
by a large increase in inflammatory cell migration to the injury site.68 Although the 
inflammatory process is closely tied to the adaptive and innate immune response, the 
control mechanisms and processes are quite different. Depending on the type of injury or 
reaction, inflammation is typically mediated by neutrophils, basophils, eosinophils, 
macrophages, lymphocytes, and monocytes.69, 70 Exosomes, as mediators of 
communication, are particularly involved in controlling the inflammatory response 
through the use of miRNA and protein genetic modulatory molecules.18 Specifically, 
exosomes released by lipopolysaccharide-injected macrophages have demonstrated 
inflammatory modulating abilities, including NF-kappaB activation.53 Furthermore, 
dendritic cell-derived exosomes have been shown to suppress inflammation in murine 
collagen-induced arthritis.71, 72 However, other dendritic cell-derived exosomes have 
shown the ability to induce inflammation in the spleen.73 Such vast and varying 
responsibilities within inflammation alone suggest that exosome-mediated responses 
depend heavily on the exosome content and the type and physiological state of the target 
cell. As such, exosome makeup and content are determined by the original cell type and 






Drug resistance is a major combatant of many newly developed cancer drug 
therapies and chemotherapies. Cancer cells, either by acquired or de novo mutations, can 
obtain means to defend against drugs and promote cancer growth. Mutations in the 
genome and epigenome ultimately result in a series of changes that may confer drug 
resistance by drug metabolism, inactivation, efflux, or DNA damage repair.74, 75 Much 
like other pathogens or microbes, cancer cells mutate quickly and thus may develop these 
genetic and epigenetic changes quickly. As exosomes are mediators of genetic 
expression, it makes sense that they may be involved in the complex network of changes 
required to develop drug resistance. Specifically, exosomes may play a role in multiple 
myeloma development of bortezomib resistance.74, 76 Exosomes may be able to aid in the 
expulsion of drugs, counteract immunotherapy drugs, and aid in the spread of 
resistance.77 Drug resistance is a developing problem for current and future cancer 
therapies and requires further investigation. Although exosomes may only play a small 
role in development of drug resistance, understanding the mechanisms behind exosome 
dissemination, transport, and loading may prove useful in the effort to develop effective 




Exosome Medical Applications 
 More and more frequently, studies are revealing the ever expansive roles that 
exosomes may play in cell communication. Since cell communication is a universal 
necessity for development of complex multicellular life, there is much speculation that 
exosomes are involved in many more processes than currently known. Consequently, 
exosomes have been given a great deal of contemplation with regards to potential 
medical applications and functional biological understanding. As of now, many exosome 
applications are being investigated including disease diagnostics, drug delivery, immune 
system modulation, and other therapeutics. The theranostic potential for exosomes is 
seemingly boundless, with patient-specific and personalized medicine at the core of these 
applications. 
Disease Diagnostics 
 Exosomes appear to be packaged in a very uniform and controlled manner so as to 
preserve the accuracy and precision of the message to be delivered. However, the 
exosome contents can actually vary greatly depending on the cell of origin and the 
physiological state of the cell of origin. Fortunately, the consistency among identical cell 
types and the variation of exosome components between distinct cell types may allow for 
tracing of the cellular origins of exosomes. In other words, the lipid, protein, and RNA 
signature of an exosome may provide enough clues to determine what type of cell 
released the exosome. This unique feature of exosomes may allow for downstream 
identification of abnormal cell types using only a body fluid sample. Specifically, several 
types of cancer exosome markers, including ovarian, breast, prostate, pancreatic, 
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glioblastoma, and colorectal, have been identified and may potentially be used for early 
cancer diagnosis.78 Furthermore, exosome markers have been found for other 
pathologies, including acute kidney injury, renal ischemia reperfusion, alcoholic liver 
disease, and nephrotic syndrome.79 Cancer exosome marker identification is occurring at 
a rapid pace and markers are quickly being translated into multiplexed marker diagnosis 
protocols. For example, Zhao et al.80 have developed a microfluidics device that captures 
and identifies ovarian cancer exosomes using the multiplexed ovarian cancer exosome 
markers, epithelium cell adhesion molecule (EpCAM) and cancer antigen 125 (CA-125). 
Although most other types of cancers are awaiting exosome marker identification and 
cataloging, circulating exosomes have been identified in lung, ovary, and gastric cancer 
patients, which bodes well for potential marker identification.37 New biochemical 
exosome RNA, protein, and lipid information is being discovered and amassed, on such 
online databases as ExoCarta, EVpedia, Vesiclepedia, and exoRBase, so as to aid in the 
creation of diagnostic profiles and the advancement of exosome knowledge. Furthermore, 
several groups are working on developing devices that will simultaneously isolate 
exosomes and provide a diagnosis.80 For these reasons, exosome biomarker disease 
diagnosis is perhaps the most promising and likely first attainable application of 
exosomes.  
Drug Delivery 
 When developing any pharmaceutical drug, it is important to keep in mind the 
pathway that the designed drug will follow. The four processes of pharmacokinetics 
(absorption, distribution, metabolism, and elimination) are critical to understand when 
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developing any drug. Particularly, the drug must be able to reach the intended target in 
the correct formation and concentration and must be capable of being eliminated or 
excreted after achieving its intended function. One strategy to combat potential drug 
degradation is to develop a drug delivery system (DDS) to deliver the drug to a location 
where it can function appropriately. Many DDSs have been developed and implemented 
in modern pharmaceuticals, including polymeric dendrimers and micelles, stimuli-
responsive carriers, nanoparticles, and biological materials.81 Exosomes are being 
investigated as a potential DDS due to their size, histocompatibility, natural targeting 
ability, and ability to cross unique barriers, such as the placenta or blood brain barrier.82-
84 Although exosomes contain major histocompatibility complex (MHC) molecules, there 
is very little immune reaction to the vesicles.54, 85, 86 However, to date, any exosome 
clinical trials have been performed using autologous exosomes to avoid greater immune 
reaction.87 Additionally, exosomes are very similar in basic composition to liposomes, 
which have been used in various DDS applications. Liposomes and exosomes are made 
up of a lipid bilayer enclosing internal media, however, exosomes are much smaller and 
have a much more complex makeup of proteins, lipids, and RNAs.88 Several investigators 
have explored different possibilities for loading drugs into exosomes, including 
exogenous and endogenous techniques with varying success.33, 83, 89-91 Another important 
factor in drug delivery, besides protecting the drug, is targeting the drug to a particular 
location to increase drug bioavailability to a subset of cells. Natural exosomes, depending 
on the source, may already target specific cell types, but may also be engineered to target 
a number of desired cell types. For instance, Alvarez et al.23 have loaded exosomes with 
19 
 
siRNA and inserted a rabies-virus glycoprotein (RVG) peptide into the surface membrane 
of the exosomes that successfully targeted the exosomes to the central nervous system in 
mice. In order to further engineer and manipulate exosomes for drug delivery purposes 
and other applications, several groups are now working on developing synthetic and 
semi-synthetic exosomes.91, 92 Given the unique exosome features, exosome drug delivery 
is a real possibility that may provide a useful DDS for treatment or therapies for 
cardiovascular diseases, neurodegenerative diseases, cancers, and countless ailments.  
Immunotherapy 
 As discussed previously, exosomes are heavily involved in immune system 
modulation, antigen presentation, and T-cell activation. Their involvement within the 
immune system offers extensive opportunities and advantages for immunotherapy 
applications. Engineering and manipulation of exosome contents and membranes may 
allow for consistent activation or suppression of the immune system.93 In particular, 
exosome cancer immunotherapy is being investigated as an alternative therapy for cancer 
treatment. By artificially activating or suppressing the immune system, immune cells may 
be specifically activated to target and destroy cancer cells. Similar to drug delivery 
applications, liposomes, artificial lipid-membrane nanocarriers, have already been used in 
cancer immunotherapy applications.88, 91 However, as immunotherapy nanocarriers, 
exosomes may provide many advantages over liposomes including natural 
histocompatibility, biocompatibility, targeting, and ability to cross biological barriers.23, 
55, 94, 95 Among the most promising exosome-based immunotherapy applications is their 
use in the generation of vaccines against diseased cells through immunization and antigen 
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presentation and immune system stimulation.19, 86, 96 However, the natural exosome 
immune system suppressive properties may be particularly useful for avoiding transplant 
rejection and treating autoimmune disorders such as rheumatoid arthritis, inflammatory 
bowel disease, and multiple sclerosis.93, 97, 98 Exosome immunotherapy is an exciting 
prospect, offering a strong alternative to artificial drug delivery for disease treatment. 
Although in the early stages of research, exosome immunotherapy treatments may be 
able to take advantage of the body’s natural defense system to combat internal disease.  
Regenerative Medicine and Other Therapeutics 
 Given the extensive number of biological processes that may involve exosome 
communication, therapeutics may be developed through manipulation of exosome 
presence and content. In recent years, regenerative medicine has focused on development 
of stem cell therapies to help regenerate or reform tissue. Stem cells are capable of 
reproducing indefinitely and differentiating into other cell types, which makes them ideal 
candidates for aiding in regeneration of tissues. Furthermore, in recent years, stem cell 
research has overcome many controversial hurdles through development of induced 
pluripotent stem cells (IPSCs) and use of adult stem cells like mesenchymal stem cells 
(MSCs) and adipose tissue-derived stem cells (ADSCs). However, cell-based therapies 
are often expensive and run into biocompatibility, histocompatibility, teratoma, and 
ectopic tissue formation issues when introducing allogeneic or autologous cells as 
therapeutic agents.97, 99 Exosomes derived from stem cells may offer an alternative 
therapy to direct stem cell therapy, but without many of the concerns associated with 
stem cell therapy. As much of the cellular changes that occur during tissue regeneration 
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and reformation are enacted by stem cell-derived exosomes, standalone stem cell-derived 
exosomes may be used to induce tissue regeneration instead.99 Thus far, exosome driven 
tissue regeneration has been investigated in many tissues including, neural, myocardial, 
hepatic, renal, cutaneous, skeletal, chondral, and muscular.99 However, despite the recent 
advances in exosome understanding, particularly within tissue regeneration, it is still 
uncertain whether exosomes will ultimately evolve into a reliable therapy for 
regenerative medicine.  
 Several maladies, including cancers and neurodegenerative diseases, have been 
found to be associated with an increased release of exosomes or exosome involvement in 
disease progression.100-105 Therefore, several groups have theorized that inhibition of 
exosome formation, release, or uptake or removal of particular exosomes or miRNAs 
found in exosomes may help prevent or slow disease progression.1 Specifically, 
exosomes have been found to aid in environmental preparation for cancer metastasis and 
acquisition of cancer cell chemoresistance.77, 103 Filtration or elimination of cancer 
exosomes may potentially slow progression of epithelial-mesenchymal transition (EMT) 
in tumor cells and aid in chemotherapy of tumors.100, 102, 106, 107 Furthermore, exosomes 
have been implicated in the prion-like propagation of neurodegenerative diseases 
including Alzheimer’s disease, Parkinson’s disease, multiple system atrophy (MSA), 
amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS) 
through transfer of toxic proteins or miRNA.108 Similarly, filtration or elimination of 
exosomes involved in the spread of neurodegenerative diseases may slow the progression 
of their pathology. To this end, further understanding of pathology and the role of 
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exosomes in cancer metastasis, cancer cell acquisition of chemoresistance, and 
propagation of neurodegenerative diseases may ultimately aid in the development of 
treatments for these maladies. 
Exosome Characterization and Biochemical Profile 
As exosomes are approximately 30-150 nm, it is often difficult to characterize 
their defining properties. Furthermore, being derived from cellular components, 
exosomes can be difficult to differentiate from other cellular debris and nanoparticles. 
Therefore, the International Society for Extracellular Vesicles (ISEV) has defined several 
basic requirements for defining and differentiating types of EVs.40, 41 The requirements 
for EV definition primarily focus on two categories of characterization: Physical and 
Chemical. 
Physical Characterization 
 Physical characterization is used to evaluate individual vesicles based on size, 
diameter, concentration, and morphology. ISEV recommends that at least two single-
vesicle technologies be used to characterize EVs. Nanoparticle tracking analysis (NTA) 
and dynamic light scattering (DLS) can be used to obtain vesicle size distributions and 
vesicle concentrations. However, both NTA and DLS can be unreliable as no distinction 
is made between vesicles and other particulate nanoparticles present in the sample. 
Likewise, the limit of resolution of NTA and DLS (approximately 30 nm)109 may hinder 
the ability to identify smaller vesicles and may lead to misidentification of other non-
vesicle particles. Thus, sample purity can affect the dependability of both NTA and DLS. 
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Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) can 
be used to characterize size, diameter, and morphology of vesicles in solution or on a 
surface. Both TEM and SEM have been used extensively to study biologics, materials, 
and processes at a nanoscale level. However, the sample preparation process can be very 
harsh and damaging, particularly toward biological samples and EVs. Despite these 
challenges the morphology and structure of EVs viewed under TEM and SEM are 
credible when consistently prepared, but the sample preparation methods employed 
should be taken into account when making conclusions. Finally, several other techniques, 
including atomic force microscopy (AFM) and super-resolution microscopy techniques, 
such as stimulated emission depletion (STED) or photoactivated localization microscopy 
(PALM), have been used to generate EV size distributions and morphology 
characterizations.110-112 Although no single-vesicle technique can perfectly qualitatively 
or quantitatively characterize EVs, when used in tandem, they can provide useful and 
reliable information to study EVs. 
Chemical Characterization and Profile 
 Chemical characterization of EVs involves identification of protein, RNA, and 
lipid markers that are typically enriched in EVs. ISEV has laid out particular guidelines 
for identification of EVs using typical EV-enriched proteins.40, 41 Membrane associated, 
cytosolic, intracellular, and extracellular proteins have all been used to identify and 
differentiate subtypes of EVs. Accordingly, ISEV recommends using at least 3 protein 
markers to identify and characterize EVs. Proteins typically used to identify and 
differentiate EVs include CD9, CD81, CD63, ALIX, TSG101, Grp94, Calnexin, and 
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many disease specific markers (See Table 1.1).16, 18, 113-116 Protein analysis can be 
completed using Western blot analysis, enzyme-linked immunosorbent assay (ELISA), 
flow cytometry (FACS), or mass spectrometry. As with any method of chemical 
profiling, positive and negative controls of cell lysate and culture medium should be 
compared to the EV samples. Extensive sequencing and compilation of data has 
identified different types of RNAs within EVs, including miRNA, mRNA, tRNA, rRNA, 
piRNA, snRNA, snoRNA, and scaRNA.13 However, miRNA is perhaps the most 
commonly used RNA for EV identification and study due to its function in gene 
regulation.32 There is likely no single exosome marker that will provide an outright 
positive or negative diagnosis for any disease. Therefore, many groups have focused on 
developing a multiplexed diagnostic approach using miRNA or protein identification (see 
Tables 1.1). Specifically, for ovarian cancer, Yokoi et al.117 developed an early stage 
diagnosis technique using expression levels of 8 different miRNAs with an area under the 
curve of 0.97. Furthermore, Zhao et al.80 have used 3 exosome ovarian cancer markers, 
EpCAM, CA-125, and CD24, in conjunction to capture and identify ovarian cancer-
specific exosomes. Lipids, which have been less frequently used to identify and 
differentiate EVs, offer an alternative method to EV biomarker detection. In particular, 
exosomes have been found to be enriched in particular lipids as compared to the parent 
cell.118 For example, Skotland et al.118, 119 have identified 9 different lipids that were 
differentially expressed in exosome membranes of prostate cancer patients. Chemical 
characterization of EVs may reveal important data about the composition and origins of 
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vesicles. Ultimately, a combination of exosome miRNA, protein, and lipid composition 




Exosome Isolation Techniques 
In order to take advantage of any of the potential benefits of exosomes, they must 
first be isolated from cell growth media or bodily fluids. Given that exosomes are 
approximately 30 to 150 nanometers in size, this is no easy task. Current techniques for 
isolating exosomes often involve a number of sequential centrifugation steps to eliminate 
larger materials from the media. Many isolation strategies follow the protocol laid out by 
Thery et al. that involves sequentially increasing ultracentrifugation of the media 
containing the exosomes.134 Others elect to use filters to eliminate larger materials and 
Associated 
Disease 




Ovarian Cancer miR-16, -21, -26a-5p, -93, -100, -
126, -130b-3p -141, -142-3p, -
200a-3p, -200b, -200c, -203, -
205, -214, -223 -320, -328-3p, -
374a-5p, -766-3p117, 120, 121 




80, 101, 122 
Lung Cancer miR-17, -3p, -21, -20b, -223, -
301, -486, -181-5p, -30a-5p, -30e-
3p, -361-5p, -10b-5p, -15b-5p, -
320b, let-7d-5p, let-7f123-125 
CD91, CD317, EGFR, 
LRG1, NY-ESO-130, 126-
128 
Breast Cancer miR-338-3p, -340-5p, and -124-
3p, -29b-3p, -20b-5p, -17-5p, -
130a-3p, -18a-5p, -195-5p, -486-
5p, -93-5p, -1246, -373129-131 
PKG1, RALGAPA2, 
NFX1, TJP2, Glypican-1, 
Her29, 132, 133 
Table 1.1. Potential exosome miRNA and protein markers for different types of 
ovarian, lung, and breast cancer. 
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then pellet the exosomes using ultracentrifugation. Both of these current techniques for 
exosome isolation and other variations require the use of ultracentrifugation, which may 
not always be available in medical settings. There are a number of exosome isolation kits 
available commercially that have produced varying results. Importantly, the type of 
exosome isolation can impact protein and RNA downstream analysis. As it stands now, 
given the difficulty and varying effectiveness of these isolation techniques, it seems 
unlikely that any of them will perform effectively, efficiently, and consistently in a 
clinical setting. For these reasons, there is a need to refine or develop new techniques of 
exosome isolation that may be more suitable for medical environments.  
 
Differential Centrifugation 
 Differential Centrifugation exosome isolation takes advantage of the ability of a 
centrifuge to separate out materials in solution based on the density and size of the 
material. Higher weight objects will move faster through the solvent and will thus 
sediment quicker from solution at lower centrifugation speeds. Lower weight objects will 
begin to sediment faster from solution at much higher centrifugation speeds.135 Therefore, 
the heavier objects in the cell growth media (e.g. cells, apoptotic bodies, and debris) will 
sediment from solution and be removed in a primary centrifugation. A faster secondary 
centrifugation will pull down lighter objects, including larger EVs and microvesicles, to 
be removed, and finally a third and fastest centrifugation will sediment the desired 
exosomes.136 Typical ultracentrifugation exosome isolations often require a final 
centrifugation speed greater than 100,000Xg. The ultracentrifugation process requires 
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upwards of 3 hours to complete depending on the number of centrifugation steps included 
and experience level of the personnel performing the isolation. Furthermore, the 
centrifuges and ultracentrifuges required for this method can very expensive (low speed 
centrifuges – several thousand dollars; high speed centrifuges - $15,000-$100,000) and 
may not be suitable for smaller labs and organizations. This exosome isolation method is 
crude, results in highly variant samples, and can potentially damage the exosomes due to 
the high speeds of centrifugation and the resuspension of the vesicles.136 By nature of 
centrifugation, the final isolated exosome sample will contain anything from the original 
cell growth media of similar or lighter weight than an exosome (for example, lipoproteins 
and proteins)137 and may contain aggregate vesicles and proteins. Furthermore, any larger 
particles that were not eliminated from the solvent may sediment along with the 
exosomes. Differential centrifugation is relatively easy to perform with the proper 
equipment and training, but often results in low purity samples with fairly low efficiency. 
However, due to the relative ease with which this method can be performed, it is one of 
the most common exosome isolation techniques used today. 
Density Gradient Centrifugation 
 Density gradient centrifugation is very similar to differential centrifugation but 
includes an extra medium that increases the viscosity of the solution. There are two types 
of gradients, isopycnic and rate zonal, that have been used to isolate exosomes.137 During 
isopycnic gradient centrifugation, samples are dispersed within the gradient medium and 
separate components based on density, whereas during zonal gradient centrifugation 
samples are layered as a narrow band at the top of the gradient medium and separate 
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components based on size (Figure 1.3).135 Exosome density gradient centrifugation 
typically uses a sucrose or iodixanol solution that is compatible with the lipid bilayer of 
the exosomes and vesicles. By increasing the viscosity of the solution, objects of very 
similar density can be differentiated and separated more easily. Therefore, this method of 
exosome isolation can result in purer exosome samples with less debris. However, even 
though the final sample can be purer than differential centrifugation, the range of 
centrifugation speeds and range of centrifuge times must be more accurate to be in the 
proper density range for exosomes. Monitoring the centrifugation times and speeds 
makes this method more difficult than differential centrifugation alone due to the 
increased density sensitivity of the solution. Variations of density gradient centrifugation 
have been used to develop exosomes samples for use in clinical trials.21, 22, 138 
 
Figure 1.3. Diagram of Isopycnic and Rate zonal density centrifugation. 
Adapted from Sigma-Aldrich (St, Louis, MO). 
29 
 
Size Exclusion Chromatography 
Size exclusion chromatography (SEC) is used to separate molecules within a 
solution based on the size of the molecule rather than the density or weight of the 
molecule. The solution flows through a size exclusion column containing small stationary 
phase beads with nanometer–sized pores. Smaller molecules in the solution will enter and 
adsorb in the pores, thus slowing their rate of flow through the column and delaying the 
time of elution. Larger molecules will flow through the column without entering the 
adsorbent material pores and elute quicker. The same principle can be applied to isolate 
exosomes from other components of the solution. Böing et al.139 use sepharose CL-2B 
beads with 75 nm pores to separate out exosomes from solution. Furthermore, several 
groups have used SEC in conjunction with other exosome purification or enrichment 
techniques, such as ultrafiltration or ultracentrifugation, to achieve higher purity 
samples.140-142 Size exclusion chromatography can very accurately separate exosomes 
from solution based on size, but the final exosome eluate may also contain other 
materials of similar size. Additionally, size exclusion chromatography limits any shear 
force damage to the exosomes and prevents protein and vesicle aggregation. Despite its 
efficiency and accuracy, size exclusion chromatography may be severely limited by the 
amount of eluate obtained and the time it takes to flow through the column.140, 143, 144 
However, recent improvements in this technique have led to faster and cheaper separation 
of molecules. Böing et al.139 demonstrate that this technique can be used to isolate a 




Much like SEC, ultrafiltration isolates exosomes based on size or molecular 
weight using pore sizes ranging from 0.8 to 0.1µm.145 Ultrafiltration is much faster and 
cheaper than ultracentrifugation, and does not require large, specialized machinery.146 
Similar to SEC, ultrafiltration has been used in tandem with ultracentrifugation or SEC to 
isolate exosomes.147, 148 Fluorescent imaging has revealed that ultrafiltration results in a 
higher RNA yield compared to ultracentrifugation.149 Unfortunately, by the nature of 
filtration, any molecules that are smaller than the pore size will pass through into the final 
sample, resulting in particle contamination.145 In order to alleviate protein contamination 
and remove molecules smaller than exosomes, a sequential ultrafiltration has been used 
to purify the exosomes further. Sequential ultrafiltration of exosomes consists of an initial 
“dead-end” filtration to remove cells and debris. A secondary tangential flow filtration is 
used to remove proteins and molecules with a 500kDa filter. Finally, a filter with a pore 
size of 100 nm is used to isolate the exosomes.137 Ultrafiltration has been used to isolate 
exosomes from a variety of cell types and biological fluids, and has been used to isolate 
exosomes from as little as 0.5 mL of urine.137, 145, 147, 150 
Polymer-based Precipitation 
Exosomes can be precipitated out of solution by manipulating the content of the 
solvent. In phosphate buffered saline, exosomes will remain in solution, but altering the 
solvent can change the solubility of the exosomes. By adding a polymer, such as 
polyethylene glycol (PEG), exosomes will precipitate out of solution at low speed 
centrifugation.146 This method requires either pre-centrifugation or pre-filtration to 
remove cells and larger debris from solution. Polymer-based precipitation can be 
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performed easily, inexpensively, effectively, and can be completed on a large scale. 
However, the precipitate may contain polymers and other undesired molecules of similar 
solubility.137, 151, 152 Further steps must be taken to fully purify the exosome sample 
including pre-isolation of lipoproteins and post-isolation of polymeric materials.137 
Several commercially available polymer-based precipitation EV isolation kits that 
operate with minimal sample exist, including Total Exosome Isolation (Invitrogen, 
Carlsbad, CA)), ExoQuick exosome precipitation solution (System Biosciences, Palo 
Alto, CA).151 The availability and ease of use of polymer-based precipitation kits makes 
them promising and convenient techniques for research and clinical purposes. 
Immunological Separation 
Immunoaffinity capture of exosomes is a promising exosome isolation technique 
with high specificity.153 Since exosome lipid membranes are composed of proteins, 
receptors, and transmembrane proteins, antibodies can be developed to specifically target, 
capture, and isolate exosomes. Immunological separation requires understanding the 
membrane content of exosomes from all sources and requires discovering a protein or 
receptor that is common to all exosomes. However, a protein or receptor common to all 
exosomes must not be common to other biological components of the cellular media. Due 
to the high specificity of antibodies in immunological separation, exosomes can be 
isolated at similar efficiency to ultracentrifugation, but with much smaller samples.113, 137, 
154 Several variations of immunoaffinity capture, including modified ELISA exosome 
isolation and magneto-immunocapture, have had success isolating exosomes with high 
efficiency.29, 155-157 Despite the efficiency, effectiveness, quality, and speed of 
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immunological separation of exosomes, there is still an incomplete understanding of 
exosome membrane content. It is difficult to differentiate proteins specific to exosomes 
when much of the content of the exosomal membrane is derived from the cellular 
membrane. Currently, a common protein targeted is CD63, a tetraspanin membrane 
protein common to many human exosomes. However, CD63, and other similar 
tetraspanin proteins can also be found in apoptotic bodies and other extracellular 
vesicles.30, 158, 159 Immunoaffinity-based separations using specific antibodies are 
excellent techniques for isolating exosomes, especially for high quantity and quality RNA 
extraction from exosomes. Even with a poor understanding of exosome membrane 
composition, immunoseparation may produce high yields and generate subpopulations of 
isolated exosomes and extracellular vesicles.137  
Microfluidics Isolation techniques 
 Newer strategies involving microfluidics devices have begun to permeate the 
realm of exosome isolation, as advancing fabrication processes have allowed for easier 
manufacturing of microfluidics devices. Many of these new techniques use a device that 
operate on one or more of the principle isolation strategies discussed above. For instance, 
Lee et al.160 have developed an acoustic nanofilter that uses ultrasound to isolate 
microvesicles based on size and density, while Wang161 et al. have developed ciliated 
micropillars for selectively capturing lipid vesicles of 40-100nm in size. According to 
Yang et al.162, microfluidic device exosome isolation techniques have the potential to be 
faster and more effective than the current standard exosome isolation techniques. 
33 
 
However, each individual microfluidics technique has drawbacks and many of the 
devices are still early in development.  
 Although there are many strategies for isolating exosomes, there is no clear 
method that stands above the rest. Each technique has its own benefits and downfalls 
whether it be isolation efficiency, exosome purity, exosome integrity, RNA extraction, 
cost, scalability or ease of use (see separation strategies summary in Table 1.2). With the 
realization of the possibilities of exosome technology, there is clearly a need for a 








Exosome Loading Techniques 
There are a number of different ways to load exosomes with drugs or other 
markers including electroporation, sonication, saponin incubation, extrusion, transfection, 
and drug incubation.83, 89, 91, 94 In general, these and other exosome loading techniques can 
be categorized as exogenous loading or endogenous loading. Exogenous loading 
techniques are methods of loading exosomes after the exosomes have been isolated. 
Conversely, endogenous loading techniques are methods of loading exosomes before the 
exosomes have been released from the cell. 
Exogenous loading 
Separated exosomes can be prone to further damage after isolation that may limit 
their viability and capability to perform functions. In order to load material into the 
exosomes, exogenous techniques often employ potentially destructive and damaging 
stimuli to open temporary holes in the exosomal membranes. These techniques, including 
electroporation, saponin permeabilization, sonication, extrusion, transfection, and drug 
incubation, while effective, destroy many vesicles in the process.23, 83, 89 Electroporation 
is a method of shocking the plasma membrane with a relatively low voltage. The electric 
shock temporarily makes the plasma membrane of the exosome more permeable and 
allows for contents in the surrounding solution to enter the exosome. Alvarez et al.23 have 
employed this technique to load siRNA into exosomes for drug delivery and treatment of 
Alzheimer’s disease. Typical applications of electroporation involve transfecting genetic 
material into cells of various types. Sonication, another potential exosome loading 
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technique, also disrupts the stability of the plasma membrane, thus making the plasma 
membrane more permeable to loading. According to Haney et al.83, saponin is a 
surfactant that is thought to remove plasma membrane cholesterol, temporarily creating 
holes in the plasma membrane allowing surrounding solution content to load into the 
exosome. Much like sonication, extrusion and freeze/thaw methods disrupt the integrity 
of the lipid bilayer and increase the permeability of the plasma membrane. All of these 
methods have been shown to enable loading of exosomes, but with varying effectiveness 
and stability. There are many advantages and disadvantages to these approaches, but 
Haney et al. and Alvarez et al. have shown that exosomes loaded with these methods are 
still effective for drug delivery.23, 83 
Endogenous loading 
Endogenous loading techniques are significantly less destructive to exosomes, but 
can be significantly more difficult to accomplish. Loading of an exosome in this manner 
could mean either modifying the membrane content of the vesicle or having the exosome-
producing cell automatically load the vesicles with the appropriate proteins or nucleic 
acids for drug delivery. In exosomes, modifying membrane protein content is primarily 
accomplished using genetically engineered plasmid vectors. The plasmids are encoded 
with particular targeting proteins or peptides that will then be expressed in the cell and 
inserted into the plasma membrane. Specifically, Alvarez et al.23, 163 inserted a modified 
targeting peptide plasmid for Lamp2b, a known exosome membrane protein. They 
verified the successful expression of the modified Lamp2b peptide using an exosome 
protein pulldown assay. The modified Lamp2b exosomes primarily targeted neurons, 
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microglia, and oligodendrocytes, as planned. Furthermore, the Lamp2b exosomes 
successfully targeted and knocked down BACE1 expression in neurons, microglia and 
oligodendrocytes by 60% and 62% using mRNA and protein respectively. BACE1 is a 
gene involved in Alzheimer’s pathogenesis that could be knocked out for potential 
therapy. Similarly, Monfared et al.164 have engineered exosomes to express membrane 
miR-21 sponges in order to induce apoptosis in tumor cells. The ability to modify 
exosome plasma membrane content is a vital step in targeted drug delivery and evidence 
has thus far shown that specific targeting with exosomes is possible and effective. One 
strategy for loading proteins or nucleic acids into the cytosol of exosomes is to engineer 
the exosome-releasing cells to overexpress the molecule to be loaded.165 Alternatively, 
Yim et al.165 have developed a more advanced method of selective drug loading during 
biogenesis using exosomes for protein loading via optically reversible protein-protein 
interaction (EXPLORs). EXPLORs uses engineered cell lines that express selective 
membrane docking proteins that are photo-activated using blue light. This technique has 
demonstrated very high loading efficiency in comparison to other loading techniques. 
Endogenous engineering of vesicle membrane proteins and protein cargo may be used to 
create a drug delivery system requiring only exosome isolation and administering to 
patients.  
Liquid Chromatography 
 Although most liquid chromatography (LC) techniques have been used to separate 
proteins and other macromolecules, there is potential for LC isolation of more complex 
bio-molecules, including extracellular vesicles and exosomes. LC is a chemical technique 
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that allows for separation of molecules from solution. Modern LC, referred to as high 
performance liquid chromatography (HPLC), can be used to separate, detect, and 
quantify molecules and can isolate molecules based on hydrophobicity, charge, or size.166  
Choice of solid and liquid phase components can determine which molecules can be 
separated from solution and often vary depending on the specific application. HPLC has 
been used to separate a variety of types of molecules including amino acids, 
carbohydrates, lipids, nucleic acids, proteins, steroids, and biological substances.144 
Depending on the physical properties being used, HPLC can be generally subdivided into 
several categories including normal-phase, reversed-phase, ion-exchange, and size-
exclusion. Normal-phase describes liquid chromatography that uses a polar stationary 
phase and hydrophobic mobile phase, whereas reversed-phase describes liquid 
chromatography that uses a hydrophobic stationary phase and polar mobile phase.166 
Furthermore, ion-exchange separates molecules based on charge properties and size-
exclusion typically uses columns packed with microbeads that slow down the flow of 
molecules based on size.139, 144, 167 Although HPLC has typically been used to isolate 
small or individual molecules, larger more complex biological components have been 
separated as well. For example, Kasanović et al.167 have used ion-exchange 
chromatography to separate EVs from amniotic fluid and An et al.142 have used size-
exclusion chromatography to separate exosomes from human serum. To this end, a 
variety of combinations and expansive methods of HPLC exist beyond the standard 
classification that have a diverse set of applications across chemical, material, and 
biological fields.  
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One particular type of LC, known as hydrophobic interaction chromatography 
(HIC), is a variant of reversed-phase LC. HIC, like reversed-phase, uses a stationary 
phase that is more hydrophobic than the mobile phase. Reversed-phase LC relies on 
adjusting the polarity of the mobile phase using an organic solvent until the mobile phase 
is more hydrophobic than the stationary phase.144 HIC, on the other hand, relies on 
adjusting the salt concentration of the mobile phase from high concentration to low 
concentration to change the polarity (see Figure 1.4).168, 169 Increased concentrations of 
chaotropic ions can influence the solubility of hydrophobic molecules and cause 
hydrophobic molecules to adsorb to the stationary phase. Molecule adherence to the 
stationary phase can be explained by the “salting-out” phenomena, thermodynamics, and 
van der Waals forces.4, 144, 168-171 In order to optimize the HIC separation gradient 
steepness, salt concentration, volume of sample, pH, type of matrix, and flow rates can be 
varied.172 HIC may be less damaging than reversed-phase LC and, thus, is often used to 
separate more sensitive bio-molecules.168, 173 Most commonly, HIC is used to separate 
proteins and large polypeptides, but many groups have used HIC for a variety of 
applications including the separation and isolation of monoclonal antibodies.168, 169, 174 
With this in mind, HIC may provide a method to isolate more complex and larger bio-
molecules under the appropriate conditions. In this case, our research group is 
investigating whether HIC combined with poly(ethylene terephthalate) Capillary-







Figure 1.4. Demonstration of hydrophobic interaction chromatography 




Ovarian Cancer Detection, Diagnosis, and Treatment 
Ovarian cancer (OC) is the 7th most diagnosed cancer in women and generally 
reflects a very poor 5-year prognosis.5 OC consists of several different histological 
subtypes that vary in genetic expression, origin, pathogenesis, prognosis, and treatments. 
Of these subtypes, epithelial ovarian cancer accounts for about 90% of all diagnosed 
benign and malignant tumors. Malignant epithelial OC can be further subdivided into 
histotypes including high-grade serous, endometrioid, clear cell, mucinous, and low-
grade serous.5 The pathogenesis and development of OC is still very unclear, but many 
types may originate from the fallopian tubes or peritoneum.176, 177 OC is typically 
detected in late stage, with a 5-year relative survival rate of 29% with early stage 1 
detection only occurring about 15% of the time. However, if OC is detected in stage 1, 
the 5-year relative survival rate is 92%.5 Early detection of OC is very difficult and 
effective means for early detection do not currently exist. However, genetic sequencing 
now allows for detection of particular gene alleles that are correlated with a higher risk of 
developing OC, including BRCA1/2, MMR, TP53, CHEK2, RAD51, BRIP1, and 
PALB2 genes.178 Even with genetic marker testing and screening available, the hallmark 
of OC remains late stage diagnosis and the corresponding stark prognosis and mortality 
rates.179, 180 
 The most common methods for OC detection include a transvaginal ultrasound 
and screening for CA-125 in serum.181 Combined, these methods are capable of detecting 
OC and differentiating malignant and benign tumors in low-risk postmenopausal women, 
but are not highly sensitive in many cases.182 Once a tumor is detected, biopsy and 
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histopathological assessment can determine the type, stage, severity, prognosis, and 
treatment options. New biomarkers in conjunction with CA-125 have been used to 
increase screening sensitivity and specificity including HE4, CEA, VCAM-1, 
transthyretin, apolipoprotein A1, β2-microglobulin, and transferrin. However, 
multiplexed biomarker testing is not prevalent or proven yet.181 Earlier detection of OC, 
once achieved, would likely improve prognosis and mortality rates, but current general 
population screens are not standard.183  
 Regardless of the type and stage, OC, once diagnosed, is typically treated by 
surgical removal of the tumor often combined with intraperitoneal and intravenous 
chemotherapy.184, 185  Interval cytoreduction combined with chemotherapy has remained 
the standard treatment for late stage treatment of OC, but has only seen a small reduction 
in mortality over the last 25 years, likely due to preventative measures and accuracy of 
surgical techniques. More recently, cytoreduction has been paired with neoadjuvant 
chemotherapy and hyperthermic intraperitoneal chemotherapy, but there is some debate 
whether or not these techniques are more effective.185 Indeed, there is a clear need for 
new strategies and therapies to treat and eradicate OC growth, metastasis, and recurrence. 
High-grade serous OC is associated with hypoxic angiogenesis, over-production 
of vascular endothelial growth factor (VEGF), and the subsequent development of 
ascites.186 Therefore, one new therapy strategy is to use anti-angiogenic drugs to combat 
OC growth and recurrence. Bevacizumab, a VEGF antagonist, has shown promise in 
reducing recurrence, but its use is controversial due to differences in regulatory approval, 
varying strategies of use, and lack of improvement over other therapies.185, 186 Other anti-
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angiogenic drugs under investigation include cediranib, pazopanib, nintedanib, and 
angiopoietin inhibitor.185 Treatment with Poly(ADP-ribose) Polymerase (PARP) 
inhibitors are also being investigated as inducers of synthetic lethality in OC and other 
cancers through disruption of DNA repair.187 PARP inhibitors, including olaparib, 
niraparib, rucaparib, have shown promise as primary and post primary treatment, 
particularly in OC patients with BRCA mutations.185 Other therapies for OC under 
investigation include epidermal growth factor receptor tyrosine kinase inhibitors, folate 
receptor α inhibitors, and immunotherapy.185 Treatment options for OC are quickly 
advancing and have demonstrated improvement in survival rates and reduction of 
recurrence. Even so, OC remains one of the most lethal gynecological maladies, likely 
due to the asymptomatic nature of early stages leading to late stage detection.186  
Role of Exosomes in Cancer Metastasis 
 Tumor invasion, metastasis, and the formation of secondary tumors is the primary 
reason for high mortality in most cancers.188 Metastatic tumors are characterized by 
invasion, intravasation and extravasation into distant tissues, often having very poor 
outcomes.189 The stages of tumor epithelial-mesenchymal transition and eventual tumor 
metastasis are controlled by a number of cascading biological pathways involving many 
cell types, cytokines, growth factors, chemokines, and small molecule mediators 
delivered by exosomes.77, 190, 191 In fact, tumors have been found to release a higher 
number of exosomes into the microenvironment compared to healthy cells.192 Typically, 
exosomes involved in tumor metastasis will influence the microenvironment and 
surrounding cells to prepare the area for tumor growth and create a pre-metastatic 
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niche.193 Such preparations may include promotion of angiogenesis, adaptation to 
hypoxic environments, immune evasion, and promotion of inflammation (see Figure 
1.5).1, 104, 105, 194-199 Specifically, exosomes can recruit bone-marrow derived cells to 
mediate vascular permissiveness and inflammation, ultimately leading to pre-metastatic 
preparation of the extracellular matrix.50, 77, 200  Additionally, pro-angiogenic factors 
transmitted by tumor-derived exosomes can boost vascular development which may aid 
in the development of the pre-metastatic niche and minimize the lethal effects of a 
hypoxic environment. Furthermore, tumor-derived exosomes may escape immune 
surveillance by inducing cytotoxic T-cell apoptosis, decreasing natural killer cell activity, 
and pushing T-helper cells to differentiate into T-regulatory cells that promote 
inflammation.1, 197, 198, 201 In short, exosomes are intricately involved in the growth and 
spread of tumors and new pathways and functions are frequently being unveiled. Greater 
understanding of the role of exosomes in tumor metastasis and any corresponding 








Role of Exosomes in Ovarian Cancer Diagnosis 
As they are carriers of proteins and nucleic acids and are heavily involved in 
tumor metastasis, exosomes are thought to be potential biomarkers for cancerous cells 
and tumor progression. By capturing exosomes from circulating fluids, the signal-to-
noise ratio of cancer-related molecules can be greatly improved when screening for tumor 
markers. In recent years, exosome marker identification has yielded an array of common 
exosome markers that may be useful for capturing and identifying specific types of 
exosomes and their origins. Identification of an exosome’s cell of origin, the molecular 
cargo carried inside, and potential target cell reveals valuable information about 
Figure 1.5. Various roles of exosomes released from primary cancer cells. 
Adapted from Rashed et al.1  
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objectives of the exosomes, the physiological state of the original cell, and potential 
diagnostic information from diseased cells. Particularly, exosomes are being investigated 
as potential early stage biomarkers for OC as a remedy for late stage diagnosis. Both 
protein and miRNA exosome marker profiles are being developed to aid in the diagnosis 
of OC. Zhao et al.80 have developed a microfluidics device that captures and identifies 
OC-specific exosomes using CA-125, EpCAM, and CD24 markers with potential 
diagnostic ability. Further advances in protein marker profiles for OC will likely enhance 
diagnostic sensitivity and specificity using multiplexed protein approaches. Similarly, 
Yokoi et al.117 have used a combination of 8 different OC-associated exosome miRNA 
molecules to achieve an area under the curve of 0.97, a sensitivity of 0.92 and a 
specificity of 0.91 for OC diagnosis. Interestingly, when capturing EpCAM positive 
exosomes, Taylor et al.120 found that exosome miRNA profiles had a high correlation 
with miRNA profiles from the associated biopsy and that miRNA profiles tended to 
differ between benign and cancerous tumors. This suggests that exosome miRNA profiles 
may vary enough to differentiate between tumor types and physiological states. 
Multiplexed exosome biomarker approaches offer promising early diagnostic capabilities 
for OC and other cancers. In particular, OC stands to benefit greatly from early stage 
diagnosis as stage 1 detection results in a 92% 5-year relative survival rate.5 
SKOV-3 and Immortalized Human Ovarian Epithelial Cells 
 Cell lines are important tools that can be used as models to be able to study 
biological phenomena. Several cell lines, including SKOV-3, OVCAR-2, OVCAR-3, 
OVCAR-433, OVCAR-5, IGROV1, and BG-1 have all been used for exosome research 
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in relation to ovarian cancer.38, 122, 202, 203 In particular, the SKOV-3 line, a high-grade 
adenocarcinoma cell line, is among the most popular and commonly used cell lines in 
publications reporting on OC. It is one of two cell lines that make up 60% of publications 
relating to OC and one of five cell lines that make up 90% of publications relating to 
OC.204 Their popularity and high-grade serous derivations, fast growth rate, and abundant 
production of extracellular vesicles are some of the main reasons SKOV-3 cells have 
emerged as popular cells for exosome study. Despite their popularity, many cells lines, 
including SKOV-3 cells, have come under scrutiny over representative accuracy or how 
well the cell line genetically and physically represents the original parent carcinoma.204, 
205 Even so, with little in the way of other available options (primary cells are not feasible 
in most research settings), cell lines remain very popular and widespread and, for the 
most part, still provide insightful and accurate results.  
 Most cell lines, by their very nature, are derived from diseased primary cells. 
Often, the disease is the purveyor of the immortality required to become an endlessly 
replicating cell line. As with any experiment, it is important to maintain a control, but 
control cells lines of normal, non-diseased cells, can be difficult to find and maintain. 
Primary cell lines, which can be used as controls, do not replicate indefinitely invitro and 
are considerably less hardy. Fortunately, immortalized primary cells have emerged as 
viable alternatives to normal primary cells.206-208 Through genetic modification of tumor 
suppressor and cell cycle controller genes, more genetic variance is introduced into the 
cell environment. Although these are major changes to the cell cycle, immortalized cells 
are considered more genetically and physically similar to primary cells than carcinoma-
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derived cell lines and thus have been used as control cell lines in research.209 In the case 
of OC, Immortalized Human Ovarian Epithelial cells, created through simian virus 
transduction, can be used as a viable control cell line in extracellular vesicle and exosome 
research 
Summary 
The mechanisms and roles of exosomes are incredibly complex and evidence thus 
far has demonstrated the intricate involvement of exosomes in a number of processes, 
including cell-cell communication and tumorigenesis.8, 104, 210 Increased understanding of 
exosomes and their roles in the body will undoubtedly result in fundamental insights that 
may lead to breakthroughs in such areas as liquid biopsy-based diagnostics, 
understanding of disease progression and development of new medical treatments. 
However, to date, exosome isolation presents a number of fundamental challenges that 
must be overcome before academic research can progress to the point of translational 
medical applications. An exosome isolation methodology that is practical for use in a 
clinical setting is greatly needed.  
In the following research, we have a developed an EV isolation method and 
model systems that will support earlier and routine OC diagnosis. The three specific aims 




1. To develop and investigate a novel poly(ethylene terephthalate)(PET) capillary-
channeled polymer (C-CP) fiber-based extracellular vesicle isolation method using 
Dictyostelium discoideum as a model organism. 
2.  To create fluorescent Immortalized Human Ovarian Epithelial (IHOE)-CD81-
GFP (non-cancerous) and SKOV-3-CD9-RFP (cancerous) cell lines to produce green 
and red small extracellular vesicles, respectively, for use as model sEVs to investigate 
PET C-CP fiber-based selective EV capture. 
3.  To investigate urine and cervical mucus as EV sample sources and explore EV 
miRNA expression data as a tool for distinguishing between ovarian cancer and non-
cancer patient samples and discovering novel ovarian cancer biomarkers for use in 
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EXOSOME ISOLATION AND PURIFICATION VIA HYDROPHOBIC 
INTERACTION CHROMATOGRAPHY USING A POLYESTER, 
CAPILLARY-CHANNELED POLYMER FIBER PHASE  
 
Abstract 
Extracellular vesicles, including microvesicles and exosomes, are lipidic 
membrane-derived vesicles that are secreted by most cell types. Exosomes, one class of 
these vesicles that are 30-100 nm in diameter, hold a great deal of promise in disease 
diagnostics, as they display the same protein biomarkers as their originating cell.  For 
exosomes to become useful in disease diagnostics, and as burgeoning drug delivery 
platforms, they must be isolated efficiently and effectively without compromising their 
structure.  Most current exosome isolation methods have practical problems including 
being too time-consuming and labor intensive, destructive to the exosomes, or too costly 
for use in clinical settings.  To this end, this study examines the use of poly(ethylene 
terephthalate) (PET) capillary-channeled polymer (C-CP) fibers in a hydrophobic 
interaction chromatography (HIC) protocol to isolate exosomes from diverse matrices of 
practical concern.  Results demonstrate the ability to isolate extracellular vesicles 
enriched in exosomes with comparable yields and size distributions on a much faster time 
scale when compared to traditional isolation methods.  As a demonstration of the 
potential analytical utility of the approach, extracellular vesicle recoveries from cell 
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culture milieu and a mock urine matrix are presented.  Scalable separations covering sub-
milliliter spin-down columns to the preparative scale are projected.  
It should be noted that this is collaborative work that has been published as a 
peer-reviewed article and was performed with Dr. Ken Marcus of the Clemson University 
Chemistry Department. Of note, the hydrophobic interaction chromatography work 
outlined in this chapter was primarily performed by Dr. Lei Wang and Ms. Sisi Huang. 
This chapter appears here directly as published (with minimal additions) for 
completeness.  
Terri F. Bruce, Tyler J. Slonecki, Lei Wang, Sisi Huang, Rhonda P. Powell, R. 
Kenneth Marcus, Exosome isolation and purification via hydrophobic interaction 
chromatography using a polyester, capillary‐channeled polymer fiber phase. 






Exosomes are tiny lipid-bound vesicles, approximately 30-100 nm in diameter, 
that are secreted by most types of cells, including both normal and disease-state cells. 
They carry internal “cargo” molecules, such as nucleic acids and proteins, which are 
derived from their cell of origin. These biomarkers make exosomes a promising means of 
minimally-invasive early disease diagnosis 1-4.  Once considered cellular debris, research 
has demonstrated that exosomes have multiple biological roles.  Exosomes may be 
involved in a myriad of normal physiological processes including cross-placental 
communication between the mother and fetus, fetal development, and bone calcification, 
as well as disease processes including metastasis, pathogenesis of thrombosis, diabetes, 
atherosclerosis, tumor growth, arthritis, and progression of neurodegenerative diseases 4, 
5.  Exosomes  can be found in most body fluids, including urine, saliva, amniotic fluid, 
semen, breast milk, plasma, and blood, making them a promising basis for the 
development of liquid biopsies 6, 7.  Exosomes have been shown to have unique 
microRNA (miRNA) signatures that could soon open the door for clinical and therapeutic 
applications 8.  Exosomes are being exploited for disease diagnostics 7, 9, 10, including 
cancer 11, 12, with potential biomarkers identified relative to a number of different types of 
cancers, including ovarian, lung, breast, prostate, and pancreatic cancer 11-14.  
Despite these promising attributes, the analysis of exosomes is currently limited 
by the processes required to isolate them from body fluids 15-17.  In most cases, exosomes 
are isolated by differential centrifugation (DC), requiring the use of a high-speed 
centrifuge over several hours, including the sedimentation of other particulate debris and 
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potentially impacting the integrity of the lipid bilayer membrane of the exosome.  Other 
emerging exosome isolation techniques include density gradient centrifugation, size 
exclusion chromatography, ultrafiltration, polymer-based precipitation, immunological 
separation, and microfluidics techniques 13, 18-23.  Some of these methods are generic with 
respect to the specific types of exosomes which can be isolated, while others solely 
capture vesicles originating from specific cell types.  Each of these exosome isolation 
techniques has benefits, but the aforementioned shortcomings are fairly universal 17, 18, 24.  
Thus, none are currently sufficient for use in clinical diagnostics or for isolation of larger 
lots from cell culture media as would be required for drug delivery applications. 
 Exosome isolation methods are generally based on the size/hydrodynamic radii of 
the vesicles, i.e, centrifugation, filtration, and sieve-based approaches, or their affinity 
towards capture surfaces used in spin-down formats.  However, methods relying on 
chemical separation and processing platforms, such as those employed in HPLC, have not 
been fully explored; yet, they may have many attractive features.  Most of the common 
LC stationary phases used for chemical separations, such as porous silica beads, would 
not be practical, as exosomes would likely be excluded from the internal pore structures, 
and clogging would be a major operational problem. This study describes the use of 
capillary-channeled polymer (C-CP) fibers as stationary phases for the isolation and 
recovery of exosome-enriched populations of extracellular vesicles (referred to as 
“exosomes” from here forward) from culture media, buffer, and urine.  C-CP fibers have 
been employed by Marcus and co-workers as stationary phases for protein separations via 
reversed phase, ion exchange, hydrophobic interaction, and affinity chromatographies 25-
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31.  These fibers are melt-extruded from commodity polymers (nylon 6, polypropylene, 
and poly(ethylene terephthalate) (polyester,PET)), having  a unique cross-sectional 
profile consisting of eight “legs” on the periphery.  When packed in column formats, the 
fibers inter-digitate to create massive numbers of 1-4 µm-wide channels that provide high 
permeability to fluid flow.  The non-porous nature of the fiber surfaces (at least on the 
size scale of proteins) means that intra-phase diffusion of solutes is prohibited.  This 
combination of macro and micro characteristics results in the ability to affect protein 
separations at exceedingly high linear velocities (>50 mm sec-1) without the mass transfer 
limitations common to porous phases.  These hydrodynamic advantages are 
complemented by a high degree of chemical separation diversity.  In addition to the range 
modalities of separation that can be affected using different base polymers, an extensive 
tool box of simple surface modification approaches has also been developed.  The fiber 
surfaces may be modified to affect high ligand densities for ion exchange (cationic and 
anionic) and affinity chromatography 30-32.   Affinity separations include the use of 
protein A for IgG purification and quantification, biotin-streptavidin interactions, and 
chelates for immobilized metal affinity chromatography (IMAC) 33-35.  In total, these 
attributes make the utilization of the C-CP fibers for exosome isolation a promising 
alternative to traditional isolation methodologies. 
This study describes the first successful use of the PET C-CP fibers to isolate and 
elute exosomes via a hydrophobic interaction chromatography (HIC) protocol.  The 
procedure, first developed for protein separations 27, is readily implemented to isolate 
exosomes from from host cell proteins and concomitant components present in cell 
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culture media, phosphate buffer, and urine.  The hydrophobic exosome surfaces adhere to 
the weakly-ionized surfaces of the PET fibers, making HIC a selective method of 
exosome isolation.  Use of an HIC approach, involving an inverse salt gradient for 
elution, is much preferred over a common reversed-phase (RP) method as organic 
solvents employed in RP might result in the loss of important species (e.g. proteins) 
adhered to the exosome surfaces.  It is important to note that while hydrophobic 
substrates have been used in previous exosome assay methods such as the Qiagen 
exoEasy Kit, use of a truly chromatographic method holds the promise for higher 
throughput and sampling/analysis of other matrix components such as host cell proteins 
as retentates can be selectively eluted.  Such advantages would be the same as argued in 
any case of solid phase extraction versus liquid chromatography.  
In order to investigate the ability of the C-CP fibers to isolate exosomes, 
Dictyostelium discoideum cells were used to generate generic exosomes. D.discoideum is 
not only simple and inexpensive to culture in the lab, but it is also a model organism used 
for studying cell signaling, the endocytic pathway, and generation of extracellular 
vesicles and exosomes 36, 37.  Under normal conditions, it is a common single-cell, soil-
dwelling amoeba; however, under environmental stress, such as lack of water and 
nutrients, its cells can form multi-cellular aggregates, the formation of which require 
direct cell-to-cell communication 37.  The ease with which Dictyostelium discoideum can 
be cultured, the prominent role of cellular communication in its life cycle, and its use as a 
model organism for exosome research, make it a useful organism for generating 
exosomes needed to investigate isolation techniques.  
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  In this demonstration study, the efficacy and efficiency of the new HIC C-CP 
fiber exosome isolation methodology are compared to two commonly utilized exosome 
isolation methods, standard differential centrifugation (DC), as it is the most widely used 
isolation method, and the exoEasy Maxi Kit (QIAGEN), as it is the most similar 
commercially-available method to the proposed HIC C-CP fiber approach 38.  The kit 
method uses post-centrifugation, spin-down processing and a membrane-based stationary 
phase to affect an “affinity” (presumably a hydrophobic interaction) binding step to 
isolate exosomes and other EVs from serum and plasma, or cell culture supernatants.  
There is no selectivity with regards to size or cellular origin of the EVs.  It relies on 
generic characterstics of the vesicle surfaces to capture all forms of EVs in the sample.  
The implementation of a chromatographic (flow through) approach versus the spin-down, 
solid phase extraction (SPE) approach, would seem to present a number of potential 
advantages.  These attributes are highlighted herein.  The utility of the C-CP fiber HPLC 
separation is further demonstrated by investigation of recovery of exosomes from 
simulated urine and standard cell culture media.   
 
Materials and methods 
Exosome Expression by Dictyostelium discoideum 
 Dictyostelium discoideum AX2 cells (provided by L. Temesvari, Clemson 
University) were grown and maintained axenically in HL5 medium supplemented with 
100 µg mL-1 ampicillin at room temperature in 25 mL culture flasks 39.  Cells were 
passaged at 70-90% confluency.   
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 For exosome expression, AX2 cells were used to inoculate 50 mL of HL5 media 
supplemented with 100 µg mL-1 ampicillin at a starting cell concentration of 5 – 10 x 105 
cells mL-1 in a 250 mL Erlenmeyer flask. After inoculation, the flask was covered in 
aluminum foil to block out light and placed on a shaker (150 RPM, 22˚C) for 48 hours 37.  
Isolation of exosomes via differential centrifugation and Qiagen exoEasy Kit 
Two widely accepted methods of exosome isolation, differential centrifugation and 
the Qiagen exoEasy Maxi Kit, were chosen as benchmarks for comparison to the 
proposed PET C-CP HIC isolation method. These specific methods were chosen because 
differential centrifugation is one of the most widely used methods for exosome isolation 
and the exoEasy Maxi Kit is most like the PET C-CP HIC isolation method in terms of 
being an exosome/surface adhesion process. While differential centrifugation is the most 
utilized method of exosome isolation, it can sediment host cell proteins along with 
exosomes. The process is also time consuming, and requires expensive equipment 18-20, 24.  
The Qiagen exoEasy Maxi kit uses a membrane-based affinity column to separate 
exosomes and other extracellular vesicles from solutions, in much less time in 
comparison to differential centrifugation; however, the process still takes up to 30 
minutes to complete and costs approximately $32 per sample 40.  Another shortcoming of 
the exoEasy method is the high carryover of host cell proteins along with the derived 
exosomes. 
 All resulting differential centrifugation and exoEasy kit exosome isolations were 
resuspended in either PBS or Qiagen elution buffer and subsequently divided into two 
aliquots. One aliquot of each sample was used for nanoparticle tracking  analysis (NTA) 
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for the determination of exosome concentration and size distribution, while the other was 
used as a concentrated exosome sample during the initial testing of the HIC C-CP fiber 
isolation method.  
Differential centrifugation  
Differential centrifugation retrieval of D. discoideum derived exosomes was 
conducted as previously described by Tatischeff et al., with slight modifications 41.  Due 
to the novelty of D. discoideum in exosome research, all centrifugation steps followed 
previous research completed by Tatischeff et al., rather than standard mammalian cell 
exosome isolation ultracentrifugation protocols.  All centrifugation steps performed 
below 12,000Xg were performed using an Eppendorf Centrifuge 5430R (Eppendorf, 
Hamburg, Germany).  Centrifugations of 12,000Xg or more were performed using a 
Beckman Coulter Avanti J-26S XPI Centrifuge with a JA-25.50 rotor (Beckman Coulter, 
Brea, CA). The first centrifugation step was performed at 700Xg (5 min., 22˚C) in a 50 
mL conical centrifuge tube.  After centrifugation, 45 mL of the supernatant was 
transferred to a new 50 mL conical centrifuge tube for further centrifugation, with the 
remaining 5 mL of supernatant saved for exosome isolation via the C-CP HIC method. 
The second centrifugation was performed at 2,000Xg (10 min., 22oC.) The final 
centrifugation step was performed at 12,000Xg (30 min., 4oC.)  The supernatant was 






Qiagen exoEasy Maxi Kit  
The QIAGEN exoEasy Maxi kit (QIAGEN, Hilden, Germany) isolations were 
accomplished per the manufacturer’s instructions. All of the centrifugation steps required 
by the kit were performed using an Eppendorf Centrifuge 5430R.  Briefly, 10 mL of the 
D. discoideum cell growth media prepared for exosome isolation were filtered using a 0.8 
µm syringe filter.  An additional 1 mL of the remaining media was filtered using a 0.8 
µm syringe filter and set aside for exosome isolation via the C-CP HIC method. The 
resulting exosomes were eluted using 400 µL of the Qiagen XE elution buffer and stored 
at 4oC. 
Hydrophobic interaction chromatography (HIC) method 
The poly(ethylene terephthalate) (PET) C-CP fibers were produced by the 
Materials Science and Engineering Department, Clemson University. All solvents were 
purchased from EMD (EMD Millipore, Billerica, MA).  Ammonium sulfate ((NH4)2SO4) 
and all other chemicals and proteins were purchased from Sigma-Aldrich (St. Louis, 
MO). Deionized water (DI-H2O) was secured from a Milli-Q water system. The 
chromatographic exosome separations were performed on a Dionex Ultimate 3000 HPLC 
system, LPG-3400SD Quaternary pump, and MWD-3000 UV–vis absorbance detector 
(Thermo Fisher Scientific, Waltham, MA).  A Rheodyne model 8125 low dispersion 
injector with 20 and 60 μL injection loops was used for exosome sample injections.  
The PET C-CP fiber microbore columns (column length: 200 mm, i.d., 0.762 mm 
PEEK, 450 fibers) prepared as described previously 28, were used for the exosome 
separations.  After flushing the column with Buffer C (10 mM potassium phosphate 
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buffer; pH = 7.4), it was equilibrated with Buffer A (1.8 M (NH4)2SO4 solution dissolved 
in PBS; pH = 7.4). As previously described in research regarding antibody purification 
using HIC, appropriate amounts of organic additives (such as methanol and acetonitrile) 
in the elution buffer demonstrate improved protein recovery 42-44.  As such, 30% 
acetonitrile (v/v) dissolved in PBS was employed as buffer B.  A mobile phase flow rate 
of 0.5 mL min-1 and a 20 min gradient from 100% buffer A to 100% buffer B was used 
for exosome separation. Briefly, exosome samples were injected onto the column during 
the high-salt (buffer A) mobile phase. Under these conditions, latent HCPs and exosomes 
are adsorbed to the PET fiber media, with the gradient subsequently eluting species of 
increasingly greater hydrophobicity.  UV absorbance at 216 nm was monitored as a 
means of detecting the eluting species (proteins and exosomes).  Based on the detector 
response reflecting their elution, purified exosomes were collected post-column.    
HIC elution and isolation of exosomes from simulated urine and standard cell culture 
media 
In order to demonstrate the HIC C-CP column isolation of exosomes from body 
fluids, and to assess the potential quantitative aspects of the exosome isolation method, 
previously isolated exosomes were spiked into a simulated urine matrix (194 g urea, 6 g 
CaCl2, 11 g Mg2SO4, and 80 g NaCl in 1 L of DI-H2O), spiked with myoglobin (Myo), α-
chymotrypsinogen A (Chymo), ribonuclease A (Ribo), bovine serum albumin (BSA), and 
lysozyme (Lyso) (0.1 mg mL-1 each), as simple representatives of the variety of proteins 
present in urine. HIC isolation of the vesicles from the simulated urine was followed by 
quantification based on the integrated peak areas of the eluted exosomes.  The gradient 
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baseline absorbance, obtained by running the gradient with no exosomes injected, was 
subtracted from the exosome-spiked separation chromatograms.     
Exosome characterization via Nanoparticle Tracking Analysis (NTA) 
Nanoparticle tracking analysis (NTA) was performed using a Nanosight 
(Malvern, Worcestershire, UK) NS500 with a 532 nm laser and 565 nm long pass cut off 
fluorescent filter (Center for Nanotechnology in Drug Delivery, UNC Eshelman School 
of Pharmacy). Samples were diluted to a concentration between 1x108 and 5x108 
particles mL-1 with 20 nm filtered PBS.  For each sample, particles moving under 
Brownian motion were recorded on video five times for 40 seconds each.  Hydrodynamic 
diameters were calculated using the Stokes-Einstein equation. 
Transmission Electron Microscopy Fixation, Staining, and Imaging 
Transmission electron microscopy (TEM) imaging was used to verify the physical 
size of single vesicles. D. discoideum differential centrifugation extracellular vesicles and 
human urine standard exosomes (Galan Laboratory Supplies, North Haven, CT) were 
fixed in 4% paraformaldehyde for 1 hour. Immediately following fixation, 5 µl of each 
sample was applied to 200 mesh formvar carbon coated copper grids (Electron 
Microscopy Sciences, Hatfield, PA) and allowed to adsorb for 5 minutes. Each sample 
grid was negatively stained with 5 µl of 2% Uranyl Acetate for 5 minutes. Grids were 
then washed 3 times in 10 µl of distilled water for 5 minutes each and allowed to dry for 
imaging. All TEM images were obtained using a Hitachi H-7600 TEM (Hitachi, Tokyo, 
Japan) in the Clemson Electron Microscopy Lab. 
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Scanning Electron Microscope Fixation and Imaging 
 The capture of intact exosomes onto the C-CP fiber surfaces was confirmed by 
scanning electron microscopy (SEM) imaging. Proprietary PET C-CP fiber-packed tips 
were produced according to a previously described method 45.  The fiber surfaces were 
wetted by flushing with 1 mL of H2O, and then rinsed in 2M (NH4)2SO4 in PBS.  100 µL 
of each sample (DC-derived exosomes, milieu or 2M (NH4)2SO4) were mixed with 2M 
(NH4)2SO4, followed by flushing through the tip (300Xg for 5 min). The prepared fibers 
were fixed in 1% osmium tetroxide for 1 hour and washed 3 times for 3 minutes each in 
distilled water to remove any excess osmium tetroxide. Next, each sample was washed in 
a 6 step gradient of ethanol-distilled water solutions starting at 50% ethanol and ending at 
100% ethanol for 3 minutes each. An additional 100% ethanol wash step was performed 
to ensure that all water had been removed from the sample. Finally, each sample was 
washed in a 50-50 hexamethyldisilazane (HMDS)-ethanol solution for 3 minutes and 
dried in 100% HMDS overnight. Samples were sputter-coated with platinum at 70 
millitorr argon for 2 minutes using a Hummer 6.2 Sputtering system (Anatech USA, 





Results and Discussion 
HIC isolation of exosomes 
In order to determine whether or not exosomes could be isolated via HIC using the 
PET C-CP fibers, aliquots of the D. discoideum-derived exosomes that had been 
previously isolated using the benchmark techniques were run on the PET C-CP columns 
with a mobile phase flow rate of 0.5 mL min-1 and a 20 minute gradient from 100% 
buffer A (1.8 M (NH4)2SO4 in PBS) to 100% buffer B (30% v/v acetonitrile in PBS).  
Figure 2.1 shows the resulting chromatograms derived from pristine HL5 media and four 
different exosome isolation lots.  In Fig. 2.1a, pristine HL5 was injected in order to 
establish a baseline chromatogram of the media components.  The detector response 
shows a broadly eluting peak from ~2 – 10 minutes, composed of a myriad of proteins 
derived from yeast extract and peptone, various salts, and sugars.  In Fig. 2.1b, exosomes 
previously isolated via differential centrifugation were injected onto the fiber column. 
The resulting HIC chromatogram displays two major peaks, a very broad band between 2 
– 11 minutes, and a fairly sharp feature reflecting more strongly retained (hydrophobic) 
species with an elution time of ~13 – 13.5 mins.  In Fig. 2.1c, exosomes previously 
isolated via the exoEasy kit were injected for HIC separation. The resulting 
chromatogram displays four prominent peaks. In this case, the first three broad peaks 
eluting within the same same time frame of 2 – 11 minutes bands in Figs. 2.1a and b.  As 
in Fig. 2.1b, a discrete feature eluting in the ~13 – 13.5 min window is seen.  Based on 
the structure of the respective chromatograms (Figs. 2.1a-c), it is not unreasonable to 
suggest that the peaks eluting between 2 – 11 minutes represent remaining HL5 media 
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components, host cell (D. discoideum) proteinaceous and genetic material, salts, and 
other small molecules left behind during the previous isolation procedures, with the later 
eluting (13 – 13.5 min) smaller, sharper peak representing exosomes.   One cannot rule 
out that there may be some EV-related material in the broad elution band, but one would 
expect that such species would be very hydrophobic in comparison to other media and 





Figure 2.1.  Representative HIC chromatograms of exosome isolation using 
using PET C-CP fibers.  Separations were performed with a mobile phase flow 
rate of 0.5 mL min-1, 60 µL aliquot injections, and a 20 min gradient from 100% 
buffer A (1.8 M (NH4)2SO4 solution dissolved in PBS; pH = 7.4) to 100% buffer 
B (30% acetonitrile (v/v) dissolved in PBS).  a) Baseline chromatogram of pristine 
HL5 media.  b) D. discoideum-derived exosomes previously isolated via 
differential centrifugation.  c) D. discoideum-derived exosomes previously 
isolated via the Qiagen exoEasy Maxi Kit.  d) D. discoideum-derived exosomes 
following centrifugation to remove cells and large debris.  e) D. discoideum-
derived exosomes following filtration through a 0.8 µm filter to remove cells 
and large debris. f) Abbreviated gradient program (injection at A (0.8 M 
(NH4)2SO4 solution dissolved in PBS; pH = 7.4), gradient initiated at t= 2 min., 




Indeed, simple Bradford assays revealed very high protein/amino acid content in 
these bands.  Further confirmation of the latter assignment is presented in particle 
tracking data and SEM images presented in subsequent sections.  These results suggest 
that the PET C-CP HIC method is effective at separating the population of exosomes 
from other chemical species inherent in the spent cell media.  Indeed, the presence of the 
broad concomitant elution bands in the HIC chromatograms reflects the non-specificity 
and carryover towards proteins, etc. that exists in the DC and exoEasy isolates.  It is 
believed that the far greater abundance of such species (based on the integrated 
absorbance of the bands) for the exoEasy case versus the DC is due to non-specific 
binding to the hydrophobic matrix versus the differential centrifugation where proteins 
and exosomes are more discretely segregated.   HIC results prove that the exosome 
fractions can indeed be readily isolated from those otherwise undesirable components, as 
in the protein carryover in the exoEasy.  Removal of such proteins would require further 
processing for both the DC and exoEasy isolation methods.  The eluted exosome 
fractions from these isolations were collected and saved for NTA.  
 To more realistically compare the efficiencies of the C-CP fiber method with the 
benchmark methods, D. discoideum cell cultures were processed in similar fashions in 
terms of removing whole cells and cellular debris.  In the case of DC,  simple 
centrifugation is the first step, while macroscale debris is filter-removed prior to exoEasy 
Kit isolation.  The resulting culture milieu solutions, having the exosomes in their native 
(relatively dilute) concentrations, were then subjected to HIC on the PET C-CP fiber 
columns using the previous gradient.  The chromatogram of the centrifuged D. 
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discoideum cell culture milieu (Fig. 2.1d), displays two prominent peaks at elution times 
of 2 - 11 and approximately 13 minutes, respectively.   The differences in retention time 
(<5 % relative) and shapes among the exosome eluents may be due to slight differences 
in the surface chemistries of the exosomes based on how they were processed prior to the 
HIC separation, especially solvent composition.  This is certainly a point for further 
investigation.   As before, the broader peak is attributed to various media components and 
cellular metabolites and debris, with the smaller second peak attributed to more 
hydrophobic species, likely exosomes.  The relative responses for the concomitant 
species and the exosomes make sense as there is apt to be more debris and proteinaceous 
material, and lower exosome concentrations, in the milieu sample than the DC isolate 
suspended in PBS.  The exosome peak from the milieu reflects their more dilute 
concentration in this stage of media processing.  The corresponding HIC chromatogram 
taken of the filtered cell culture media is structurally the same as those seen in Figs. 2.1b-
d, though with a lower relative exosome yield versus the other media components.  This 
suggests that there may be some exosome loss in the initial filtration process in the 
exoEasy kit protocol, which is not unreasonable as the filter material itself is composed 
of both hydrophobic and hydrophilic layers.   
 As in any new chromatographic method, there are many aspects of the separation 
that can be optimized.  The ability to improve the HIC method throughput is illustrated in 
Fig. 2.1f, where the initial DC milieu sample was injected at a reduced salt concentration 
of 0.8 M ammonium sulfate.  In this way, the components making up the broad elution 
peak are not retained on the column.  Following passage of the injection peak, the reverse 
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salt gradient was then initiated, with clean elution of the exosomes.  A  simple 
comparison to the analogous full gradient (Fig. 2.1b) reveals that there is little or no 
difference in the exosome recovery for the abbreviated gradient method.  Thus, there is 
an expectation  that further improvements in throughput may be realized.  Certainly, 
larger column formats would also improve processing speeds. 
Comparison of exosome recoveries for the different isolation methodologies 
 NTA is a widely-accepted method for the evaluation of exosome concentration 
and size distribution, and so was used to characterize the exosome isolation from the DC 
and exoEasy kit procedures and those of the exosome fractions from the HIC isolations.  
Figure 2.2 provides a graphic overview of the procedural steps and NTA-determined 
exosome concentrations for each exosome isolation protocol.  The initial entrees into the 
flow charts (starting milieu volumes) were chosen based on previous experience in the 
use of DC and exoEasy methods, with the ultimate particle densities normalized to a 
common 50 mL volume sample. 
Since all particles counted during the NTA may not be exosomes (protein 
aggregates, other classes of extracellular vesicles, including microvesicles, and other 
cellular debris would also be counted), the resulting values (presented as particles-per-
mL) in Fig. 2.2 should be compared to one another on an order-of-magnitude basis as 
opposed to absolute values.  When compared in this manner, it can be seen that the 
differential centrifugation (Fig. 2.2a) and exoEasy kit (Fig. 2.2b) yield comparable 
exosome/particle recoveries.  Figure 2.2 also shows that the PET C-CP HIC exosome 
isolation method, regardless of whether the cell culture was first centrifuged (Fig. 2.2c) or 
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filtered (Fig. 2.2d) to remove cells and large debris, yields the same order of magnitude 
values as the benchmark methods following the initial debris removal steps.  
The particle size distributions, as measured by NTA, were also very similar across 
all of the isolated exosome samples, regardless of the isolation method (Table 2.1).  In 
general, the D. discoideum exosome size distributions were very similar to those 
previously reported by Tatischeff et al.41   Histograms of the NTA size distributions (Fig. 
2.3) each contained a prominant high concentration peak on the lower range of the size 
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Figure 2.2. Comparison of NTA-determined particle population 
characteristics following the various exosome isolation methodologies.  All 
values were normalized to number of particles (exosomes) derived from 50 mL 
of starting cell culture. Reported values are averages from triplicate isolations. 
a) Exosomes isolated via differential centrifugation. b) Exosomes isolated via 
Qiagen exoEasy Maxi Kit. c) Cell culture media cleared of cells and large 
debris via centrifugation, followed by exosome isolation via PET C-CP HIC. d) 
Cell culture media cleared of cells and large debris via filtration, followed by 




distribution scale ranging from  ~90  to  160 nm, typically representing ~70 % of the total 
population.  Beyond this, a minor, larger-sized fraction is also seen in each distribution, 
most prominently in the DC-generated populations.  These populations reflect protein and 
exosome agglomerates, as well as other classes of extracellular vesicles, including 
microvesicles, which would be most expected in the case of differential centrifugation.  
  
 Such populations would also reflect the time-lag associated with sampling, packaging, 
and shipping of the materials for NTA characterization.  Performing NTA/SEM/TEM 
measurements immediately following exosome isolation may help remediate the level of 
potential exosome or protein aggregation. Collectively, the NTA results demonstrate that 
the PET C-CP fiber exosome isolation method does not adversely bias exosome 
population recoveries (density or sizing) versus the benchmark isolation methods.    
As a final point of comparison, Fig. 2.2 also demonstrates the isolation time 
Table 1.  Comparison of exosome size population characteristics for the different isolation 
procedures as determined by NTA.  Values represent averages for triplicate isolations. 
 
 










  90th             
Percentile  
(nm) 
Differential centrifugation 183 143 66.3 119              257 
Qiagen exoEasy Maxi kit 154 97.1 80.2 87.6              263 
Centrifuged milieu +  
          PET C-CP fibers  
155 121 60.1 106             228 
Filtered milieu +  
          PET C-CP fibers  
142 108 60.4 87.6             206 
Table 2.1 Compariso  of EV size population characteristics for the different 
isolation procedures as determined by NTA 
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required for each of the processes.  Differential centrifugation is the most time-
consuming method, requiring more than 2 hours to perform (Figs. 2.2a).  In comparison, 
the exoEasy kit requires approximately 30 minutes (Figs. 2.2b), while the PET C-CP HIC 
method can be affected in only 8 minutes (Figs. 2.2 c,d).  The C-CP fiber-based method 
is appreciably faster than either benchmark method, a major asset with regards to its 
potential usefulness for exosome isolation in a clinical setting.   Indeed, the HIC method 
could be easilly affected in less than 3 minutes with the use of a step-gradient program as 





Imaging of exosomes adsorbed onto C-CP fibers 
While the size distributions of the D. discoideum EVs were very similar to those 
previously reported by Tatischeff et al. 38, the standard method of verifying the presence 
of EVs or exosomes generally includes NTA size distribution results in conjunction with 
Western Blot verification of the presence of known exosomal protein markers, and a 
TEM micrograph to visualize and verify sizes of individual vesicles. However, this trio of 
a b
c d
Figure 2.3. Representative nanoparticle tracking analysis (NTA) size 
distributions. a) differential centrifugation, b) Qiagen exoEasy Maxi kit, c) 





verification methodologies is for mammalian cell‐derived exosomes, where exosomal 
marker proteins have been verified and antibodies to these proteins are commercially 
available. To this end, no commercial antibodies exist for D. discoideum EV surface 
proteins. Therefore, we rely herein upon the resultant NTA data in combination with 
TEM micrographs of the commercially available exosome standards as compared to D. 
discoideum EVs resulting from the differential centrifugation method employed for 
isolation throughout this study (Fig. 2.4).  
The resulting micrographs show that the sizes and general morphology of the 
standard exosomes and those exosomes derived from D. discoideum are very similar. 
Figure 2.4. TEM images of exosomes immobilized on copper grids. (Left) 
Standard exosomes derived from human urine (Right)  D. discoideum-derived 




Therefore, we contend that the differential centrifugation method employed resulted in 
the isolation of D. discoideum exosomes. These purified exosomes were subsequently 
utilized to produce SEM images of the exosomes on the experimental columns as 
outlined below. 
 SEM images were collected to verify the presence and integrity of the exosomes 
and to investigate how they interact with the PET C-CP fiber channels.  Exosomes that 
had been isolated from D. discoideum cell culture media via differential centrifugation 
a b
c
Figure 2.5. SEM images of exosomes immobilized on PET C-CP fibers. a) 2M 
ammonium sulfate control (no exosomes exposed).  b)  D. discoideum-derived 
exosomes previously isolated via differential centrifugation. c)  Higher 
magnification image of exosomes depicted in micrograph b, showing detail of 




and re-suspended in PBS were added to 2M ammonium sulfate chromatographic mobile 
phase and then each spun through PET C-CP fiber micropipette tips using the described 
solid phase extraction technique.33, 45  In addition, 2M ammonium sulfate was spun 
through a separate tip as a non-exosome control.   
In each case, an aqueous wash step was employed following exposure to remove 
any accumulated media particulates.  As seen in Fig. 2.5a, the fibers exposed only to the 
salt media show a very smooth surface, with multiple channels of the same fiber seen at 
this 10 µm-scale micrograph.  Passage of the DC–derived media through the fibers 
results in the adsorption of vesicle material as seen in Fig. 2.5b (2.0 µm-scale).  A large 
number of vesicles are present as individual entities, but some appear as aggregates.  It 
remains to be confirmed whether or not the agglomerates were formed on the fiber 
surface or originated in the milieu.  Further magnification of the DC-derived aliquot (Fig. 
2.5c, 500 nm scale) shows exquisite detail of individual exosomes, with diameters of 100 
nm or less, on the PET fiber surfaces with some neighboring exosomes touching one 
another, perhaps stretching or elongating as they adhere to the fiber.  This morphology 
could be early signs of aggregation or exosome fusion.  While the SEM imaging 
demonstrates the phenomenon of the immobilization of the exosomes on the fiber 
surfaces, it also suggests that the fiber platform might be a valuable means of studying 
exosome agglomeration or other phenomena. 
Isolation of exosomes via HIC from a simulated urine matrix 
Following verification that exosomes could be isolated directly from D. discoideum 
culture milieu, the ability to isolate exosomes from synthetic urine (an ability needed for 
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diagnostic applications) was investigated.  For this experiment, exosomes that had been 
previously isolated via differential centrifugation were spiked into a simulated urine 
matrix which was also spiked with the model proteins Myo, Chymo, Ribo, BSA and 
Lyso, each at a concentration of 0.1 mg mL-1.  In this way, isolation from both urine 
matrix components and concomitant proteins is demonstrated using the same HIC 
gradient as employed in the Fig. 2.1 separations.  Figure 2.6 shows the HIC 
chromatogram of the simulated urine matrix to establish baseline elution times for the 
matrix components and the spiked proteins.  The five proteins are very well resolved in 
this case, with the other matrix species eluting as a band over the 8 – 10 min elution 
window.  As seen in Fig. 2.6, when the simulated urine was spiked 50:50 with DC-
isolated exosomes and subsequently run on the C-CP columns, HIC revealed the 
expected peaks for the spiked proteins along with an additional, later-eluting prominent 
peak attributed to the exosomes.  Importantly, the added proteins appear as discrete peaks 
superimposed on a broader peak previously attributed to remnant proteins and debris 
associated with the spiked exosomes following their DC-isolation (Fig. 2.1b).   (The 0.1 
mg mL-1 concentrations spiked here are clearly higher than those present from the spiked, 
equal-volume, milieu isolate.)  The ability to cleanly separate exosomes from other 
species in a urine matrix suggests that C-CP fiber HIC (or simple solid phase 












Figure 2.6.  PET C-CP fiber HIC chromatograms of simulated urine matrix 
spiked at 0.1 mg ml-1 concentration of model proteins and 50:50 mixture of 
simulated urine and DC-isolated exosomes. Separations were performed with 
a mobile phase flow rate of 0.5 mL min-1, 20 µL aliquot injections, and a 20 min 
gradient from 100% buffer A (1.8 M (NH4)2SO4 solution dissolved in PBS; pH = 




Potential for Exosome Quantification 
In order to make exosome retrieval easier to verify and potentially quantify, a 
simple measure of recovery is needed.  In the context of the HPLC isolation step, UV-vis 
absorbance at 216 nm is a viable approach.  This is a common wavelength used in protein 
chromatography, and fortuitously, the exosomes absorb at this wavelength.  It is most 
common to quantify exosomes based on lysing the vesicles and quantifying the total 
protein content via Western blot separations or a Bradford-type assay, or counting/sizing 
particles via NTA.  Of course, this assumes no protein carryover in the isolation step, the 
protein content in each exosome is the same, and no extraneous cellular debris is present.  
Hook and co-workers have employed a surface plasmon resonance (SPR) approach to 
quantification 46, wherein target proteins are captured onto a gold substrate through a 
surface immobilized antibody.  Solution concentrations were extrapolated from first 
principles relationships, but not verified by any external standards.  To establish a 
quantitative relationship between exosome concentration and absorbance, increasingly 
larger aliquots of exosomes (previously isolated via DC) were added to 100 µL aliquots 
of the simulated urine and the culture milieu (HL5) matrices, and the integrated 
absorbance values for the peaks eluting between 13 - 14 minutes were recorded.  As 
shown in Fig. 2.7, a direct proportionality exists, suggesting quantitative recovery of 
exosomes from the C-CP fiber separation method.  While the robustness of the method as 
employed here requires far greater evaluation, the results plotted in Fig. 2.7 represent a 
total of 24 and 15 injections of the respective samples (urine and media), each on a single 





regarding the analytical precision.  This suggests insignificant carryover or irreversible 
binding of the exosome solutes.  The number of cycles that milieu-derived samples might 
be run is a more stringent and practical metric which is currently under review.   
Importantly, the slopes of the two response curves are virtually identical, 
implying that the purity of the isolated fractions is very consistent between the two matrix 
forms.  Note, we are in no position to place firm concentration values on the results of 
these experiments, as no appropriate certified reference materials (CRMs) exists.  
Sources of quantified exosomes will be investigated to provide more definitive figures of 
Figure 2.7.  Analytical response curves for separations of mixtures of 100 
µL of the test matrices (simulated urine and HL5 media) and the 
designated volumes of DC-isolated exosomes.  Separations were performed 
with a mobile phase flow rate of 0.5 mL min-1, 20 µL aliquot injections, and a 
20 min gradient from 100% buffer A to 100% buffer B.  Error bars reflect the 




metrics.  Based on the NTA values presented in Table 2.1, the working range presented in 
Fig. 2.7 is ~0.1 – 7 X109 particles for the 20 µL injections.  Accordingly, it is not difficult 
to imagine limits of detection for this method to be approximately 5 X107 particles.  Of 
course, UV-vis absorbance post-column quantification could also be applied for 
preparative purposes.  One could also envision other LC-compatible detection methods, 
for example, multi-angle light scatter (MALS), which would also provide size 
information for the eluting particles. 
Conclusions 
In order for  basic research and potential application of exosomes to continue to 
grow, lower cost, more time-efficient methods of exosome isolation are needed.  This 
report introduces a promising new isolation platform using PET C-CP fibers as stationary 
phases for HIC isolation of exosomes.  The method isolates exosome populations of 
similar number density and size distribution as currently accepted isolation methods 
involving advanced centrifugation or solid phase extraction.  The fiber platform is 
inexpensive ($5 USD per column which can be used >20 times on the analytical scale), 
while providing comparatively high throughput.  Additionally, the versatility of the C-CP 
fibers will allow for the addition of antibodies, surface chemistries, and other isolation 
modalities to transform the generic (hydrophobic interaction) exosome isolation method 
demonstrated here into a type-specific method.  In an alternative approach, the fibers may 
be used in spin-down column format (i.e., micropipette tips) to isolate exosomes from 
body fluids such as urine 47, providing high purity, high throughput, and cost-effective 
exosome isolation for potential clinical use.   Selective capture can be augmented with 
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spectroscopic or visual imaging as means of verifying the presence of target exosome 
species on the fiber surfaces.   
Much fundamental work remains towards realizing the practical utility of the 
method on the clinical, analytical, and preparative scales.  Each of these areas will pose 
challenges and require evaluation regarding selectivity, robustness, loading capacity, 
throughput, and column structure/operation parameters.  Many basic challenges towards 
this end remain.  For example, there exist no reference materials which contain 
quantitative amounts (either mass or number) of exosomes in defined media.  Ultimately, 
the potential impact of exosomes in modern medicine is a tremendous driving force for 
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A MODEL SYSTEM TO INVESTIGATE SELECTIVE 
EXTRACELLULAR VESICLE CAPTURE  
Abstract 
Ovarian cancer (OC) is one of the deadliest cancers for women, in part due to its 
often late stage discovery. Given current advanced treatment options, earlier diagnosis of 
OC could greatly improve overall survival rates. Presently, there are no routinely 
administered early OC screening techniques for non-symptomatic women. This is crucial, 
as there is no symptomology associated with early stage, and late stage OC 
symptomology is generally vague, including abdominal bloating, gastrointestinal upset, 
nausea and fatigue. Exosomes are a subpopulation of extracellular vesicles (EVs) 
approximately 30-150 nm in diameter that may hold promise for the development of 
early OC diagnostics. However, despite promising studies, exosome diagnosis has been 
mainly limited to research laboratories primarily due to inconsistencies in isolation and 
characterization methodologies. The poly(ethylene terephthalate) (PET) capillary‐
channeled polymer (C‐CP) fiber-based EV isolation platform, discussed in Chapter 2, 
may result in quicker, cheaper, and easier exosome isolations, but requires refinement to 
improve the selectivity, specificity, and diagnostic accuracy required for clinical OC 
diagnostics. The model system of cancerous and non-cancerous fluorescent EVs and the 
immunoaffinity capture protocol developed and analyzed here will allow for quicker and 
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easier development and optimization of a selective PET C-CP EV isolation platform for 
use in OC diagnostics.  
These investigations include collaborative work with Dr. Ken Marcus of the 





Late stage diagnosis of severe maladies, particularly cancers, has led to poor 
outcomes and high mortality among patients.1-3 Early diagnosis of these diseases, 
regardless of treatment strategies, can greatly increase survival and outcome for patients. 
For example, patients with melanomas, if diagnosed early, have an average 5-year 
survival rate of 98%. However, when the patient is diagnosed late and melanoma reaches 
the lymph nodes or metastasizes to other organs during later stages, the 5-year survival 
rate drops to 64% and 23%, respectively.4 Likewise, pancreas, lung, ovarian, and breast 
cancer, among others, demonstrate similar 5-year survival patterns.3, 5-13 Improvements in 
early diagnosis and standardization of preventative screening are crucial components in 
improving cancer survival rates.  
Exosomes, a type of extracellular vesicle (EV), have recently garnered attention 
as diagnostic tools and have several unique properties that make them ideal candidates as 
biomarkers for early cancer diagnostics. First, as exosomes appear to be selectively 
packaged with particular contents, including exosomal protein, lipid, and RNA markers, 
they may be identified and traced back to the originating cell.14, 15 In particular, protein 
marker identification and miRNA expression pattern recognition through advanced data 
analysis may help develop exosome marker profiles for particular diseased cell-derived 
exosomes.5, 16, 17 Second, exosomes are released by nearly all types of cells and are found 
in nearly all types of body fluids.18 The ability to identify the same category of biomarker 
from nearly all cell types may allow for development of a universal test to screen for a 
multitude of diseases. Furthermore, a wide variety of body fluids from which to isolate 
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EVs provides flexibility with regards to the types of exosome isolation methods that may 
be utilized. Finally, exosomes are very stable and can protect protein and RNA contents 
from protease and RNase degradation.19-21 This high exosome stability may allow for the 
use of more severe isolation methods to enhance the speed and lower the cost of exosome 
isolations. In addition, this quality makes them a more reliable species for use in liquid 
biopsies than free DNA and RNA species that may be easily degraded.22  
To date, the full potential of exosome-based diagnostics has yet to be realized in 
clinical trials. However, several groups have developed promising exosome-based 
diagnostic platforms using protein and miRNA markers. For example, Zhao et al. have 
developed a microfluidics device that uses microbeads to capture and identify ovarian 
cancer (OC) exosomal protein markers.23 Similarly, Yokoi et al. have developed an 
analytical method to better diagnose OC using a combination of 8 exosome miRNAs with 
a sensitivity of 0.92 and a specificity of 0.91.16 As evidenced by these studies, OC has 
emerged as a desirable exosome diagnostic target due to its morbidity and the diagnostic 
difficulties associated with the disease. OC, when diagnosed in stage 3 or 4, has a 5 year 
survival rate of 29%. However, when OC is diagnosed and treated in stage 1, the 5 year 
survival rate is 92%.24 Unfortunately, due to lack of effective diagnostic technologies and 
indistinct early symptomology, most OC cases are diagnosed in stage 3 or 4.25, 26 
Exosome-based diagnostics may provide an opportunity for early stage OC detection, 
allowing treatments to be started earlier and potentially increasing the overall survival 
rate of OC patients. 
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There is now an ongoing effort to identify the patterns of protein and miRNA 
expression within malignant tumor-derived exosomes to establish biological pathways 
and discover new potential cancer biomarkers. By utilizing mass spectroscopy-based 
proteomics and miRNA sequencing analysis in conjunction with machine learning and 
pattern recognition algorithms, exosome expression patterns are being identified and 
categorized by cancer type, stage, malignancy, origin, and pathology.5, 27-39 As the 
available data continues to amass, more patterns that can be used for diagnosis will 
emerge. However, the quickly changing classifications, isolations, and terminologies 
surrounding exosomes and EVs may require that these analyses be revisited. Despite 
these early challenges, it is anticipated that the differentiation of cancerous and non-
cancerous exosome expression patterns from this data will ultimately be an important 
step in the development of quick, easy, and non-invasive exosome-based cancer 
diagnostics.  
Complete exosome proteomes and miRNA profiles are excellent for identification 
of proteins and miRNAs enriched in cancerous exosomes, but not realistic for affordable 
and efficient clinical diagnostics. Development of comprehensive proteomes and miRNA 
profiles is expensive, time consuming, and would require extensive data analysis 
amounting to long time periods passing between sample collection and diagnosis. A 
much simpler, cheaper, and faster strategy has been to utilize identified enriched protein 
and miRNA exosomal biomarkers to capture subpopulations to determine the origins of 
the exosomes.18, 22, 36, 37, 40-43 Through these kinds of  efforts, OC tumor cells have been 
found to release exosomes enriched in protein biomarkers including, EpCAM (epithelial 
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adhesion molecule), CA-125 (cancer antigen 125), CD24 (cluster of differentiation 24), 
HER-2 (human epidermal growth factor receptor 2), CLDN3 (claudin 3), CLDN4 
(claudin 4), L1CAM (L1 cell adhesion molecule), EGFR (epidermal growth factor 
receptor), PCNA (proliferating cell nuclear antigen), TGF-β1 (transforming growth factor 
- β1) , MAGE3/6 (melanoma antigen gene 3/6), FASN (fatty acid synthase), ERBB2 
(receptor tyrosine-protein kinase), and APOE (apolipoprotein E).43-47 Furthermore, 
antibodies to these biomarker proteins have demonstrated the ability to specifically 
capture and/or identify subpopulations of exosomes for potential disease diagnostics. 
Despite the promising medical applications and biomarker discovery underway, 
reliable exosome isolation remains a large hurdle for their use in diagnostics.18, 48-52 Slight 
variations in exosome isolation methods can greatly alter both the exosome proteome and 
miRNA profile40, 52-54, making comparisons across datasets difficult. Additionally, 
different exosome isolations may alter the integrity of the vesicles and their contents, 
further contributing to alterations in proteome and miRNA signatures.22, 36, 55 Although 
the EV community is working to create standards to increase consistency across the field, 
there remains a need for an improved exosome isolation method that can become a 
dominant protocol within the field. Current standards and commercially available 
isolation methods are often expensive, slow, inefficient, or retain non-exosomal 
impurities, making them unreliable in a clinical setting. A diagnostic test for early OC 
needs to be quick, easy, and cost effective so that it can be performed routinely as a 
preventative screening tool for women. Additionally, diagnostic accuracy has yet to be 
verified for each type of exosome isolation. Developing an improved exosome isolation 
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method that preserves exosome stability and integrity for downstream analysis is not only 
critical for clinical translation but will also improve the accuracy, speed, and cost of 
research laboratory protocols. 
To increase the signal to noise ratio inherent in discovery of exosomal markers 
and further improve diagnostic accuracy, it will be essential to efficiently separate 
exosomes from healthy and diseased sources. Immunoaffinity capture will almost 
certainly play a large role in this; however, differentiating capture of healthy and diseased 
exosome populations may prove difficult. The separation will likely require time 
consuming, costly protein assays to verify the results of each test and involve variable 
and costly patient samples. Alternatively, model systems are frequently used to speed up 
the protocol optimization process and reduce costs for early research. In this case, a 
model system of cancerous and non-cancerous cell lines capable of producing 
fluorescently-labeled exosomes would enable efficient optimization of the poly(ethylene 
terephthalate)(PET) capillary-channeled polymer (C-CP) fiber-based EV isolation 
platform, developed by Bruce et al.56, for use in OC diagnostics. This study details the 
development and analysis of two new cells lines, one cancerous and one non-cancerous, 
that constitutively express fluorescently-tagged exosomal marker proteins that allow for 
simple, colorimetric-based differentiation between their individually released exosomes. 
As there are several known exosomal OC protein biomarkers and OC is a prime 
target for exosome-based diagnostics, cancerous (SKOV-3) and non-cancerous (IHOE) 
ovarian cell lines were selected for the development of a model system for the production 
of fluorescently-labeled exosomes. Each cell line was genetically transduced to express 
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known exosomal markers, CD81 and CD9, with fluorescent tags of different excitation 
and emission wavelengths (GFP and RFP, respectively). Exosomes isolated from each of 
the resulting cell lines, IHOE-CD81-GFP and SKOV-3-CD9-RFP, express fluorescent 
markers that allow for easier differentiation, separation, and detection of cancerous and 
non-cancerous ovarian cell-derived exosome populations. To test the ability of PET C-CP 
fibers to capture the model vesicles and to check for any potential adverse effects of the 
fluorescent tags on the binding of the exosomes to the fibers, IHOE-CD81-GFP and 
SKOV-3-CD9-RFP exosomes were used to evaluate adherence to the surface of the PET 
C-CP fibers and fluorescence images were collected. Finally, in a proof-of-concept 
investigation aimed at future efforts for the direct translation to OC diagnostics based 
upon the new PET C-CP fiber-based EV isolation platform, antibodies to known 
universal exosomal biomarkers and exosomal OC biomarkers were used to capture pre-
enriched IHOE-CD81-GFP and SKOV-3-CD9-RFP exosomes on nitrocellulose 
membranes to demonstrate the specific capture of the cancerous and non-cancerous 
fluorescent exosomes. By utilizing these model cancer and non-cancer cell-derived 
exosomes, the accuracy, selectivity, and specificity of the new PET C-CP EV isolation 
platform may be studied without the need for more costly and difficult to obtain patient 
samples. With improvements as a result of the fluorescent exosome model system 
developed here, this diagnostic platform may be optimized for the identification of early 
stage ovarian cancer and hopefully provide a quick, easy-to-use, and inexpensive tool for 
routine and early ovarian cancer screening in the future. 
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As the EV research field expands, experts have expressed a growing concern that 
vesicles referred to generically as exosomes may actually be a mix of EV subtypes. Due 
to the complex debate surrounding EV classification and nomenclature currently 
underway, all EVs discussed herein will be referred to as small EVs (sEVs) rather than 
exosomes specifically. 
 
Materials and Methods 
Cell and culture conditions 
 Immortalized Human Ovarian Epithelial (IHOE) cells (Applied Biological 
Materials, Richmond, BC, Canada) were maintained in Prigrow I medium (Applied 
Biological Materials, Richmond, BC, Canada) supplemented with 10% exosome-depleted 
fetal bovine serum (FBS) (A2720801, Thermo Fisher Scientific, Waltham, MA), 100 
IU/mL penicillin and 100 µg/mL streptomycin at 37˚C and 5% CO2. Human ovarian 
adenocarcinoma epithelial SKOV-3 cells (ATCC, Manassas, VA) were maintained in 
McCoy’s 5a Medium Modified supplemented with 10% exosome-depleted fetal bovine 
serum (FBS), 100 IU/mL penicillin and 100 µg/mL streptomycin at 37˚C and 5% CO2. 
Additionally, IHOE-CD81-GFP and SKOV-3-CD9-RFP cells were supplemented with 
puromycin at a concentration of 2.5 µg/mL to maintain selection. All cells were passaged 
at 70-90% confluency.  
SKOV-3 and IHOE plasmid transduction and clone development 
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 Approximately 9x104 SKOV-3 and IHOE cells were seeded in each well of a 96 
well plate and incubated in media supplemented with 10% exosome-depleted FBS for 10-
18 hours before transduction. IHOE cells were transduced using an HIV lentivector 
system pre-packaged with either pCT-CD81-GFP or pCT-Cyto-GFP plasmid (CYTO124-
VA-1, CYTO118-VA-1, System Biosciences, Palo Alto, CA). SKOV-3 cells were 
transduced using an HIV lentivector system pre-packaged with either pCT-CD9-RFP or 
pCT-Cyto-RFP plasmid (CYTO123-VA-1, CYTO119-VA-1, System Biosciences, Palo 
Alto, CA). Both cell lines were transduced at a multiplicity of infections (MOI) of 1, 2, 5, 
and 10 using the TransDux MAX Lentivirus Transduction Reagent (LV860A-1, System 
Biosciences, Palo Alto, CA). After 72 hours of incubation at 37˚C and 5% CO2, cells 
were screened for fluorescence using a GE INCell Analyzer 2500HS (General Electric, 
Boston, MA), and cell culture media was replaced and supplemented with 2.5 µg/mL 
puromycin for selection. All cells were incubated for 7-14 days until stable transduction 
produced confluent polyclonal cultures. Afterward, dilution cloning was used to obtain 
single cells for the development of monoclonal stable cell lines. 
Small extracellular vesicle isolation using ultracentrifugation 
 All SKOV-3 and IHOE cells were cultured in Falcon 75 cm2 cell culture flasks 
with vented caps (Corning, Corning, NY) to approximately 80% confluency and 
replenished with fresh media. Cultures were incubated for 3 days and then conditioned 
media was collected for sEV isolation. sEV isolation was performed in a series of 
differential centrifugation steps starting with 45 mL of conditioned cell culture media. 
Using an Eppendorf Centrifuge 5430R (Eppendorf, Hamburg, Germany), the conditioned 
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media was centrifuged at 700 x g for 5 minutes at 22˚C. The resulting supernatant was 
then centrifuged at 2,000 x g for 10 minutes at 22˚C. Next, the resulting supernatant was 
centrifuged at 10,000 x g for 30 minutes at 4˚C using a Beckman Coulter Avanti J-26S 
XPI Centrifuge equipped with a JA-25.50 rotor (Beckman Coulter, Brea, CA) and the 
supernatant was collected. Finally, the collected supernatant was centrifuged at 120,000 x 
g for 60 minutes at 4˚C using a Beckman Coulter Optima XPN-80 Ultracentrifuge 
equipped with a Type 45 Ti rotor (Beckman Coulter, Brea, CA) and the supernatant was 
discarded. The final pellet was then resuspended in 400 µL of phosphate buffered saline 
(PBS). 
Fixation and staining of samples for transmission electron microscopy 
 Samples being prepared for transmission electron microscopy (TEM) were first 
fixed in 4% paraformaldehyde for 30 minutes on ice. Grid adhesion, staining, and 
washing steps were performed on parafilm by moving 200 mesh copper formvar grids 
(Electron Microscopy Sciences, Hatfield, PA) from drop to drop. Following fixation, 
grids were placed on 5 µL drops of each sample for 5 minutes. Grids were washed 3 
times with DI water for 4 minutes each, stained with 2% Uranyl Acetate for 5 minutes, 
and then washed 3 times with DI water for 4 minutes each. Grids were air dried in a low-
humidity environment and then imaged using a Hitachi H7600 TEM  (Hitachi, Tokyo, 
Japan). 
Production of cell lysate 
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Approximately 2.5 – 5 x 105 cells were resuspended in 1 mL of ice-cold 1X 
radioimmunoprecipitation assay (RIPA) lysis buffer (50672585, Thermo Fisher 
Scientific, Waltham, MA) and incubated with agitation for 30 minutes. Samples were 
then centrifuged at 13,000 x g for 20 minutes at 22˚C using an Eppendorf Centrifuge 
5424 (Eppendorf, Hamburg, Germany). The resulting supernatant (lysate) was collected 
and saved for subsequent analysis. 
Protein Quantification 
All sEV and cell lysate samples were quantified using a NanoVue Plus UV-Vis 
spectrophotometer (GE Healthcare, Chicago, IL). The spectrophotometer was blanked 
between each sample using phosphate buffered saline and samples were quantified at 280 
nm absorbance according to the manufacturer’s instructions. 
SDS-PAGE and western blot analysis of extracellular vesicles and cell lysates 
All samples were separated using a 12% gel and NuPAGE XCell SureLock Mini-
Cell electrophoresis system (Thermo Fisher Scientific, Waltham, MA) under reduced or 
non-reduced conditions. Cell lysate, recombinant TurboGFP protein (EVN-FP552, 
Axxora, Farmingdale, NY), and purified RFP protein (NBP199583, Fisher Scientific, 
Hampton, NH) were used as positive controls. All gels were run at 170 mV for 
approximately 45 minutes. Wet transfer was performed using a Genie Electrophoretic 
transfer system (Idea Scientific Co, Minneapolis, MN) with a polyvinylidene difluoride 
(PVDF) membrane in 1X Towbin buffer run at 12 V for approximately 90 minutes. 
PVDF membranes were blocked in 5% non-fat milk in 1X Tris buffered saline 
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supplemented with 0.5% Tween 20 (TBS-Tween) for 40 minutes at 37°C. Blocked 
membranes were rinsed with 0.5%Tween 20/TBS, and incubated overnight at 4oC with 
primary antibody (1:2000 rabbit anti-TurboGFP (PIPA522688, Fisher Scientific, 
Hampton, NH) or 1:1000 rabbit anti-RFP (600-401-379, Rockland Immunochemicals, 
Inc., Pottstown, PA)). After washing in TBS-Tween for 1 hour at 22°C with 6 buffer 
changes, membranes were incubated with secondary 1:5000 goat anti-mouse IgG 
horseradish peroxidase (1:5000; GTXMU004DHRPX, Immunoreagents, Inc., Raleigh, 
NC) or 1:10,000 goat anti-rabbit IgG horseradish peroxidase (GTXRB003FHRPX, 
Immunoreagents, Inc., Raleigh, NC) antibody for 1 hour at room temperature. Probed 
membranes were then washed in high salt tris buffered saline supplemented with 0.05% 
Tween (TS-Tween) for 1 hour at 22°C with 6 buffer changes. Finally, protein was 
detected using the Pierce ECL Western blotting substrate kit (32106, Thermo Fisher 
Scientific, Waltham, MA) following the manufacturer’s instructions. Western blot gels 
were loaded according to the following scheme. IHOE-CD81-GFP, SKOV-3-CD9-RFP, 
IHOE, and SKOV-3 cell lysate lanes were loaded with 150 µg of protein each. IHOE-
CD81-GFP, SKOV-3-CD9-RFP, IHOE, and SKOV-3 sEV lanes were loaded with 10 µg 
of protein each. Differences in cell lysate and sEV loading amounts are to account for 
differences in concentration of the protein of interest. Finally, the purified, control tGFP 
protein lane was loaded with 50 ng of protein and the purified, control RFP protein lane 
was loaded with 40 ng of protein.   
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C-CP fiber tip assembly 
 Polymer extruded polyethylene terephthalate capillary-channeled fibers (C-CP), 
produced by the Material Science and Engineering Department at Clemson University, 
were wound on a circular frame 8 times (450 fibers) then rinsed with hot water, 
acetonitrile, isopropanol, and ultra-pure water. Wound fibers were pulled through a 30 
cm length, 0.762 mm internal diameter polyether ether ketone (PEEK)(IDEX Health & 
Science LLC, Oak Harbor, WA) tubing using a plastic monofilament. Packed tubing 
sections were attached to the end of 200 µl micropipette tips and subsequently inserted 
through pierced centrifuge tube caps for sample spin-down and wash collection. 
sEV capture and isolation on C-CP tips 
 Following C-CP tip assembly, sEV or PBS samples of 100 µl were loaded into 
the tips and spun down at 300 x g for 1 minute using an Eppendorf Centrifuge 5430R 
(Eppendorf, Hamburg, Germany). Afterward, the loaded tubing was prepared for either 
SEM or fluorescence imaging.  
C-CP Fiber sample preparation for scanning electron microscopy 
 C-CP fiber samples being prepared for SEM were fixed in 1% osmium tetroxide 
for 1 hour with shaking. After removing the osmium tetroxide, samples were washed in 
deionized water 3 times for 3-5 minutes. Next, the samples were washed in an ethanol-
water mixture of the following ethanol percentages for 3 minutes each: 50%, 70%, 80%, 
90%, 95%, 100%, 100%. The samples were then washed in a 50:50 
hexamethyldisilazane(HMDS) –ethanol mixture for 3 minutes and then washed in 100% 
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HMDS and left to dry for 2-3 days. After drying, samples were attached to a metal stage 
using adhesive and platinum coated using the Hummer 6.2 Sputtering system (Anatech, 
Battle Creek, MI) at 70 millitorr for 2 minutes. A Hitachi SU5000 Field Emission 
Scanning Electron Microscope (FE-SEM) (Hitachi, Tokyo, Japan) was used to capture 
SEM images. 
Immunoaffinity blot capture technique 
 Antibodies for turboGFP, RFP, CD63, CD24, Her2, L1CAM, and EGFR (Table 
3.1) were used to capture sEVs on nitrocellulose membranes (See Figure 3.1 for visual 
experimental setup). To prepare the membranes, 0.25 µL of each primary antibody at a 
concentration of 1 mg/mL was applied to the nitrocellulose membrane and allowed to dry 
for 1 hour. Prepared membranes were blocked with 0.5% bovine serum albumin (BSA) in 
tris buffered saline supplemented with 0.5% Tween (TBS-Tween) for 30 minutes at 37˚ C 
to prevent non-specific binding. Blocked membranes were then exposed to IHOE-CD81-
GFP and/or SKOV-3-CD9-RFP sEVs in TBS-Tween at a concentration of 125 µg/mL for 
2 hours at room temperature with shaking. Finally, membranes were washed in TBS-
Tween for 1 hour with 6 buffer changes to remove any excess sample and decrease 
background signal. Fluorescent images of membranes were captured immediately while 









Figure 3.1. Diagram of sEV immunoaffinity blot capture experimental setup. 
IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs were incubated in solution with 
antibody-dotted nitrocellulose membranes. Capture studies were performed with 
IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV samples in a) independent 
experiments and b) mixed sample experiments. Capture antibodies used in the 
complete experiment are detailed in Table 3.1. 
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Fluorescence Intensity, Super-Resolution Confocal Imaging, and Image Analysis 
 Confocal fluorescent and differential interference contrast (DIC) images 
were captured using a Leica SP8 confocal microscope with Hyvolution super-resolution 
(Leica, Wetzlar, Germany). IHOE, IHOE-Cyto-GFP, IHOE-CD81-GFP, SKOV-3, 
SKOV-3-cyto-RFP, and SKOV-3-CD9-RFP cells were seeded in 8-well, coverslip 
bottom imaging plates at a concentration of 1 – 5  x 104 cells/mL. Cells were fixed in 4% 
paraformaldehyde (EMS, Hatfield, PA) for 15 minutes at 22˚C and washed 3 times in 1X 
PBS. Cells were then stained with 300 nM DAPI (4',6-Diamidino-2-Phenylindole, 
Dihydrochloride) for 5 minutes at 22˚C and washed 3 times in PBS prior to imaging. All 
images were captured using an HC PL APO CS2 63x/1.40 oil immersion objective. DAPI 
images were obtained using 405 nm excitation (15% power; gain=50), and a gateable 
HyD detector (411-449 nm detection; time gate = 8.5-12 ns). GFP images were obtained 
using 488 nm excitation (15% power; gain=100), and a gateable HyD detector (512-564 
nm detection, time gate = 0.01-6 ns).  RFP images were obtained using 558 nm excitation 
(25% power; gain=300), and a gateable HyD detector (575-650 nm detection, timegate = 
0.08-3.58 ns).  
Relative fluorescence intensity measurements of IHOE-CD81-GFP and SKOV-3-
CD9-RFP sEVs isolated by UC and resuspended in PBS were obtained using a Biotek 
Synergy H1 Hybrid Reader (Biotek, Winooski, VT) with a 100 ms exposure time for all 
samples. The suspended IHOE-CD81-GFP sEVs were excited at 488 nm with 
fluorescence measured at 525 nm and suspended SKOV-3-CD9-RFP sEVs were excited 
at 550 nm with fluorescence measured at 590 nm. 
120 
 
All fluorescent C-CP fiber images were captured using a Leica SP8 HyVolution 
confocal microscope (Leica, Wetzlar, Germany). PET C-CP fibers prepared with samples 
were removed from the packed columns and spread evenly across a slide prior to 
imaging. All green fluorescent protein (GFP) images were obtained using a 488 nm 
excitation laser line at 25% intensity, an emission detection range from 500-541 nm, with 
a detector gain of 300, and a time gate from 0.08-3.58 ns. All red fluorescent protein 
(RFP) images were obtained using a 558 nm excitation laser line at 25% intensity, an 
emission detection range from 564-628 nm, with a detector gain of 300, and a time gate 
from 0.3-6 ns. 
Relative fluorescence intensity measurements of the dot blots on nitrocellulose 
membranes, prepared as described in the immunoaffinity blot capture technique above, 
were obtained using a Leica Thunder- Model Organism imaging system (Leica, Wetzlar, 
Germany). Single-channel images for GFP and RFP were captured using a Plan APO 
1.0X objective (0.09 numeral aperture, no immersion) with a 5x zoom for a total of 50x 
magnification (GFP - 100 ms exposure; ET GFP filter set (450-490 nm excitation/500-
550 nm detection); RFP- 2s exposure; ET mCherry filter set (540-580 nm excitation/592-
667 nm detection).  Following image capture, average relative fluorescence intensity was 
measured using ImageJ version 1.48 software (NIH, Bethesda, MD). Relative 
fluorescence intensity values were normalized to the average intensities of UC isolated 
sEVs from IHOE CD81-GFP and SKOV-3-CD9-RFP cells dotted (3 µl) on a 
nitrocellulose membrane at a protein concentration of 2,500 µg/mL and imaged under the 
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same conditions. All intensity values were adjusted using appropriate background 
subtractions.  
Statistical Analysis 
 All numeric values are presented as sample means ± 1 standard deviation. Data 
were analyzed using a one-tailed t-test (α=0.05) in Microsoft Excel’s data analysis 








Antibody Antigen Description Catalog Number 
Rabbit anti-
TurboGFP 
Brighter variant of the traditional green 






Red fluorescent protein – a commonly 






Tetraspanin involved in signal 
transduction and trafficking. Common 
sEV marker.89 





Tetraspanin involved in cell adhesion and 
migration. Common sEV marker.89 





Tetraspanin involved in cell signaling 






Sialoglycoprotein associated with 
development, invasion, and metastasis of 







Human Epidermal Growth Factor 
Receptor 2 - Tyrosine kinase receptor 
involved in cell proliferation and tumor 
cell metastasis. Associated with poor 







Cell adhesion molecule involved in cell 
proliferation, adhesion, migration, and 
chemoresistance. Associated with poor 
prognosis in various carcinomas and 
ovarian cancer.91 
L4543 (Sigma-Aldrich, 
St. Louis, MO) 
Mouse anti-
EGFR 
Epidermal Growth Factor Receptor – 
Tyrosine kinase receptor involved in cell 
proliferation, migration, and invasion. 
Highly expressed in ovarian tumors.92 
555996 (BD 
Biosciences, San Jose, 
CA) 
Table 3.1. Description and catalog number of antibodies used in western 




Establishment and verification of IHOE-CD81-GFP and SKOV-3-CD9-RFP model 
system 
Initial lentiviral-mediated transduction of IHOE and SKOV-3 cells with pCT-
Cyto-GFP (CYTO118-VA-1, SBI, Palo Alto, CA) and pCT-Cyto-RFP (CYTO119-VA-1, 
SBI, Palo Alto, CA), respectively, revealed an optimal transduction efficiency of 10 pCT-
Cyto-GFP virus particles per IHOE cell and 5 pCT-Cyto-RFP virus particles per SKOV-3 
cell. Transduction of IHOE cells with pCT-CD81-GFP or the pCT-Cyto-GFP control 
plasmid resulted in production of IHOE-CD81-GFP and IHOE-Cyto-GFP control cells, 
respectively. Transduction of SKOV-3 cells resulted in production of SKOV-3-CD9-RFP 
and SKOV-3-Cyto-RFP control cells, respectively. Confocal imaging of IHOE-CD81-
GFP cells, stained with DAPI (see Figure 3.2), revealed punctate expression of GFP 
throughout the cytoplasm of the cell. Under the same imaging conditions, IHOE-Cyto-
GFP control cells (see Figure 3.2) demonstrated even GFP distribution throughout the 
entire cell, including potential expression within the nucleus. Non-transduced control 
IHOE cells (see Figure 3.2) demonstrated no GFP expression while none of the samples 




Figure 3.2.  Confocal Fluorescence and DIC Images of transduced cells fixed 
and stained with DAPI. Fluorescence and DIC images of IHOE-CD81-GFP; 
IHOE-Cyto-GFP; and IHOE cells. Blue emission spectra (425-500 nm), green 
emission spectra (510-590 nm), and red emission spectra (575-650 nm) were 
captured in single channels and overlaid in confocal images.  
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Similarly, confocal imaging of SKOV-3-CD9-RFP cells, stained with DAPI (see 
Figure 3.3), showed punctate expression of RFP throughout the cytoplasm with little 
evidence of RFP expression in the nucleus. Imaging of the SKOV-3-Cyto-RFP control 
cells (see Figure 3.3) revealed even RFP expression throughout the entire cell, including 
strong expression overlapping the nucleus. Non-transduced control SKOV-3 cells 
displayed no evidence of RFP expression under the same imaging conditions (Figure 






Figure 3.3.  Confocal Fluorescence and DIC Images of transduced cells 
fixed and stained with DAPI. Fluorescence and DIC images of SKOV-3-
CD9-RFP; SKOV-3-Cyto-RFP; and SKOV-3 cells. Blue emission spectra 
(425-500 nm), green emission spectra (510-590 nm), and red emission spectra 




TEM of sEV samples isolated from IHOE-CD81-GFP and SKOV-3-CD9-RFP 
cells revealed the presence of single vesicles of approximately 80-140 nm in diameter 
(see Figure 3.4). Observed vesicles from both IHOE-CD81-GFP and SKOV-3-CD9-RFP 
cells demonstrated a slight “dimpled” morphology as well as darker staining around the 
exterior of the vesicle. The vesicles appeared intact and demonstrated no signs of damage 





Figure 3.4. Transmission electron microscopy of small extracellular 
vesicles. TEM of sEVs isolated from (a) IHOE-CD81-GFP and (b) SKOV-
3-RFP cells by ultracentrifugation.  
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Upon western blot analysis, GFP normally expresses a protein band size of ~26 
kDa57, 58, as does CD8159, while RFP normally expresses a protein band size of ~ 27 
kDa60 and CD9 a protein band size of ~ 25 kDa.61 As such, CD81-GFP should express a 
protein band size of ~ 52 kDa, as should CD9-RFP. Western blot analysis of IHOE-
CD81-GFP sEVs and cell lysate using rabbit anti-turboGFP (tGFP) (see Figure 3.5a) 
revealed multiple bands at approximately 24 kDa (Band I), 41 kDa (Band II), 55 kDa 
(Band III), and > 62 kDa (Band IV), while non-transduced control IHOE sEVs and cell 
lysate showed no bands. Purified, control tGFP protein displayed bands at approximately 
26 kDa and 43 kDa. SKOV-3-CD9-RFP sEVs and cell lysate probed with rabbit anti-RFP 
showed bands at ~ 45 kDa (Band V) and  ~54 kDa (Band VI) (see Figure 3.5b), while 
non-transduced control SKOV-3 sEVs and cell lysate showed no bands. Purified, control 




Figure 3.5.  GFP and RFP western blots of IHOE-CD81-GFP sEVs and cell 
lysate and SKOV-3-CD9-RFP sEVs and cell lysate. a) Rabbit anti-tGFP and b) 
rabbit anti-RFP primary antibody probing. Arrows and Roman numeral indicate 
regions of interest. 
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The dotting of isolated, enriched IHOE-CD81-GFP sEVs and SKOV-3-CD9-RFP 
sEVs on a nitrocellulose membrane with protein concentrations of 2500 µg/mL revealed 
visibly greater relative fluorescence intensity for both sEV samples compared to the 
vesicle-free PBS controls (see Figure 3.6). The sample images (Figures 3.6a,c) also 
demonstrated distinct puncta. Average fluorescence intensities of these images (Figures 








Figure 3.6.  Fluorescence images of GFP and RFP tagged vesicles dotted on 
nitrocellulose membrane. (a) Immortalized Human Ovarian Epithelial (IHOE)-
derived CD81-GFP tagged, (b) IHOE-derived, (d) SKOV-3-derived CD9-RFP 
tagged, and (d) SKOV-3-derived sEVs were isolated by ultracentrifugation and 
dotted on a nitrocellulose membrane. Extracellular vesicle isolations were dotted 
at a concentration of 2500 µg/mL of protein. (e, f) PBS controls dotted on 
nitrocellulose. Images were obtained using both a GFP filter with a 100 ms 
exposure (a,b,c) and an mCherry filter with a 2 s exposure (d,e,f).  
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Following imaging of the IHOE-CD81-GFP and SKOV-3-CD81-RFP sEVs on 
nitrocellulose (see Figure 3.7), average relative fluorescence intensity per µg of total 
protein of the IHOE-CD81-GFP and SKOV-3-CD81-RFP sEVs was compared to normal 
IHOE and SKOV-3 sEVs as well as to IHOE-CD81-GFP, SKOV-3-CD9-RFP, IHOE, 
and SKOV-3 cell lysates. Relative fluorescence intensities per µg of protein of IHOE-
CD81-GFP and SKOV-3-CD9-RFP sEVs (see Figure 3.7) were significantly higher than 
those of their respective cell lysates and non-transduced control cell sEVs. Additionally, 
relative fluorescence intensities of IHOE-CD81-GFP and SKOV-3-CD9-RFP cell lysates 
were significantly higher than non-transduced IHOE and SKOV-3 cell lysates. It should 
be noted that while the relative fluorescence intensities of the fluorescent cell lysate 
samples were much higher than the corresponding fluorescent sEV samples, the total 
protein in the fluorescent cell lysate samples were much higher. Thus, relative 





Figure 3.7.  Relative fluorescence intensity per µg of protein of sEVs and cell 
lysate imaged on nitrocellulose membranes. Green bars represent samples derived 
from IHOE cells and red bars represent samples derived from SKOV-3 cells. 
Fluorescent sEVs and cell lysate were derived from IHOE-CD81-GFP and SKOV-3-
CD9-RFP cells. Normal sEVs and cell lysate were derived from non-transduced 
IHOE and SKOV-3 control cells. Corresponding samples were subjected to a 
student’s t-test ( ** - significantly different from corresponding sample and control, 
p<0.05) ( * - significantly different from control alone, p<0.05); error bars 
demonstrate one standard deviation, n=3. 
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 The relative fluorescence intensity of IHOE-CD81-GFP sEVs in solution 
measured at 525 nm over varied protein concentrations (see Figure 3.8a) demonstrated 
consistent intensities and a coefficient of determination (R2) of 0.9805. Similarly, the 
relative fluorescence intensity of SKOV-3-CD9-RFP sEVs in solution measured at 590 
nm over varied protein concentrations (see Figure 8b) demonstrated consistent intensities 
and a coefficient of determination (R2) of 0.9190. 
 
  
Figure 3.8.  Relative fluorescence intensity per µg of suspended protein.  a) 
IHOE-CD81-GFP sEVs excited at 488 nm with fluorescence measured at 525 
nm and b) SKOV-3-CD9-RFP sEVs excited at 550 nm with fluorescence 
measured at 590 nm. Relative fluorescence intensity was measured with a 100 
ms exposure time for all samples. Calculated coefficient of determination (R2) 
represents the level of explained variability within the sample group. Coefficient 
of determination values: a) 0.9805 and b) 0.919. 
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PET C-CP fiber sEV capture 
Following cell line establishment and verification, IHOE-CD81-GFP and SKOV-
3-CD9-RFP sEVs, initially isolated and concentrated via UC, were spun down onto C-CP 
fibers in a micropipette tip format. Observation of the fibers under SEM revealed 
significant vesicle capture along the surfaces of the PET C-CP fibers loaded with the 
IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV samples, while no vesicles were seen on 
the PET C-CP fiber surfaces exposed to the sEV-free PBS control (see Figure 3.9). 
IHOE-CD81-GFP vesicles on the fiber surface appeared more evenly distributed, while 
SKOV-3-CD9-RFP vesicles on the fiber surface appeared to have greater amounts of 
vesicle aggregation. Neither sample demonstrated significant vesicle damage.  
  
Figure 3.9. Scanning electron microscopy of small extracellular vesicles on 
PET C-CP fibers. SEM of sEVs isolated from (a) IHOE-CD81-GFP and (b) 
SKOV-3-CD9-RFP cells by ultracentrifugation and (c) an sEV-free PBS control 
spun down onto PET C-CP fibers in a micropipette tip format. 
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Super-resolution confocal microscopy of IHOE-CD81-GFP sEVs (see Figure 
3.10a) revealed small fluorescent particles, approximately 0.2-1 µm in diameter, scattered 
across the surface of the PET C-CP fibers. While the fibers emitted significant 
autofluorescence in the observed GFP emission range (500-541 nm; see PBS control in 
Figure 3.10c), fluorescent puncta remained observable in micrographs of the IHOE-
CD81-GFP samples. Non-transduced IHOE sEVs (non-fluorescent) captured on the fiber 
surfaces appeared no different than the PBS control-treated fibers (see Figure 3.10b). 
Similarly, super-resolution confocal microscopy of SKOV-3-CD9-RFP sEVs (see Figure 
3.10d) revealed small fluorescent particles, approximately 0.2-1 µm in diameter, 
scattered across the surface of the PET C-CP fibers. While the fibers emitted significant 
autofluorescence in the observed RFP emission range (564-628 nm; see PBS control in 
Figure 13f), additional fluorescent puncta were visible in the micrographs of the SKOV-
3-CD9-RFP samples. Non-transduced SKOV-3 sEVs (non-fluorescent) captured on the 






Figure 3.10. Super-resolution confocal fluorescence microscopy of 
IHOE-CD81-GFP and SKOV-3-CD9-RFP-expressing small extracellular 
vesicles on PET C-CP fibers. Super-resolution confocal fluorescence 
microscopy of (a) IHOE-CD81-GFP sEVs, (b) non-transduced IHOE sEVs 
(non-fluorescent), (c) PBS (d) SKOV-3-CD9-RFP sEVs, (e) non-transduced 
SKOV-3 sEVs (non-fluorescent) and (f) PBS spun down onto PET C-CP 
fibers in a micropipette tip format. Images a, b, and c were captured under 
GFP imaging conditions (see Materials and Methods) and images d, e, and f 
were captured under RFP imaging conditions. Arrows indicate distinct 




IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV mixed samples spun onto PET C-
CP fibers demonstrated similar patterns to the IHOE-CD81-GFP and SKOV-3-CD9-RFP 
samples alone (see Figure 3.11). The mixed samples demonstrated fluorescent particles 
within both the green emission range (500-541 nm, see Figure 3.11a) and red emission 
range (564-628 nm, see Figure 3.11b). An overlaid image of the green and red emission 
channels (see Figure 3.11c), revealed the presence of green and red fluorescent particles 





Figure 3.11. Super-resolution confocal fluorescence microscopy of IHOE-
CD81-GFP and SKOV-3-CD9-RFP small extracellular vesicles on PET C-CP 
fibers. Super-resolution confocal fluorescence microscopy of IHOE-CD81-GFP 
and SKOV-3-CD9-RFP sEVs mixed prior to being spun down onto PET C-CP 
fibers in a micropipette format. Observations in (a) green and (b) red channels were 




Selective immunoaffinity capture of sEVs 
 Following determination of average fluorescence values for the sample area of the 
controls for normalization (Figure 3.6), immunoaffinity capture experiments were set up 
as described in Figure 3.1 using nitrocellulose strips dotted with the antibodies listed in 
Table 3.1. IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV samples were added to 
separate nitrocellulose antibody-dotted capture strips (see Figure 3.1a and Table 3.1) and 
imaged with multichannel widefield fluorescence microscopy (see Figures 3.12-3.16, 
Table 3.2). In a separate experiment, IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs 
were mixed prior to addition to a single nitrocellulose antibody-dotted capture strip (see 
Figure 3.1b and Table 3.1) and imaged with multichannel widefield fluorescence 
microscopy (see Figures 3.17-3.18, Table 3.2). The positive control capture antibody 
against tGFP (rabbit anti-tGFP) demonstrated significant GFP fluorescence intensity 
when incubated with IHOE-CD81-GFP sEVs alone (see Figure 3.12a) or with a sample 
containing both IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs (see Figure 3.12c), as 
compared to the negative PBS controls (no antibody, IHOE-CD81-GFP or SKOV-3-
CD9-RFP sEV samples; see Figure 3.12e,f). Similarly, the positive control capture 
antibody against RFP (rabbit anti-RFP) demonstrated significant mCherry fluorescence 
intensity when incubated with SKOV-3-CD9-RFP sEVs alone (see Figure 3.12h) or with 
a sample containing both IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs(see Figure 
3.12j), as compared to the negative PBS controls (no antibody, IHOE-CD81-GFP or 
SKOV-3-CD9-RFP sEV samples; see Figure 3.12k,l). No spectral crossover was 
observed between the red and green channels (see Figure 3.12g,i,b,d) Fluorescence of the 
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captured IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs appeared to be more 
homogeneous as opposed to punctate in nature as compared to IHOE-CD81-GFP and 
SKOV-3-CD9-RFP sEV samples dotted directly onto a nitrocellulose surface without 





Figure 3.12. Immunoaffinity blot capture using rabbit anti-tGFP and 
rabbit anti-RFP antibodies. IHOE-CD81-GFP and/or SKOV-3-CD9-RFP 
sEVs were isolated by UC and captured on a nitrocellulose membrane using 
rabbit anti-tGFP or rabbit anti-RFP antibodies. Each type of sEV was exposed 
to antibody-dotted nitrocellulose for 2 hours at a protein concentration of 125 
µg/mL followed by a 1 hour wash in TBS-Tween. GFP images were obtained 




 CD63 is a generic exosomal marker protein. When rabbit anti-CD63 antibodies 
were used to capture IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs, there was 
significant relative fluorescence intensity for IHOE-CD81-GFP sEVs (Figures 3.13-3.14, 
Table 3.2) and mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs (Figures 3.17-
3.18, Table 3.2) in the green channel. Rabbit anti-CD63 dots also demonstrated 
significant relative fluorescence intensity for SKOV-3-CD9-RFP sEVs (Figures 3.15-
3.16, Table 3.2) and mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs (Figures 
3.17-3.18, Table 3.2) in the red channel. The rabbit anti-CD63 normalized relative 
fluorescence intensity for IHOE-CD81-GFP sEVs in the green channel and the 
normalized relative fluorescence intensity for SKOV-3-CD9-RFP sEVs in the red 
channel were not significantly different (see Figures 3.13-3.16). Likewise, the rabbit anti-
CD63 normalized relative fluorescence intensities in both the green and red channels for 
mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs were not significantly different 




Figure 3.13. IHOE-CD81-GFP sEVs immuno-captured on a nitrocellulose 
membrane and imaged with multichannel microscopy. IHOE-CD81-GFP 
sEVs were exposed to antibody-dotted nitrocellulose for 2 hours at a protein 
concentration of 125 µg/mL followed by a 1 hour wash in TBS-Tween. GFP 
images were obtained using a 100 ms exposure and mCherry images were 





Figure 3.14. Normalized relative fluorescence intensities of IHOE-CD81-GFP 
immuno-captured on a nitrocellulose membrane and imaged with multichannel 
microscopy. IHOE-CD81-GFP sEVs were captured and imaged on a nitrocellulose 
test strips. sEVs were exposed to the multiple antibody-dotted nitrocellulose test 
strip for 2 hours at a protein concentration of 125 µg/mL followed by a 1 hour wash 
in TBS-Tween. GFP (green bar) images were obtained using a 100 ms exposure and 
mCherry (red bar) images were obtained using a 2 s exposure. (* - Significantly 






Figure 3.15. SKOV-3-CD9-RFP sEVs immuno-captured on a nitrocellulose 
membrane and imaged with multichannel microscopy. SKOV-3-CD9-RFP 
sEVs were exposed to antibody-dotted nitrocellulose for 2 hours at a protein 
concentration of 125 µg/mL followed by a 1 hour wash in TBS-Tween. GFP 
images were obtained using a 100 ms exposure and mCherry images were 






Figure 3.16. Normalized relative fluorescence intensities of SKOV-3-CD9-
RFP sEVs immuno-captured on a nitrocellulose membrane and imaged with 
multichannel microscopy. SKOV-3-CD9-RFP sEVs were captured and imaged 
on nitrocellulose test strips. sEVs were exposed to multiple antibody-dotted 
nitrocellulose test strips for 2 hours at a protein concentration of 125 µg/mL 
followed by a 1 hour wash in TBS-Tween. GFP (green bar) images were obtained 
using a 100 ms exposure and mCherry (red bar) images were obtained using a 2 s 
exposure. (* - Significantly different from the PBS control, based on a one-tailed 
t-test; **- Significantly different from PBS control and corresponding 




Dot blots with antibodies against the ovarian cancer sEV marker proteins, CD24, 
Her2, L1CAM, and EGFR, demonstrated significantly greater red relative fluorescence 
intensities when incubated with the SKOV-3-CD9-RFP sEVs than green relative 
fluorescence intensity when incubated with IHOE-CD81-GFP sEVs (see Figures 3.13-
3.16, Table 3.2). Similarly, the dot blots demonstrated significantly greater red relative 
fluorescence intensity than green relative fluorescence intensities when incubated with 
mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs (see Figures 3.17-3.18, Table 
3.2). Dot blots with mouse anti-L1CAM antibody did not show significantly greater red 
relative fluorescence intensity than green fluorescent intensity when incubated with 
mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs. However, the mouse anti-
L1CAM dot blots did show slightly lower mean red relative fluorescence intensity with 
higher variance when incubated with mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP 
sEVs compared to dot blots with mouse anti-Her2 and mouse anti-EGFR (see Figure 
3.17-3.18, Table 3.2). Dot blots using ovarian cancer sEV marker antibodies 
demonstrating significant relative fluorescence intensities following sEV incubations had 
normalized relative fluorescence intensities ranging from approximately 0.10 to 0.24 





Figure 3.17. IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs immuno-
captured on a nitrocellulose membrane and imaged with multichannel 
widefield fluorescence microscopy. IHOE-CD81-GFP and SKOV-3-CD9-RFP 
sEVs were mixed prior to capture on a single test strip. Mixed sEVs were exposed 
to multiple antibody-dotted nitrocellulose for 2 hours at a protein concentration of 
125 µg/mL followed by a 1 hour wash in TBS-Tween. GFP images were obtained 






Figure 3.18. Normalized relative fluorescence intensities of mixed IHOE-CD81-
GFP and SKOV-3-CD9-RFP sEVs captured by ovarian cancer EV marker 
antibodies. IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs were mixed prior to 
capture on a single test strip. Mixed sEVs were exposed to antibody-dotted 
nitrocellulose for 2 hours at a protein concentration of 125 µg/mL followed by a 1 
hour wash in TBS-Tween and then imaged using multichannel widefield 
fluorescence microscopy. GFP (green bar) images were obtained using a 100 ms 
exposure and mCherry (red bar)  images were obtained using a 2 s exposure. (* - 
Significantly different from the PBS control, based on a one-tailed t-test; **- 
Significantly different from PBS control and corresponding fluorescence channel 





 Sample Type 















Rabbit anti-tGFP 1.082 1.592 0.001 0.007 
Rabbit anti-RFP -0.005 -0.002 0.843 1.109 
Rabbit anti-CD63 0.061 0.075 0.119 0.101 
Mouse anti-CD24 0.012 0.020 0.174 0.241 
Mouse anti-Her2 0.009 0.011 0.125 0.139 
Mouse anti-L1CAM 0.003 -0.004 0.154 0.100 
Mouse anti-EGFR 0.006 0.010 0.108 0.144 
PBS 0.004 0.004 0.009 -0.002 
Table 3.2. Relative fluorescence intensities (a.u.) of captured IHOE-CD81-GFP 
and SKOV-3-CD9-RFP sEVS using multichannel widefield fluorescence 
imaging with GFP filter set (450-490 nm excitation/500-550 nm detection) and 




Although there is currently no agreement or official guidelines on the 
classification of EV populations, there is consensus on the need for new EV isolation 
methods, particularly those with greater specificity, selectivity, purity, and yield. In 
response, immunoaffinity sEV isolation techniques have emerged as promising methods 
with respect to sEV specificity and selectivity and have demonstrated results similar to or 
better than those of ultracentrifugation.50 Thus far, immunoaffinity capture techniques 
have largely been dominated by magnetic bead and microfluidics approaches. Magnetic 
bead approaches have demonstrated high capture efficiency and sensitivity due the to 
enhanced surface area available for capture and mixture homogeneity.62 Microfluidics 
devices employing immunoaffinity approaches in tandem with other separation factors, 
including size, density, hydrophobicity, and biochemical profile, may allow for the 
greatest specificity and selectivity and may prove ideal for diagnostic purposes. Strategies 
employed in these methods include generic capture of sEVs using tetraspanin marker 
antibodies followed by tumor-specific marker identification, as well as sEV capture using 
tetraspanin and tumor-specific markers simultaneously. While both strategies have 
certain advantages, recent studies appear to primarily focus on tetraspanin capture alone 
prior to tumor-specific sEV marker identification. This workflow is likely due to low 
overall sEV yield values. 
As new EV isolation and quantification methods are designed, they will require 
more systematic comparison protocols for overall efficacy evaluation. The overall goal of 
this study was to develop a model system (IHOE-CD81-GFP- and SKOV-3-CD9-RFP-
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expressing cells) to produce fluorescent sEVs for use in optimization of the newly 
developed PET C-CP EV isolation platform. Specifically, this model system, by 
distinguishing between cancerous and non-cancerous cell-derived sEVs via fluorescence, 
will be used to develop the selective capture component of the PET C-CP EV isolation 
platform in a quick and cost-effective manner prior to patient sample investigation. Once 
refined, selective OC-specific capture antibodies coupled to the isolation platform may be 
able to streamline EV capture and be employed for early OC diagnosis. The aims of this 
work included establishment and verification of the IHOE-CD81-GFP- and SKOV-3-
CD9-RFP-expressing cell lines for production of fluorescently-labelled sEVs, 
demonstration of the ability of PET C-CP fibers to capture IHOE-CD81-GFP and SKOV-
3-CD9-RFP sEVs effectively, and demonstration of OC-specific antibody capture and 
discrimination of IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs, thus demonstrating 
the ability to distinguish between non-cancerous and cancerous cell-derived sEVs. This 
study details the development of a model system that can be used to further develop the 
PET C-CP EV isolation platform by improving selectivity and specificity and allowing 
for its optimization prior to testing with highly variable and costly patient samples.  
Development and analysis of the cell line model system 
In order to engineer non-cancerous (IHOE) and cancerous (SKOV-3) cell lines to 
release fluorescent sEVs for downstream selective capture, generic endosomal proteins 
were identified as candidates for addition of fluorescent tags. Both CD81 and CD9 are 
tetraspanin proteins that, due to their involvement in endosomal vesicle transport, are 
expressed on plasma membrane components of cells. They are both reported sEV 
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markers, are typically highly expressed in populations of sEVs, and are often used as 
protein controls in sEV experiments.63, 64 Specifically, IHOE cell sEVs contain high 
amounts of CD81 and SKOV-3 cell sEVs are highly enriched in CD9.65 Therefore, to 
create fluorescent sEVs from IHOE and SKOV-3 cells, IHOE and SKOV-3 cells were 
transduced with commercially obtained pCT-CD81-GFP (CYTO124-VA-1, System 
Biosciences, Palo Alto, CA) or pCT-CD9-RFP (CYTO125-VA-1, System Biosciences, 
Palo Alto, CA) plasmids, respectively. The plasmids were designed by System 
Biosciences to add fluorescent tags to the C-terminus, intracellular domains of the 
specific tetraspanin proteins (CD81 and CD9).66 Each plasmid was independently 
prepackaged into an HIV lentiviral construct purchased from System Biosciences to be 
used for transduction of the appropriate cell line. To assess the optimal multiplicity of 
infection (MOI, the ratio of virus particles to cells) required, transduction efficiency was 
calculated using the pre-packaged control plasmids, pCT-Cyto-GFP (CYTO118-VA-1, 
SBI, Palo Alto, CA) and pCT-Cyto-RFP (CYTO119-VA-1, SBI, Palo Alto, CA) for the 
IHOE and SKOV-3 cells, respectively. pCT-Cyto-GFP showed an optimal transduction 
efficiency at an MOI of 5 and pCT-Cyto-RFP showed optimal and maximum 
transduction efficiency at an MOI of 10. Given these results, an MOI of 5 for pCT-CD81-
GFP and IHOE cells and a MOI of 10 for pCT-CD9-RFP and SKOV-3 cells were chosen 
for future experiments.  
IHOE cells and SKOV-3 cells were successfully transduced with either pCT-
CD81-GFP or pCT-CD9-RFP, respectively, selected for plasmid expression with 
puromycin, and subjected to limited dilution cloning. Clones with the highest cell lysate 
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fluorescence intensities, as measured using a Biotek Synergy H1 Hybrid Reader (Biotek, 
Winooski, VT), from identical cell densities were chosen for use in subsequent 
experiments. Laser scanning confocal images of IHOE-CD81-GFP and SKOV-3-CD9-
RFP cells, as seen in Figures 3.2 and 3.3, demonstrate the successful cell transductions 
and expression patterns of fluorescently-labelled CD81 and CD9 in the IHOE and 
SKOV-3 cell lines. As the CD81 and CD9 transmembrane proteins are typically enriched 
in extracellular vesicles, they would be expected to be expressed in many small, punctate 
transport vesicles across the cell, resulting in scattered, intense fluorescence spots as 
opposed to uniform fluorescence expression throughout the cytoplasm. The micrographs 
of the IHOE-CD81-GFP and SKOV-3-CD9-RFP expressing cells (see Figures 3.2 and 
3.3) as compared to the micrographs of the IHOE-Cyto-GFP and SKOV-3-Cyto-RFP 
expressing control cells (general cytoplasm expression; see Figures 3.2 and 3.3) 
demonstrate these expected localization patterns. TEM imaging (see Figure 3.4) of sEVs 
isolated from IHOE-CD81-GFP and SKOV-3-CD9-RFP cells demonstrated typical 
“dimpled” EV morphology and maintenance of EV structure. Additionally, IHOE-CD81-
GFP and SKOV-3-CD9-RFP sEV samples demonstrated higher relative fluorescence 
intensity per µg of protein than cell lysates from the corresponding cell types (see Figure 
3.7), further indicating that the expressed CD81-GFP and CD9-RFP proteins are 
localized to extracellular vesicles, rather than generically expressed throughout the 
cytoplasm.  
An important step in the development of a new cell line is to verify that the 
engineered cell line expresses the correct recombinant proteins using semi-quantitative 
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methods. However, there are several factors that make this challenging for sEV specific 
recombinant proteins. First, sEVs can be difficult to quantify due to their size and 
heterogeneous makeup and, to date, there is no reliable method for accurate 
quantification.67 Thus, obtaining a correct measure of protein concentration per vesicle is 
difficult. Furthermore, it can be problematic to normalize protein data against standard 
loading controls when dealing with sEVs, as there is significant variation in sEV protein 
expression and enrichment, which can also be influenced by different sEV isolation 
methods.68 Even when populations of sEVs are isolated from the same cell type, there can 
be considerable variation between resulting isolate densities due to the crude, and 
sometimes difficult, isolation processes often employed. While antibodies against 
standard loading control proteins, such as IgG or GAPDH, can be used in certain 
situations, the replication of samples is not always reliable or trustworthy for semi-
quantification via western blot analysis.40, 64, 69-71 Despite these issues, in an effort to 
move forward with fundamental research, the EV community has deemed certain sEV 
markers, such as CD81 and CD9, as suitable loading controls for sEV research.72 
However, when using these loading controls, it is important to understand that they are 
quite limited as they are only reliable when comparing sEVs from the same source or cell 
type. With this in mind, any attempt to normalize or quantify this data based on western 
blot band intensity would be unreliable. Therefore, there was no attempt to quantify or 
statistically compare intensity values among western blot results. All western blot results 
were evaluated only for specific protein presence or absence with limited relative 
comparison based on amount of total protein loaded in each well. 
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To verify the recombinant protein expression of CD81-GFP and CD9-RFP in the 
IHOE-CD81-GFP and SKOV-3-CD9-RFP cells and sEVs, western blots using primary 
antibodies against tGFP or RFP (see Figure 3.5) were performed. As seen in Figure 3.5a, 
probing IHOE-CD81-GFP sEVs with rabbit anti-tGFP reveals bands at approximately 24 
kDa, 41 kDa, 55 kDa, and > 62 kDa as compared to the non-transduced control IHOE 
sEVs and cell lysate controls. The copGFP tag is a monomer with a molecular weight of 
26 kDa and the CD81 protein has a molecular weight of 26 kDa.57, 59 Thus, CD81 with 
the addition of a GFP molecule should have a molecular weight of ~52 kDa. According 
to the manufacturer’s instructions, rabbit anti-tGFP antibody only detects copGFP under 
non-reduced conditions. During western blots, reduced conditions are used to break the 
disulfide bridges that maintain protein tertiary structure73 but, in some cases, they may 
restrict antibody access to the protein epitope. Therefore, the western blot was run under 
non-reduced conditions to preserve protein disulfide bridges and maintain antibody 
access to the epitope. This can change the migration properties of the recombinant CD81-
GFP protein as the two disulfide bonds of the CD81 portion do not unfold properly, 
causing an uneven charge distribution across the entire molecule.59 A change in the 
migration properties can lead to a slightly higher indicated size than expected (~55kDa), 
as was observed. The IHOE-CD81-GFP cell lysate sample displayed a similar, albeit less 
intense band at ~55 kDa, representative of CD81-GFP as well. As non-transduced control 
IHOE sEVs and cell lysate did not display any bands, western blot evidence suggests that 
the CD81-GFP recombinant protein is being successfully expressed in the IHOE-CD81-
GFP cells. Furthermore, GFP fluorescence is detected in the IHOE-CD81-GFP cell 
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micrographs (see Figure 3.2) and IHOE-CD81-GFP sEVs and cell lysate dotted on 
nitrocellulose (see Figure 3.6 and 3.7), suggesting CD81-GFP is being expressed in the 
IHOE-CD81-GFP cells.  
The RFP tag used in this experiment has a molecular weight of approximately 27 
kDa and CD9 molecules have a molecular weight of approximately 25 kDa.17, 60, 61 
Therefore, CD9-RFP molecules should have a theoretical molecular weight of ~52 kDa. 
SKOV-3-CD9-RFP sEVs and cell lysate probed with rabbit anti-RFP show a band at 
approximately 54 kDa (see Figure 3.5b, band VI), suggesting that CD9-RFP molecules 
are present in the sEV and cell lysate samples. Moreover, RFP fluorescence is also 
detected in SKOV-3-CD9-RFP cell images (see Figure 3.3) and in micrographs of 
SKOV-3-CD9-RFP sEVs and cell lysate (see Figure 3.6 and 3.7) dotted on nitrocellulose, 
further suggesting that CD9-RFP is being expressed in the SKOV-3-CD9-RFP cells.  
To investigate the potential additional feature of using IHOE-CD81-GFP and 
SKOV-3-CD9-RFP sEVs for testing the PET C-CP EV isolation platform, protein 
concentrations were compared to relative fluorescence intensities as a means for simple 
sEV quantification. The fluorescently-labeled IHOE-CD81-GFP and SKOV-3-CD9-RFP 
sEVs demonstrated a high correlation between protein content and relative fluorescence 
compared to non-fluorescent IHOE and SKOV-3 sEV controls (see Figure 3.8), 
suggesting that the relative fluorescence of IHOE-CD81-GFP and SKOV-3-CD9-RFP 
sEVs may be an alternative means of sEV quantification. Although protein concentration 
is by no means considered an accurate method of sEV quantification, it does provide an 
sEV concentration approximation and is widely reported in literature. With the use of 
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fluorescence detectors (which are already incorporated into the PET C-CP fiber HIC 
isolation platform reported in Chapter 2), sEV fluorescence protein correlation may hold 
value as a simple method of sEV quantification approximation during PET C-CP fiber-
based EV isolation. 
Taken together, these results demonstrate that IHOE-CD81-GFP and SKOV-3-
CD9-RFP cells were successfully established and verified to express the fluorescent tags 
on the appropriate proteins (CD81-GFP and CD9-RFP). Therefore, IHOE-CD81-GFP 
and SKOV-3-CD9-RFP cells may assist in the development of the PET C-CP EV 
isolation platform through EV binding verification via fluorescence imaging and EV 
quantitative analysis through fluorescence detection. However, in order for the sEVs 
derived from the IHOE-CD81-GFP and SKOV-3-CD9-RFP cells to be utilized for 
evaluation of PET C-CP fibers, they must first be captured on the fiber surfaces.  
PET C-CP fiber-based sEV capture 
To evaluate the PET C-CP fiber utility for EV separation of and compatibility 
with IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs, IHOE-CD81-GFP and SKOV-3-
CD9-RFP sEVs were isolated by UC and spun down through PET C-CP fibers in a 
micropipette tip format (see Materials and Methods). Under SEM observation, IHOE-
CD81-GFP (see Figure 3.9a) and SKOV-3-CD9-RFP (see Figure 3.9b) sEVs demonstrate 
capture without significant morphological damage. Some vesicle aggregation on the 
fibers is observed but is likely due to the tendency for UC to cause vesicles to aggregate 
prior to spinning through the C-CP fibers. 
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While this study did observe GFP and RFP extracellular vesicle aggregates and 
vesicles in close proximity through fluorescent microscopy, it is important to note that 
single vesicle observation is not possible with a limit of resolution of approximately 150 
nm using the Leica SP8 Hyvolution super-resolution imaging system and software. 
However, in future studies, the addition of stimulated emission depletion (STED) super-
resolution to the existing Leica SP8, with resolutions down to 50 nm, may make 
individual vesicle imaging of fluorescent sEVs possible and allow samples to be more 
easily distinguishable.74, 75 With this in mind, IHOE-CD81-GFP and SKOV-3-CD9-RFP 
vesicles, again collected by UC and spun down through PET C-CP fibers, were observed 
using super-resolution (~150 nm) fluorescence confocal microscopy. Initial observation 
of PBS controls revealed significant autofluorescence from the PET fibers in both the 
green (see Figure 3.10c) and red (see Figure 3.10f) channels with RFP emission 
wavelengths displaying greater intensity than GFP emission wavelengths. However, after 
application of the IHOE-CD81-GFP (see Figure 3.10a) and SKOV-3-CD9-RFP (see 
Figure 3.10a) sEVs, groups of fluorescent particles could be observed beyond the fiber 
autofluorescence. To verify that the IHOE-CD81-GFP and SKOV-3-CD9-RFP samples 
were not emitting significant autofluorescence, non-transduced IHOE (see Figure 3.10b) 
and SKOV-3 (see Figure 3.10e) sEVs, collected by UC and spun down through PET C-
CP fibers were observed under the same fluorescence imaging conditions. Non-
transduced IHOE and SKOV-3 sEVs did not display any evidence of additional 
fluorescence as compared to the PBS controls. This further demonstrates that the 
fluorescent particles observed in the IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV 
161 
 
sample micrographs are fluorescently-labelled sEVs captured on the PET C-CP fiber 
surfaces (Figures 3.10a,c). This observation is further confirmed by SEM images (see 
Figure 3.9) and the previous protein and fluorescence analyses of the IHOE-CD81-GFP 
and SKOV-3-CD9-RFP sEVs (see Figures 3.2, 3.3, 3.5-3.7). In addition, mixed IHOE-
CD81-GFP and SKOV-3-CD9-RFP sEV samples were spun down on PET C-CP fibers 
and imaged under the same conditions as the IHOE-CD81-GFP and SKOV-3-CD9-RFP 
samples alone (see Figure 3.11). After overlaying the channels, both GFP and RFP sEVs 
can be observed in separate and coinciding locations, suggesting that, while there is 
significant overlap, IHOE-CD81-GFP and SKOV-3-CD9-RFP vesicle groupings may be 
distinguished from each other on fiber surfaces using super-resolution confocal 
microscopy.  
As these results show, IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs are 
captured on the surface of PET C-CP fibers and can be detected and distinguished using 
fluorescence microscopy. The addition of the fluorescent labels do not appear to impede 
the adherence of the tagged sEVs to the PET C-CP fiber surfaces, therefore, the model 
fluorescent sEVs provide a useful tool for validation and optimization of the PET C-CP 
fiber-based EV isolation platform. Additionally, the ability to readily distinguish between 
non-cancerous and cancerous cell-derived sEVs via green and red fluorescence provides 
a means of evaluating the specificity of exosomal biomarker antibodies for use in lateral 





Selective immunoaffinity capture of sEVs 
 Like any complex system, access to a complete dataset would be ideal 
when observing the properties of a population. However, as sampling can rarely, if ever, 
include every member of a population, statistical analysis is used to look for patterns and 
correlations that may explain or predict characteristics and sub-populations based on a 
few variables. In lieu of technology capable of selectively identifying the proteome of 
individual sEVs and for clinical practicality, only a few parameters are employed to 
distinguish cancerous and non-cancerous sEVs. Although the number of parameters is 
limited, as OC is a heterogeneous disease with many subtypes and origins, multiple 
markers would be more effective for early screening. Here, selective immunoaffinity 
capture provides a means to identify sEV sub-populations via multiple biomarker 
antibodies with the goal of distinguishing between cancerous and non-cancerous ovarian 
cell-derived sEVs and translating that technology to the PET C-CP EV isolation platform. 
As only a fraction of an sEV population may express a specific OC tumor-specific 
sEV marker, such as CD24 or Her246, 76, sEV capture using only one of these sEV OC 
markers may lead to lower numbers of captured sEVs, resulting in low signal and 
decreased disease screening success. Generic sEV markers, such as CD9, CD81, and 
CD63 are present in a higher proportion of sEVs31, 64, 77 and would likely lead to higher 
capture yields. However, ovarian cancer tumor-specific sEV marker capture may allow 
for greater sEV population selectivity. The immunocapture experiment described here 
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employs strategies from other sEV lateral flow and immunoaffinity blot techniques and 
provides a means for validating the model sEV system for use in the development of 
immunoaffinity capture and isolation techniques for ovarian cancer diagnostics.78, 79  
 To provide a means of appropriate comparison and normalization of sEV 
immunocapture, dotting of concentrated IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs 
on nitrocellulose was used to set a threshold of maximum fluorescence intensity (Figure 
3.6). (Of note, IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV samples captured on 
nitrocellulose were imaged with exposure times of 100 ms and 2 s, respectively. The 
discrepancy in these exposure times was appropriated to account for the differences in 
documented brightness between copGFP (42 cm-1 M-1)57, 58 and mRFP (12.5 cm-1 M-1)60 
molecules and any potential quenching due to the molecular environment in vitro). The 
ability to selectively capture GFP- or RFP-expressing sEVs from independent and mixed 
IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV (see Figure 3.1 for experimental setup) 
samples via a dot blot immunoaffinity assay using rabbit anti-tGFP and rabbit anti-RFP 
antibodies was successfully demonstrated These positive controls show that the dot blot 
technique can be used to visually confirm the capture of specific sEVs based on their 
protein expression.  
 Once it was demonstrated that selective capture of IHOE-CD81-GFP and SKOV-
3-CD9-RFP sEVs  was possible via rabbit anti-tGFP and rabbit anti-RFP antibodies (see 
Figure 3.12, Table 3.2) the next step was to show that specific capture of the cancer and 
non-cancer cell-derived sEVs could be performed using antibodies to known ovarian 
cancer exosomal biomarkers. In addition to using specific ovarian cancer biomarkers, a 
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known universal exosomal biomarker was also investigated as a capture antibody. In this 
manner, the capture results from mixed cancer and non-cancer cell-derived sEV samples 
may be interpreted in terms of capture specificity. The universal exosomal biomarker, 
CD63, was selected as a positive control for the validation of the study dot blot assays. 
For the control assays, IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs were 
immunocaptured from both independent (see Figures 3.13-3.16, Table 3.2) and mixed 
(see Figures 3.17-3.18 , Table 3.2) samples on dot blots with rabbit anti-CD63 antibody.64 
When imaged, the dot blots displayed similar fluorescence intensities for all of the 
samples. Although CD63 expression likely differs somewhat between the IHOE-CD81-
GFP and SKOV-3-CD9-RFP cells, positive fluorescence in both the red and green 
channels for the mixed samples indicates that CD-63 can be used as a positive control for 
the immunocapture assays. This positive control antibody may be used to show that sEVs 
are present and that the capture assay is working properly, just as the positive control line 
functions in a lateral flow immunoassay. 
The potential to differentiate between IHOE-CD81-GFP and SKOV-3-CD9-RFP 
sEVs was assessed using antibodies to various known ovarian cancer tumor-specific 
exosomal marker proteins.  CD24, Her2, EGFR, and L1CAM molecular markers have all 
been identified in previous studies as candidate biomarkers for the diagnosis and 
prognosis of ovarian cancer.17, 23, 46, 76, 80-82 Therefore, dot blots using antibodies to these 
ovarian cancer exosomal marker proteins were designed to test whether or not 
immunoaffinity assays could be used to specifically capture cancer-cell derived sEVs 
(see Figures 3.13-3.18, Table 3.2). For these assays, individual and mixed samples of 
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IHOE-CD81-GFP (non-cancerous cell-derived) and SKOV-3-CD9-RFP (cancerous cell-
derived) sEVs were added to the dot blots. Dot blot results for the non-cancer cell-
derived (IHOE-CD81-GFP) sEVs alone showed no red fluorescence and significant green 
fluorescence only for dots containing antibodies to CD63 (control). This indicates that 
these non-cancer cell-derived sEVs were captured by the antibody to the generic 
exosomal marker tetraspanin protein, CD63, but were not captured by antibodies to any 
of the ovarian cancer exosomal marker proteins (CD24, Her2, EGFR, L1CAM). 
Conversely, the dot blot results for the cancer cell-derived (SKOV-3-CD9-RFP) sEVs 
alone showed no green fluorescence and significant red fluorescence for the dots 
containing antibodies to the CD63 control and for all of the dots containing antibodies to 
the ovarian cancer exosomal marker proteins (CD24, Her2, EGFR, LICAM). Finally, the 
dot blot results of a mixture of the non-cancer and cancer cell-derived sEVs showed 
significant green and red fluorescence for the dots containing antibody to CD63, while 
significant fluorescence was only seen in the red channel for the dots containing 
antibodies to the ovarian cancer marker proteins. These results indicate that sEVs from 
the model cell lines may be employed in the future development and optimization of 
lateral flow immunocapture assays for rapid, early ovarian cancer diagnostics. 
Compared to the utilization of single markers, use of a multiplexed approach to 
identify multiple exosomal biomarkers at once may diagnose a greater proportion of 
ovarian cancers.16 In this case, a panel of tumor-specific protein markers was successfully 
used to differentiate between cancerous and non-cancerous sEVs. Multiple marker “hits” 
provides greater assurance that less false negative test results will occur. As cells in the 
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tumor environment may undergo changes that can lead to differences in exosomal 
biomarker expression83-85, screening for a panel of biomarkers can increase the overall 
robustness of an exosomal liquid biopsy-based diagnostic test.9, 22, 38, 40  
The impact of IHOE-CD81-GFP and SKOV-3-CD9-RFP cell lines and immunoaffinity 
capture on development of a PET C-CP fiber-based EV isolation platform 
The IHOE-CD81-GFP and SKOV-3-CD9-RFP cell lines developed in this study 
provide an extremely valuable tool for the development, optimization, and proof of 
concept testing of the PET C-CP EV isolation platform, and its potential use in a simple, 
cost effective, early ovarian cancer diagnostics test. As the Marcus group has previously 
shown, antibodies may be grafted onto the surfaces of the PET C-CP fibers or 
alternatively to channeled films for selective protein capture.86-90 This study shows that 
sEVs expressing biomarker proteins may be selectively captured using immobilized 
antibodies. The model system may be used to produce sEVs for laboratory use instead of 
having to rely on expensive, limited availability human patient samples. Specifically, the 
incorporation of fluorescent markers into sEVs and the proven utility of the tagged sEVs 
for self-reporting immunocapture characterization studies provide a framework to further 
investigate selective sEV capture parameters, PET C-CP fiber and film-based sEV 
selective capture and separation, diagnostic accuracy, and clinical replication. Moreover, 
multiplexed immunoaffinity capture using OC tumor-specific EV markers has 
demonstrated the potential for these methods to distinguish between malignant and 
benign tumor cell-derived sEVs. The IHOE-CD81-GFP and SKOV-3-CD9-RFP cell 
model system may also allow for advancement of EV imaging and quantification via 
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efficient sample prep, easier live cell imaging, and quantitative fluorescence correlations. 
The versatility of the sEVs generated by these cell lines will prove useful as new 
applications come to light and the EV community begins to focus more on selective EV 
capture and super-resolution microscopy.  
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POTENTIAL IMPACTS OF ISOLATION METHOD AND SAMPLE SOURCE ON 




 Extracellular vesicles (EVs) have emerged as promising diagnostic, drug delivery, 
and therapeutic agents, particularly with regards to cancer. Although research is 
progressing quickly, progression of EV applications is hindered by the limitations of EV 
isolation and separation technologies. Current EV isolation techniques are in need of 
standardization across the industry for translational progression to continue. In particular, 
sample source is an important factor that may influence EV isolation choice and outcome. 
In this research, urine and cervical mucus are compared as potential sources for EV 
isolation and downstream EV analysis for potential ovarian cancer diagnostic and 
treatment applications. In addition, a larger study of microRNA (miRNA) content of EVs 
isolated from cervical mucus samples from patients with and without ovarian cancer 
revealed several potential miRNA biomarkers. In-depth analysis of this miRNA data, 
along with corresponding proteomic data, is ongoing in an attempt to reveal pathology 
and characteristic-specific miRNA and protein biomarkers for early ovarian cancer 
detection. Together, these studies demonstrate that cervical mucus may be useful for 
ovarian cancer-specific EV diagnostics. Ultimately, investigations of sample source-
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specific applications, such as this, may lead to more accurate and specific EV diagnostics 
and therapeutic outcomes, as well as greater standardization across the EV field. 
It should be noted that this is collaborative work and was performed with Dr. Brian Dean 
of the Clemson University Biomedical Data Science and Informatics Program. The 
bioinformatics work outlined in this chapter was primarily performed by Ms. Paritra 
Mandal. All patient samples used in this work were provided by Dr. Larry Puls, who 




Extracellular vesicle (EV) and exosome research has quickly developed into an 
expansive area of study focusing on vesicle biogenesis, classification, transport, uptake, 
dissemination, isolation and separation, biomarker discovery, drug delivery, and 
therapeutics.2-6 Broadly, these areas of focus can be divided into basic research and 
knowledge discovery and medical application development. Both sides of EV research 
are making significant progress but lack a strong base to make definitive and repeatable 
claims. Every discovery and development is highly dependent on the source of the 
vesicles, the method of separation, and the micro- and macro-environments from which 
the vesicles originate. With so many sources and methods of isolating EVs, paired with 
the diverse subcategories of EVs, it is both remarkable and encouraging that such 
significant progress has been made in the understanding of these bio-nanoparticles. 
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However, with each new discovery, the complexities surrounding EVs grow ever more 
intricate. 
 Before investigating either basic research or medical application development, it 
is important for the EV community to come to agreement by setting standards in 
classification and isolation methods. While Thery et al. and the International Society for 
Extracellular Vesicles (ISEV) have made significant progress toward formulating vesicle 
classifications and benchmarks of identification, the standards are still continually 
debated and evolving.7, 8 There are many commonly used isolation techniques, including 
ultracentrifugation (UC), ultrafiltration (UF), chromatography, precipitation, and 
immunocapture, but very little agreement upon which technique should be used for 
principal comparison.9-11 Perhaps the best way to develop greater consistency and 
experimental reproducibility is to develop standards for EV separation and isolation. 
Classification of EV isolation strategies into methods better suited for particular 
applications may be a good place to start.  
Of the most common EV isolation methods, ultracentrifugation is perhaps the 
most readily available technique, requiring equipment that is already found at most 
biology research institutions.12-14 Although UC output can vary greatly depending on 
sample viscosity, sample source, pellet disturbance, and rotor characteristics,15-17 UC has 
proven to be a useful starting point for EV research and applications.14 Furthermore, 
although other EV separation methods have shown greater promise, UC still holds value 
as a tool of comparison when developing new EV isolation methods.12, 16, 18, 19 UC has 
demonstrated the ability to isolate EVs from conditioned cell media and most body fluids 
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including urine, blood plasma, cerebrospinal fluid, amniotic fluid, saliva, and cervical 
mucus.11, 16, 17, 20-25 The flexibility and ease with which UC can be performed make it an 
excellent tool for comparison as it serves as an acceptable standard across the industry. 
Unlike UC, which relies on vesicle density and molecular weight to separate cell 
components and EVs, UF and size exclusion chromatography (SEC) rely on vesicle 
diameter.26-28 Stratification based on size allows for greater control of EV sub-
populations compared to UC, but struggles to classify larger vesicles. Vesicle size 
provides a general picture of vesicle classification, but discounts many key characteristics 
including biogenesis, protein, RNA, lipid profiles, density, zeta potential, and 
morphology. That said, any EV isolation technique using only one metric of comparison 
will likely struggle with classification. Size exclusion EV separation techniques have 
demonstrated high throughput, fast isolation, and high yield26-29, but, due to the use of 
force, have struggled to limit vesicle deformation and may cause damage to larger 
vesicles.9 The use of size limit thresholds and multiple filtration or exclusion steps has 
greatly improved the purity and population selection of these techniques.27, 28, 30 With 
increased EV purity and population selection, size exclusion techniques may serve best in 
applications requiring high through-put and large samples. 
Due to the presence and diversity of proteins in EV membranes, immunoaffinity 
capture techniques have emerged as popular methods for increasing EV population 
specificity and purity. Immunoaffinity steps have been incorporated into microfluidics 
devices and combined with other effective EV isolation methods with great success.31-35 
For example, Mathivanan et al. identified several colon cancer-related proteins and 
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potential EV diagnostic markers using a combination of UC, UF, and immune-affinity 
approaches35, while Ueda et al. coupled antibodies to mass spectroscopy to create an 
immuno-assay useful for increasing specificity and quickly identifying proteins for 
biomarker discovery.36 With the ability to increase specificity and purity, immunoaffinity 
methods are continually being incorporated into EV diagnostic techniques and will likely 
play an important role in developing EV isolation methods for specific and unique 
applications, particularly disease diagnostics. 
From diagnosis of cancer, neurodegenerative diseases, and cardiovascular disease 
to treatment of Parkinson’s Disease through drug delivery, EV applications can vary 
widely.3, 37-39 In particular, ovarian cancer is a prime candidate for EV-based early 
diagnostics due to its propensity for late stage diagnosis and poor 5-year survival rate.40 
Each application may require vastly different EV population purity, consistency, 
specificity, proteomics, transcriptomics, lipidomics, and morphology. Ideally, different 
EV separation methods may be able to control these characteristics with limited vesicle 
damage. Additionally, sample source (urine, plasma, etc.) may influence the 
effectiveness, efficiency, practicality, and accuracy of EV separation. While consistency 
across samples is always important, it is unclear whether it is necessary to calibrate each 
EV population characteristic for each application or sample source and whether an EV 
separation dominant design will emerge as the most practical method. 
While developing individualized EV separation methods for each application may 
prove useful, practicality, speed, and ease of use are important considerations that may 
push EV isolation research in a different direction. A single consistent isolation, while 
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less individualized for applications or sample sources, may ultimately be the most useful 
in clinical settings and for vesicle comparison in the EV community. However, just as 
immunocapture EV isolation may separate sub-populations of EVs, it is hypothesized that 
body fluid samples originating from or near a region of interest may contain more 
relevant EV information for specific conditions. For instance, urinary EVs have been 
frequently investigated as biomarkers for prostate cancer and kidney diseases as a means 
of improving the accuracy and sensitivity of diagnostics.20, 41-46 Additionally, breast milk-
derived EVs have been shown to directly promote the epithelial-mesenchymal transition 
in breast cancer tumor cells and breast milk-derived EVs with high expression of TGFβ2 
may be associated with a higher risk of breast cancer.47, 48 Diagnosis via EVs isolated 
from plasma may use a more generic EV population and demonstrate lower specific 
disease detection accuracy due to low signal to noise ratios. Therefore, establishing a 
consistent dominant design for EV isolation, while easier to study and evaluate, may 
prove impractical for many applications. Finding a balance between consistency in EV 
separation and customization for a given EV application will be required to advance EV 
understanding and achieve clinical translation. 
Much of the EV community has focused on improving or comparing isolation and 
diagnostic methods and has focused very little on comparing EV sample sources.49 While 
several studies have compared urine and plasma EV diagnostic potential10, 25, 50, 51, 
comparison of region-specific sources, such as cervical mucus, breast milk, amniotic 
fluid, tears, semen, and cerebrospinal fluid, is uncommon. The size distributions and 
RNA makeup of urine and blood plasma EVs have been shown to vary significantly 
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when isolated via ultracentrifugation52 potentially due to the presence of Tamm–Horsfall 
protein (THP, one of the most common glycoproteins in urine), albumin, and other 
protein contaminants in urine and blood.14, 53 Removal or reduction of THP and other 
contaminating agents may decrease the variance in size distribution and biomarker 
detection from urine and blood EV samples.54 However, if elimination of contamination 
proves difficult, other sample sources may allow EV isolation with reduced or 
manageable contaminants. Although no individual study has compared the characteristics 
of EVs from different sources (other than urine and blood plasma) under controlled 
conditions, sample source comparison across studies reveals variance in EV size 
distribution and RNA makeup.24, 52, 55-68 
With such variation in EV characteristics and transcriptomics, it is difficult to 
determine which body fluid matrix is optimal for each isolation method and downstream 
application. Furthermore, it is unclear whether sample proximity to a region of interest 
may improve diagnostic accuracy. More analysis and comparison across studies is needed 
before any conclusions can be drawn. However, this study aims to compare the 
morphology and miRNA content of EVs isolated from urine and cervical mucus samples 
of patients with benign or malignant ovarian tumors. In doing so, this study highlights the 
differences in morphology and miRNA content between urine and cervical mucus EVs 
and may provide evidence for increased use of sample sources near regions of interest 
with regard to diagnostic accuracy. Furthermore, this study contributes ovarian cancer 
EV miRNA differential expression analysis that can be used to develop more accurate 
and potentially earlier EV-based diagnoses for ovarian cancer. Notably, early diagnosis 
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(stage 1 or 2) of ovarian cancer, may increase the 5-year survival rate of the disease to 
92% from 29% when discovered in stage 3 or 4.40 
Due to concerns over the classification and nomenclature of EVs among the EV 
community, all EVs discussed in this study will be referred to as small extracellular 
vesicles (sEVs) rather than exosomes specifically. 
 
 Materials and Methods 
Urine, cervical mucus, and plasma collection and storage 
Urine, cervical mucus (CM), and blood plasma samples were obtained from 
patients through the Prisma Health System (Greenville Campus, Institute for 
Translational Oncology Research (ITOR) biorepository responsible for sample 
processing and storage). All procedures were approved and performed with adherence to 
the Prisma Health Institutional Review Board and Clemson University Institutional 
Biosafety Committee safety guidelines. Upon collection, 50 mL urine samples were 
supplemented with 1.67 mL of 100 mM sodium azide, 2.5 mL of 2 mg/mL 
phenylmethylsulfonyl fluoride (PMSF), and 50 µL of 1 mg/mL Leupeptin. After 
supplementation, urine samples were frozen and stored at -80˚C until further processing. 
To collect CM samples, the cervical mucus plug and a swab of cervical mucus were 
placed in 10 mL of phosphate buffered saline (PBS) supplemented with 334 µL of 100 
mM sodium azide, 500 µL of 2 mg/mL PMSF, and 10 µL of 1 mg/mL Leupeptin. After 
supplementation, CM samples were placed on ice for 30 minutes, vortexed for 30 
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seconds, frozen and stored at -80˚C until further processing. Blood samples were 
collected via standard phlebotomy procedures in an ethylenediaminetetraacetic acid 
(EDTA) coated tube. Within 30 minutes of sample collection, blood samples were 
inverted 8 to 10 times and centrifuged at 1500 x g at 22˚C for at least 15 minutes. 
Supernatant of centrifuged blood samples were aliquoted into 1.5 mL cryovials, frozen 
and stored at -80˚C. 
sEV isolation via ultracentrifugation 
 Patient urine and cervical mucus were thawed at 22°C prior to sEV isolation. 
After thawing completely, urine samples were vortexed for 30 seconds while CM 
samples were vortexed for 3 minutes to ensure even mixing, breakup of mucus, and 
removal of mucus from the collection swab. After being vortexed, collection swabs were 
removed from the CM and scraped into the tube to retain any excess mucus still on the 
swab. Briefly, 8 mL of urine or CM was centrifuged at 2,000 x g for 20 minutes at 22˚C 
using an Eppendorf Centrifuge 5430R (Eppendorf, Hamburg, Germany). The resultant 
supernatant was centrifuged at 10,000 x g for 30 minutes at 4˚C using a Beckman Coulter 
Avanti J-26S XPI Centrifuge with a JA-25.50 rotor (Beckman Coulter, Brea, CA). The 
resultant supernatant was filtered using a 0.2 µm sterile syringe filter (Thermo Fisher 
Scientific, Waltham, MA). After filtration, the supernatant was transferred to a 
compatible ultracentrifuge tube (Beckman Coulter, Brea, CA) and centrifuged at 120,000 
x g for 60 minutes at 4˚C using a Beckman Coulter Optima XPN-80 Ultracentrifuge and 
a Type 45 Ti rotor (Beckman Coulter, Brea, CA). Finally, the resultant pellet was 
resuspended in 400 µL of 1x PBS and stored at -80oC for downstream analysis. 
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C-CP fiber sEV isolation method 
 Chemicals used during sEV separation include ammonium sulfate ((NH4)2 SO4) 
(VWR, Radnor, PA), 10x PBS (Hyclone Laboratories Inc., Logan, UT), acetonitrile 
(ACN) (EMD Millipore, Burlington, MA), glycerol (Fisher Scientific, Waltham, MA), 
and ultra-pure water (obtained using a Milli-Q water system, Millipore, Burlington, MA). 
Extruded polyethylene terephthalate (PET) capillary-channeled polymer (C-CP) fibers, 
produced by the Material Science and Engineering Department at Clemson University, 
were wound on a circular frame 8 times (450 fibers) then rinsed with hot water, 
acetonitrile, isopropanol, and ultra-pure water. Wound fibers were pulled through a 30 
cm length, 0.762 mm internal diameter polyether ether ketone (PEEK)(IDEX Health & 
Science LLC, Oak Harbor, WA) tubing using a plastic monofilament. Using a Dionex 
Ultimate 3000 HPLC system (LPG-3400SD quaternary pump and MWD-3000 UV–Vis 
absorbance detector; Thermo Fisher Scientific, Sunnyvale, CA, USA), packed columns 
were washed using ultra-pure water, acetonitrile, and then ultra-pure water at 0.5 mL min-
1. Chromatography was performed using the Dionex Ultimate 3000 HPLC system and 
controlled by the Chromeleon 7 software system. Samples were injected using a 
Rheodyne model 8125 low dispersion injector with a 60 μL injection loop (Rheodyne, 
Rohnert Park, CA). The baseline case (no sample, step gradient mobile phase) was 
performed with mobile phase flow rate of 0.5 mL min-1 and subtracted from sample 
chromatograms. After being flushed with 1X PBS, the column was equilibrated with 2 M 
ammonium sulfate solution dissolved in 1X PBS, pH = 7.4. A step gradient mobile phase 
of 25% glycerol with 1M (NH4)2 SO4 (0.5 mL min-1) was introduced 3 minutes following 
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sample injection. Column elution was initiated by a second step gradient of 50% glycerol 
in 1X PBS (0.5 mL min-1) 5 minutes after sample injection. Eluting species (proteins and 
sEVs) were detected at 216 nm and recovered using an R1 fraction collector (Teledyne 
Isco, Lincoln, NE, USA) based on detector absorbance response. 
C-CP Fiber-based film wicking sample preparation 
 Samples used in the film wicking experiments included patient urine and blood 
plasma, obtained through Prisma Health and standard exosomes (HBM-PEU-100, 
HansaBioMed, Tallinn, Estonia) diluted in mock urine, reconstituted milk, and mock 
saliva to a concentration of 9.3 x 105 particles/mL. Mock urine and saliva were prepared 
according to recipes from previous studies69, 70, while reconstituted milk was prepared as 
2% non-fat dry milk (Bio-Rad, Hercules, CA) dissolved in DI water. All samples were 
supplemented with 1% red food coloring (McCormick, Baltimore, MD) by volume.  
C-CP channeled film wicking studies 
 C-CP channeled films, produced by the Material Science and Engineering 
Department at Clemson University, were cut into 5 cm strips and taped down to 1 x 3 
inch glass microscope slides, ridges face-up. A micropipette was used to apply 10 µl of 
patient urine, patient plasma, 1X PBS diluted standard exosomes, or 1X PBS directly to 
the center of the film. The applied drop was allowed to wick along the film for 20 
minutes at 22˚C while exposed to air. Following wicking, the films were removed from 
the glass slides and the film regions where sample visibly wicked were clipped off using 
scissors and prepared for scanning electron microscopy (SEM).  
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 In a separate experiment, 3 µl of 1X PBS, patient urine, patient plasma, or 
standard exosomes diluted in mock urine, mock saliva, reconstituted milk, or 1X PBS 
were applied directly to the center of the C-CP films via micropipette and allowed to 
wick for 15 minutes at 22˚C while exposed to air and under 5X magnification (Plan APO 
1.0X objective, 0.09 numeral aperture, no immersion) stereoscopic observation using a 
Leica Thunder Model Organism Imaging System (Leica, Wetzlar, Germany). Images 
were captured at a rate of one frame per second and compiled into time-lapse movies. 
Tracker Video Analysis and Modeling Tool, available through Open Source Physics 
(https://www.compadre.org), was used to track the fluid front in order to determine the 
velocity of sample wicking on the films. Any velocities below 2x10-7 m/s (periods of 
little to no movement) were not included in the average (n=8) calculations (see Figure 
4.4a). Flow rate was calculated as velocity multiplied by the C-CP film cross-sectional 
area as measured by SEM.  
Sample preparation for scanning electron microscopy 
 C-CP films being prepared for SEM were fixed in 1% osmium tetroxide for 1 
hour with shaking immediately after sample wicking. After removing the osmium 
tetroxide, samples were washed in deionized water 3 times for 3-5 minutes per wash. 
Next, the samples were washed in an ethanol-water mixture of the following ethanol 
percentages for 3 minutes each: 50%, 70%, 80%, 90%, 95%, 100%, 100%. The samples 
were then washed in a 50:50 hexamethyldisilazane(HMDS) –ethanol mixture for 3 
minutes and then finally washed in 100% HMDS and left to dry at 20˚C in a chemical 
fume hood for 2-3 days. After drying was complete, samples were attached to a metal 
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stage using adhesive and platinum coated using the Hummer 6.2 Sputtering system 
(Anatech, Battle Creek, MI) at 70 millitorr for 2 minutes. Images were captured using a 
Hitachi SU5000 Field Emission Scanning Electron Microscope (FE-SEM) (Hitachi, 
Tokyo, Japan). 
Sample preparation for transmission electron microscopy 
 To prepare for transmission electron microscopy (TEM), 40 µL of urine or CM 
sEVs isolated by UC or C-CP fiber separation were fixed in 4% paraformaldehyde for 30 
minutes on ice. All grid adhesion and staining steps were performed by pipetting drops of 
sample, stain, or wash onto parafilm and moving 200 mesh copper formvar coated grids 
(Electron Microscopy Sciences, Hatfield, PA) from one drop to the next. After sample 
fixation, grids were placed coated side down on 5 µL drops of each sample for 5 minutes. 
Grids were washed 3 times with DI water for 4 minutes each, stained with 2% uranyl 
acetate for 5 minutes, and then washed 3 times with DI water for 4 minutes each. Grids 
were air dried in a low-humidity environment and then imaged using a Hitachi H7600 
TEM (Hitachi, Tokyo, Japan). SEM measurements were made using ImageJ version 1.48 
software (NIH, Bethesda, MD) 
RNA sequencing 
 After isolation via ultracentrifugation, 4 patient urine sEV samples of 200 µL (2 
cancerous and 2 non-cancerous) and 4 patient cervical mucus sEV samples of 200 µL (2 
cancerous and 2 non-cancerous) were sent to Qiagen (Hilden, Germany) for RNA 
isolation, quality control, and differential expression analysis.  
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 In a second study, 42 patient cervical mucus-derived sEV samples (26 cancerous 
and 16 non-cancerous), isolated by ultracentrifugation were sent to Qiagen (Hilden, 
Germany) for RNA isolation, quality control, and differential expression analysis. In both 
studies, sample quality was assessed via average read quality and average base quality, 
prior to next generation sequencing.  
miRNA analysis 
 Analysis, (completed by Qiagen) included adaptor trimming, sequence mapping, 
principal component analysis, and miRNA differential expression analysis. 
Statistical Analysis 
 C-CP film sample flow velocity means were presented with ± 1 standard 
deviation. A one-tailed t-test with α=0.05, using Microsoft Excel’s data analysis software 
(Microsoft, Redmond, WA), was used to analyze film flow velocity numeric values. 
Tests with p<0.05 were considered statistically significant. RNAseq data, analyzed using 
the EdgeR package in R statistical software (r-project.org), was evaluated using a 






SEM imaging was performed on the C-CP films following wicking of 1X PBS-
diluted standard exosomes, patient urine, and patient plasma (Figure 4.1). The 1X PBS-
diluted standard exosomes demonstrated adherence along the length of the films while 
wicking and displayed typical vesicular morphology when adhered to the film surface 
(Figure 4.1a,b). The patient urine sample, much like the standard exosome sample, 
demonstrated sEV adherence along the length of the film surface and demonstrated sEV 
morphology similar to the standard exosome sample (Figure 4.1c,d). Finally, the patient 
plasma sample, while containing vesicular structures similar in morphology to the 
standard exosome sample, also included other plasma components, which were 





Figure 4.1. Scanning electron microscopy of C-CP films after wicking of 
various media. Film wicking of (a,b) 1X PBS-diluted standard exosomes, (c,d) 
patient urine, (e,f) patient plasma, and (g,h) 1X PBS, no sEV control. Images 




 Next, the flow rates of patient urine, patient plasma, and standard exosomes 
diluted in PBS, mock urine, reconstituted milk, or mock saliva on the films were 
measured and calculated using videos of sample wicking under stereoscopic observation. 
The average and maximum volumetric flow rates were calculated by multiplying the 
velocity of each sample observed during sample movement (see Figure 4.2)(Table 4.1) 
and the cross-sectional area of the film as measured from SEM images (see Figure 4.3, 
cross-section area: 9,310 µm2). Velocities during periods of minimal movement (velocity 
< 2x10-7 m/s)(see Figure 4.4a and Materials and Methods for explanation) were not 
included in the average flow calculations. Halting of fluid flow was due to the limited 
source pool and uneven sample distribution. PBS control samples demonstrated a 
significantly higher flow rate than all other samples. Patient urine average volumetric 
flow was significantly higher than mock urine + Std Exo, patient plasma, reconstituted 
milk + Std Exo, and mock saliva + Std Exo. Although PBS + Std Exo demonstrated a 
significantly lower average volumetric flow rate as compared to PBS, its average 
volumetric flow rate was significantly higher than those of patient plasma, mock urine + 
Std Exo, reconstituted milk + Std Exo, and mock saliva + Std Exo. Patient urine and PBS 
+ Std Exo flow rates were not significantly different. Additionally, the maximum 
volumetric flow rates for less viscous samples (PBS, patient urine, PBS + Std Exo, mock 
urine + Std Exo, and reconstituted milk + Std Exo) were generally higher than more 

































Figure 4.2. Average volumetric flow rates of C-CP film wicking. Results 
demonstrating the average volumetric flow rates for various matrices, including 
phosphate buffered saline (PBS), patient urine, patient plasma, PBS + standard 
exosomes (Std Exo), mock urine + Std Exo, reconstituted milk + Std Exo, and 
mock saliva + Std Exo (* - PBS; significantly different from all samples, p<0.05) 






film wicking. Matrices wicked on C-CP fiber-based films include phosphate 
buffered saline (PBS), patient urine, patient plasma, PBS + standard exosomes (Std 
Exo), mock urine + Std Exo, reconstituted (Reconst) milk + Std Exo, and mock 
saliva + Std Exo. Error is represented by 1 standard deviation from the mean. 
Table 4.1. Average and maximum volumetric flow rates of C-CP film wicking. 
Matrices wicked on C-CP films include phosphate buffered saline (PBS), patient 
urine, patient plasma, PBS + standard exosomes (Std Exo), mock urine + Std Exo, 
reconstituted (Reconst) milk + Std Exo, and mock saliva + Std Exo. Error is 
represented by 1 standard deviation from the mean, n=8. 
Figure 4.3. SEM of C-CP film cross-section. A cross-sectional image was 
captured of a C-CP film using SEM at 315x magnification. Area measurements 
























Figure 4.4. Patient urine C-CP fiber-based film wicking velocity and 
stereoscopic image. (a) Change in distance over time of patient urine 
wicking on C-CP film. Time points with a velocity below 2x10-7 m/s 
(periods of little movement, marked by red arrows) were removed from 
average velocity and flow calculations. (b) C-CP film stereoscopic image 
(5x magnification) of patient urine wicking experiment measured using 





When imaged via TEM, patient urine and CM sEVs isolated using a C-CP fiber 
column and the glycerol stepwise elution protocol (see Materials & Methods; Figure 4.5) 
revealed similar morphologies to those isolated from the same sample type by UC. 
Patient urine sEVs isolated by UC (Figure 4.5a) ranged in size from approximately 50-
200 nm, while the patient urine sEVs isolated by C-CP fiber-based HIC (Figure 4.5b) 
were approximately 200 nm in diameter. CM sEVs isolated by UC (Figure 4.5c) ranged 
in size from approximately 30-70 nm, while CM sEVs isolated by C-CP fiber-based HIC 
(Figure 4.5d) ranged in size from 60-100 nm. Samples derived from patient urine retained 
similar staining characteristics regardless of isolation protocol (Figure 4.5a,b), but CM 







Figure 4.5. Transmission electron microscopy of small extracellular 
vesicles derived from urine and cervical mucus via UC or C-CP fiber 
HIC. Samples include sEVs from a) patient urine, isolated by UC, b) 
patient urine, isolated by C-CP fibers using HIC with glycerol elution, c) 
cervical mucus, isolated by UC, and d) cervical mucus, isolated by C-CP 
fibers using HIC with glycerol elution. 
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 Initial pilot study sEVs (2 CM-derived – cancerous, 2 CM-derived – benign, 2 
urine-derived – cancerous, 2 urine-derived – benign) were run through quality control, 
library prepped, sequenced for miRNA, and analyzed for miRNA expression patterns. 
Principal component analysis (PCA), which dimensionally reduces and clusters samples 
based on the most influential variables (largest coefficient of variation), was used to look 
at similarities between samples (Figure 4.6). Principal component 1 is weighed more 
heavily than principal component 2, meaning sample proximity within principal 
component 1 indicates higher sample similarity than comparable sample proximity within 
principal component 2. Cancerous CM-derived sEV miRNA appeared to be grouping 
together with cancerous urine-derived sEV miRNA. Benign urine-derived sEV miRNA 
appeared to be comparable to cancerous CM- and urine-derived sEV miRNA in one 
sample, but not similar in the other sample. Both benign CM-derived sEV miRNA 
samples did not appear to group well together, but also differed significantly from 







Figure 4.6. Principal Component Analysis (PCA) plot of benign and 
cancerous cervical mucus- or urine-derived sEV miRNA expression (Pilot 
Study). Cancerous CM- (n=2), benign CM- (n=2), cancerous urine- (n=2), and 
benign urine- (n=2) derived sEV miRNAs were dimensionally reduced and 
clustered for easier interpretation. Data was normalized using the weighted 
trimmed mean of M-values (TMM) method.1 PCA completed using 50 miRNAs 
with the largest coefficient of variation based on TMM. Principal component 1 is 
the largest component in the variation and principal component 2 is the second 
largest component in the variation.  
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Differential expression analysis between pilot study benign (n=2) and cancerous 
(n=2) urine-derived sEV miRNA revealed numerous miRNAs that were highly 
differentially expressed and statistically different (Figure 4.7). Several cancerous urine-
derived sEV miRNAs appeared significantly upregulated or downregulated in 
comparison to benign counterparts. Specifically, 2 cancerous urine-derived miRNAs 
were highly downregulated and statistically significant (log10(p-value)>1.301) and 5 
cancerous urine-derived miRNAs were highly upregulated and statistically significant 
when compared to benign miRNA counterparts. The maximum log2 fold change 
magnitude between benign and cancerous urine-derived sEV miRNA was 3.85. Of those 
miRNAs that were highly differentially expressed and statistically significant in the 
cancerous urine-derived sEV samples, highly expressed miRNAs (high log of counts per 
million – logCPM) with tumor-related published literature were identified as potential 






Figure 4.7. Volcano plot of miRNA differential expression of benign vs 
cancerous urine-derived sEVs (Pilot Study). Benign urine-derived sEV samples 
(n = 2) serve as the basis of comparison against cancerous urine-derived sEV 
samples (n=2). A log2 fold change > 0 indicates miRNA expression upregulation 
while a log2 fold change < 0 indicates miRNA expression downregulation. 
Differential expression and statistical significance (p<0.05 or –log10(p-
value)>1.301) determined using the EdgeR package for R and statistical test 





















Differential expression analysis of pilot study benign (n=2) and cancerous (n=2) 
CM-derived sEV miRNAs primarily demonstrated high upregulation of miRNAs (Figure 
4.8). In the cancerous CM-derived sEV samples, 4 miRNAs were downregulated and 
statistically significant and 72 miRNAs were upregulated and statistically significant 
compared to benign CM-derived miRNAs. The maximum log2 fold change magnitude 
between benign and cancerous CM-derived sEV miRNA observed was 7.34 (Figure 4.8). 
Several miRNAs were identified as being highly expressed (high log CPM), highly 
differentially expressed (log2 fold change) and statistically significant (p-value <0.05) 
(Table 4.3) between benign and cancerous CM-derived sEVs. 
  
miRNA Name Log2 FC LogCPM p-value Direction 
hsa-mir-299-5p -3.842 4.161 0.0081 Downregulated 
hsa-mir-205-5p 3.687 10.807 0.0095 Upregulated 
hsa-mir-320d 2.597 4.281 0.018 Upregulated 
Table 4.2. Differentially expressed miRNAs of interest from benign (n=2) vs 
cancerous (n=2) urine-derived sEVs (Pilot Study). Significantly different miRNAs 
of interest were selected by looking for a high absolute value log2 fold change (Log2 





Figure 4.8. Volcano plot of miRNA differential expression of benign vs 
cancerous cervical mucus-derived sEVs (Pilot Study). Benign CM-derived sEV 
samples (n=2) serve as the basis of comparison against cancerous CM-derived 
sEV samples (n=2). Upregulation of miRNA expression (log2 fold change >0), 
downregulation of miRNA expression (log2 fold change <0), and statistical 
significance (p<0.05 or –log10(p-value)>1.301) determined using the EdgeR 
package for R and statistical test analogous to Fisher’s exact test that follows a 
























As part of a larger study, 42 CM-derived sEV (16 benign, 26 cancerous) samples 
were sequenced and analyzed (by Qiagen) for miRNA expression. After quality control, 
library prep, and sequencing, sample miRNA expression levels were analyzed using 
principal component analysis (PCA) to more easily understand clustering and similarities 
in expression between samples (Figure 4.9).Visually, cancerous CM-derived sEV 
miRNA profiles appeared to cluster closer along the first principal component compared 
to benign CM-derived sEV miRNAs. Overall, much of the variance in expression for all 
43 miRNAs appear very similar for both cancerous and benign CM-derived sEVs, as 
indicated by PCA overlap and close proximity. 
miRNA Name Log2 FC LogCPM p-value Direction 















Table 4.3. Differentially expressed miRNAs of interest from benign (n=2) vs 
cancerous (n=2) cervical mucus-derived sEVs (Pilot Study). Significantly different 
miRNAs of interest were selected by looking for a high absolute value log2 fold 







Figure 4.9. Principal Component Analysis (PCA) plot of benign and 
cancerous CM-derived sEV miRNA expression. Dimensional reduction and 
clustering was used to analyze miRNA expression similarities between benign 
CM-derived sEV samples (n=16) and cancerous CM-derived sEV samples (n=26). 
Data was normalized using the weighted trimmed mean of M-values (TMM) 
method.1 PCA completed using 43 miRNAs with the largest coefficient of 
variation based on TMM. Principal component 1 is the largest component in the 




In a larger analysis, benign (n=16) and cancerous (n=26) CM-derived sEV 
miRNAs were analyzed for differential expression based on benign CM-derived sEV 
miRNAs (Figure 4.10). Of the miRNAs analyzed, 18 were downregulated and 
statistically significant (log10(p-value) >1.301) and 4 were upregulated and statistically 
significant in the cancerous CM-derived sEVs. Additionally, the maximum log2 fold 
change magnitude observed between benign and cancerous CM-derived sEV miRNA 
expression was 3.14. By filtering miRNA expression by high fold change (log2 FC), high 
log of counts per million (logCPM), and statistical significance (p-value<0.05) as well as 
looking for cancer-related published literature, several potential biomarker candidates 
were identified (Table 4.4). Notably, hsa-mir-184 was identified with these qualifications 
in both the pilot study (2 benign, 2 cancerous, Figure 4.8, Table 4.3) and larger study (16 





Figure 4.10. Volcano plot of miRNA differential expression of benign vs 
cancerous cervical mucus-derived sEVs. Benign CM-derived sEV samples 
(n=16) serve as the basis of comparison against cancerous CM-derived sEV 
samples (n=26). MicroRNA expression upregulation (log2 fold change >0), 
downregulation (log2 fold change <0), and statistical significance (p<0.05 or –
log10(p-value)>1.301) determined using the EdgeR package for R and statistical 












































hsa-mir-223-3p -1.288 15.523 0.0500 
 
Downregulated 
Table 4.4. Differentially expressed miRNAs of interest from benign vs cancerous 
cervical mucus-derived sEVs. Differential expression determined using 16 benign 
and 26 cancerous CM-derived sEV samples. Significantly different miRNAs of 
interest were selected by looking for a high absolute value log2 fold change (Log2 
FC), a high log of counts per million (logCPM), a p-value<0.05, and tumor-related 
literature. 
Figure 4.11. Re-clustering of cervical mucus miRNA expression data. Ongoing 
research has observed clustering of samples into high-grade (G1) and low-
grade/benign (G2) rather than cancerous and non-cancerous. Top differentially 




 The impact that EVs may have on disease diagnostics and therapies is becoming 
more apparent. As EV biogenesis and classifications become clearer, more efficient, and 
effective EV isolations emerge, and EV technology moves closer to clinical translation.2, 
72 Specifically, EV isolation maintains a great deal of promise for early cancer 
detection.46 Due to frequent late stage discovery and severity, ovarian cancer (OC) is a 
prime candidate for EV-based diagnostics. According to a recent epidemiology review, 
patients diagnosed with OC at stages 3 or 4 have a 5-year survival rate of 29% and a 5-
year survival rate of 92% when diagnosed at stages 1 or 2.40, 73 As most OC patients are 
diagnosed in stages 3 or 474, early stage discovery via EV-based diagnosis may be used to 
greatly improve OC survival rates. Clinical routine screening for cancer cell-derived EVs 
is plausible, practical, inexpensive, and could substantially reduce instances of cancer-
related deaths. 
Although EVs have demonstrated promising and powerful therapeutic and 
diagnostic abilities in vitro, only a handful of clinical trials have reported results from 
phase 1-3 (dosage, safety, and efficacy)75-79 studies. The trials reporting results have 
demonstrated that therapeutic EV dosing has been well-tolerated in most instances with 
only a few cases of moderate adverse events.80 To date, no clinical trials regarding EV 
diagnostic ability have reported results. While these trials are promising, the number of 
trial applications has been limited primarily due to EV isolation inconsistencies, changing 
EV characterization definitions, and mutable good manufacturing practices (GMP). For 
EV technology to be translated to the clinic, it is vitally important that the EV community 
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establish greater consistency within EV isolation, classification, characterization, and 
sample source selection. The International Society of Extracellular Vesicles (ISEV) has 
thus far done an excellent job establishing standards of classification and 
characterization8, but much more research and discussion will be required to fully 
understand the complexities surrounding EV biogenesis and classification.  
 A large hurdle impeding consistency across EV research is choice of EV source. 
The majority of EVs used in clinical trials come from either autologous or allogeneic 
dendritic cells (DCs), mesenchymal stem cells (MSCs) or patient body fluids.80 Sources 
of EVs investigated in vitro may include human, plant, or other eukaryotic cell lines and 
numerous human body fluids.2, 3, 52, 80-89 Sample source can greatly impact the results of a 
study and should be carefully chosen for each application. By defining isolation strategies 
starting with sample source, the EV community may be able to improve EV diagnostic 
consistency, precision, and accuracy needed to progress toward clinical translation. While 
several studies have demonstrated diagnostic correlations using urine or plasma, more 
body fluids are worth investigating for region-specific diagnostic potential. For instance, 
hypothetically speaking, urine may provide the most accurate diagnosis for renal cell or 
bladder carcinomas, while breast milk may provide the most accurate diagnosis for breast 
cancer. Moreover, the strategies employed to isolate EVs should largely depend on the 
sample source and application desired. By investigating how EV separation techniques 
using various sample sources impacts downstream EV applications, the EV community 
may find correlations that help develop improved guidelines and standards for EV 
isolation and diagnostics. 
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 When choosing an EV isolation design, both physical characteristics and potential 
application should be considered. Vesicle properties including size, morphology, 
concentration, and protein, nucleotide, and lipid content can influence EV separation 
parameters.12, 15, 30, 48, 90, 91 Furthermore, the EV source fluid viscosity, protein profile, 
volume, and contaminants can affect process efficiency or resulting sample purity. For 
instance, a highly viscous source, such as blood plasma or cervical mucus, may not flow 
through microfluidics devices under the same conditions as urine, thus potentially 
influencing capture efficiency. As applications are considered, it is important to 
understand the EV sub-populations and contaminants present in each EV source. For 
instance, blood sample EV separations have demonstrated the highest level of 
contamination (proteins, non-vesicular membranous species, lipoproteins), which may 
influence downstream proteomics, lipidomics, or therapies.92, 93 Even while considering 
the EV physical characteristics, source, and application, with the lack of comparison of 
EV isolation techniques and sources, it can be difficult to ascertain the optimal approach. 
This study aims to compare the effects of separation method and sEV source (urine or 
cervical mucus), on recovered sEV morphology, and RNA sequencing (miRNA) results. 
In particular, this study provides important preliminary data for the study of ovarian 
cancer diagnostic potential of urine- and cervical mucus-derived sEV miRNA. The 
ultimate aim of these investigations and those of the cohort is to determine which EV 
source is optimal for downstream predictive ovarian cancer diagnostics and to optimize 




The Case for Urine-derived EVs 
Urine was chosen first for EV investigation as it has become a popular choice for 
EV study due to its availability and ease of collection. Urine-derived EVs have been 
characterized by morphology, proteome, and miRNA content numerous times, providing 
an abundance of information for comparison.42, 52, 94 Furthermore, ultracentrifugation, 
size exclusion, microfluidics, polymer precipitation, and immunoaffinity separation 
approaches have been used to isolate urine-derived EVs.20, 52, 56, 95, 96 Given the lack of 
standards within the EV community, size characterization and quantification of urinary 
EVs appears heavily dependent on isolation protocol, purification steps, sample 
preparation, and characterization method. However, when developed under identical 
protocols, different size distribution and concentrations of urinary EVs could indicate 
underlying disease states.42 Urinary EVs may be particularly useful for downstream 
miRNA analysis as the abundant protein content in urine does not prohibit RNA 
extraction43 and extravesicular RNA does not tend to co-precipitate with urinary EVs.43, 97 
Moreover, publications have identified more than 5,000 urinary EV proteins (many of 
which can be analyzed online at EVpedia and Vesiclepedia) that researchers can 
investigate further as potential biomarkers.42 Compared to other body fluids, urine and 
blood have amassed the most EV-related literature and, given the large amount of data 
available and ease of access, may be ideal for biomarker discovery and disease 
diagnostics.  
Since plasma EVs cannot easily cross the glomerular filtration apparatus, the 
majority of urinary EVs are derived from the kidneys.58 Based on the premise that EV 
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sources in close proximity to diseased tissue may allow for better diagnostic accuracy, 
most studies of urinary EV diagnostic potential have focused on urinary tract diseases.20, 
44, 45, 55, 97, 98 However, proteomics analysis of urinary EVs has demonstrated significant 
diagnostic potential for urogenital tract diseases, metastatic cancers, and non-urologic 
diseases. For instance, Wang et al found that SNAP23 and calbindin were elevated in 
Parkinson’s Disease urinary EVs and predicted disease 86% of the time.57 The suggestion 
that urinary EVs can be used to diagnose urogenital tract diseases is valid, but, likely due 
to glomerular filtration of proteins, urinary EVs may also have the potential to diagnose 
distant diseases or injuries, such as neurodegenerative diseases, cardiovascular diseases, 
liver injury, and cancers.35, 57, 92, 95, 99, 100  
The early results of this study suggest that urine may be an excellent EV source 
for isolation techniques involving wicking or capillary movement. Initial TEM images of 
sample wicking on C-CP fiber-based films (Figure 4.1) demonstrated high similarity in 
EV capture and morphology between PBS-diluted standard exosomes (Figure 4.1a,b) and 
patient urine (Figure 4.1c,d) samples. Vesicles in both PBS-diluted standard exosomes 
and patient urine samples appeared to adhere to the film surface in large aggregates. 
Although, it remains to be seen if capturing vesicles in aggregates or with even surface 
distribution is more or less beneficial for easy vesicle detection. When compared to 
patient plasma wicked on C-CP films (Figure 4.1e,f), urine presented clearer and cleaner 
capture of EVs, suggesting that urine may be more compatible with wicking-based EV 
separation and capture. Plasma samples may require further purification or 
supplementation (to reduce protein contamination or viscosity) in this format in order to 
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wick and separate plasma sEVs. Analysis of the flow rates of the various matrices on C-
CP films (see Figure 4.2) revealed that PBS-diluted standard exosomes and urine flow at 
significantly lower rates than PBS, but significantly higher rates than patient plasma and 
standard exosomes diluted in mock urine, reconstituted milk, or mock saliva. The 
presence of standard exosomes in PBS appeared to decrease the sample flow rate 
compared to PBS alone. The significant difference in flow rates of patient urine and 
mock urine suggests that the samples have significantly different composition. As the 
mock urine is not capable of representing the large range and variation of patient urine 
(especially in regard to water content and solute concentrations), the difference in flow 
rates is not surprising. Additionally, it seems unlikely that the urine collection 
preservatives (protease inhibitors and a bacteriostatic) may be altering the sample surface 
tension, viscosity, or interaction with the fiber surface. However, as urine samples can 
vary widely from patient to patient, more sample replicates would be required to make 
substantial claims.  
Due to its widespread use, availability of proteomic information , compatibility 
with wicking and capillary flow applications, and diverse EV population, urine may act 
as an optimal EV source in most situations. However, as one of the primary goals of these 
investigations is to determine which EV source is optimal for downstream predictive 
ovarian cancer diagnosis, body fluids more closely associated with the female 
reproductive tract needed to be explored. While urine may provide heterogenous EV 
populations useful for a variety of applications, greater homogeneity in EV population 
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may provide enhanced diagnostic sensitivity for certain diseases. Hence, the next logical 
step was to investigate a body fluid with greater proximity to the ovaries. 
The Case for Cervical Mucus-derived EVs 
Recently, cervical mucus (CM) has generated interest as an EV source for 
diagnosis of diseases or injury in the female reproductive tract. Like urine, CM proximity 
to potential diseased areas (cervix, endometrial lining, ovaries, fallopian tubes, etc.) may 
allow for greater diagnostic specificity. While blood-derived EV disease diagnosis is 
promising, low specificity, heterogeneous EV populations, and EV sub-population 
masking by other EV populations may affect diagnostic accuracy in certain applications. 
In the case of ovarian cancer, the potential of CM specificity may outweigh diagnostic 
potential of more heterogenous EV population sources, such as blood and urine.  
Although CM may be an appealing source of EVs for diagnosis, there has been 
very little investigation into CM-derived EVs by researchers. Since EVs are found in 
most body fluids6, 101, are heavily involved in placental barrier communication during 
pregnancy102, 103, and Flori et al. found that cervical mucus from pregnant and non-
pregnant women contain membranous vesicles having exosome-like structure,24 there is 
reasonable evidence that CM contains EVs. However, the CM-derived vesicle 
concentrations and characteristics are not well documented. With so little available 
information, it can be challenging to develop new protocols that produce consistent EV 
populations and downstream results from CM. However, the lack of CM-derived EV 
research offers an opportunity to expand understanding of EV separation, morphology, 
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and downstream analysis of CM. The practicality or ease of collection of CM may also 
generate concern, especially compared to urine; however, CM can be easily obtained 
during routine gynecological examinations. 
In this study, initial analysis suggests that sEVs may be separated from CM in a 
similar fashion to urine. TEM imaging of urine and CM samples subjected to UC and 
glycerol elution (see Figure 4.5) all revealed small dimpled vesicles meeting the 
description of sEVs. The similarity in morphology between UC and glycerol elution 
samples for each sample type suggests that the glycerol elution method may provide an 
alternative to UC isolation. Furthermore, the similarity in morphology across CM UC and 
glycerol elution samples suggests that CM may be compatible with chromatography 
techniques despite high sample viscosity.  
After literature investigation and experimental demonstration of CM sEV 
separation, the potential of CM sEV downstream analysis needed to be investigated. With 
an eye toward comparison of urine and CM downstream analyses and ensuing OC 
diagnostics investigations, an sEV miRNA sequencing pilot study was designed to 
examine miRNA differential expression of cancerous and benign urine and CM sEV 
samples.  
Comparison of urine- and CM-derived EV miRNA sequencing 
 Urine and CM-derived EV samples were prepared via UC prior to miRNA 
isolation, sequencing, and analysis. The pilot study consisted of 2 cancerous urine-
derived, 2 non-cancerous urine-derived, 2 cancerous CM-derived, and 2 non-cancerous 
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CM-derived EV samples with all 4 urine-derived and 4 CM-derived EV samples sourced 
from the same 4 patients (one urine and one CM sample from each patient). Although the 
sample sizes were not large enough to make conclusive statements, the pilot study 
allowed for assessment of sample source compatibility with the given protocol and 
provided small insights into the miRNA differential expression of urine- and CM-derived 
EVs. 
 Initial completion of quality control and observation of the PCA (see Figure 4.6) 
suggests that the UC method used here can produce viable urine- and CM-derived EVs 
for downstream miRNA analysis. A more thorough analysis of the quality and 
differential expression of miRNA may be required when developing or comparing new 
isolation methods. In this case, UC is already a well-established EV isolation protocol 
with many studies demonstrating viable miRNA analysis.16, 19, 59, 65, 104 For this study, as 
CM-derived EVs have never been sequenced for miRNA, it was very important to verify 
miRNA quality in the CM-derived EV samples. 
 The pilot study PCA of benign and cancerous cervical mucus- or urine-derived 
sEV miRNA expression (see Figure 4.6), although based on small sample size, suggested 
that CM-derived EV miRNAs may cluster better into benign and cancerous groups than 
urine-derived EV miRNAs. Both urine- (Figure 4.7) and CM-derived (Figure 4.8) sEV 
miRNA profiles demonstrated several miRNAs that were highly differentially expressed 
and statistically different; however, the number of miRNAs meeting this criteria was 
much greater for CM-derived sEVs than urine-derived sEVs (CM-derived: 4 
downregulated, 72 upregulated; Urine-derived: 2 downregulated, 5 upregulated). 
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Moreover, the maximum log2 fold change for CM-derived sEV miRNAs was 7.34 while 
the maximum log2 fold change for urine-derived sEV miRNAs was 3.85. It is unclear 
why the differentially expressed CM-derived sEV miRNAs are skewed toward 
upregulation, but a larger sample size would provide more extensive data and possible 
insights. It is notable that several of the miRNAs identified as highly expressed and 
highly differentially expressed in urine- and CM-derived sEVs were found in tumor-
related literature (see Table 4.2 and Table 4.3). This suggests that both urine- and CM-
derived sEVs may facilitate diagnosis of cancerous tumors using specific miRNA 
markers. However, the greater number of differentially expressed and statistically 
different miRNAs, and the greater maximum log2 fold change suggests that CM-derived 
sEVs may provide clearer demonstrations of benign and cancerous sEV miRNA 
differential expression. Thus, CM-derived sEV-identified miRNA markers may enable 
more accurate and specific downstream OC diagnoses than urine-derived sEV miRNA 
markers. 
 After discussion and comparison of urine- and CM-derived sEVs, CM-derived 
sEVs were chosen for a subsequent, more comprehensive miRNA study. The larger study 
group was comprised of 16 benign CM-derived sEV and 26 cancerous CM-derived sEV 
samples. Ideally, the control benign patient samples would comprise half of the group; 
however, the total number of potential benign CM samples were difficult to predict ahead 
of time as patients who were asked to supply samples were undergoing hysterectomies 
because they had ovarian tumors were not biopsied until after surgery. PCA of all 42 
samples (see Figure 4.9) did not reveal distinct groupings between benign and cancerous. 
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Although this is concerning, especially regarding differential expression, more in-depth 
analysis of groupings based on cancer type, stage, and physical characteristics revealed 
more representative clustering. Early bioinformatics indicates that high-grade tumor 
sample cluster together, while low-grade tumor and benign samples are more similar in 
expression (see Figure 4.11). This may be an indication that low-grade tumors and benign 
samples may be more difficult to distinguish based on these parameters. As ovarian 
cancer is a highly heterogeneous disease, this is not surprising, and additional 
categorization beyond these simplistic cancerous and non-cancerous groupings will likely 
be required to fully characterize the complexities of the data. Concerning this 
observation, more research is ongoing to classify and discriminate characteristics 
between these groups to better analyze biomarker candidates. However, differential 
expression analysis of the 42 samples (see Figure 4.10) based on simple benign and 
cancerous groupings still provided insightful patterns and demonstrated significant 
miRNA upregulation (4 miRNAs) and downregulation (18 miRNAs). Significant 
differential expression, even with simple benign and cancerous groupings, is evidence 
that specific miRNA markers may be used either in single or multiplexed formats to 
identify ovarian cancer CM-derived sEVs. Similar to the pilot study, these 22 
significantly differentially expressed miRNAs were cross-referenced with tumor-related 
literature and the markers that were highly differentially expressed and relevant to 
ovarian cancer were identified (see Table 4.4).  
Of the markers identified, hsa-miR-184 was of particular interest as it was highly 
upregulated in both the pilot and 42-sample miRNA studies and early indications from 
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ongoing research suggest that it is also highly upregulated in the clustered high-grade 
tumor samples as compared to the low-grade tumor and benign samples. Further 
investigation into published research revealed that hsa-miR-184 has been identified as a 
potential prognostic marker in epithelial ovarian cancer.105 Functionally, hsa-miR-184 
has been categorized as a tumor suppressor for renal cell carcinoma, colorectal cancer, 
retinoblastoma, and epithelial ovarian cancer and, accordingly, is typically downregulated 
in these tumor environments.105-107 While the exact mechanism is unclear, hsa-miR-184 
appears to regulate cell proliferation, apoptosis, and inflammation.105 However, this study 
suggests that hsa-miR-184 is highly upregulated in ovarian tumor sEVs, a marked 
difference from most investigations. This appears puzzling at first, but there are several 
rationales that may explain the disparity. First, no study has used sEV-derived miRNA to 
link hsa-miR-184 to a tumor environment. While sEV contents are derived from the cell 
cytoplasm, specific molecules are often selectively packaged into sEVs to direct exact 
cell communication.4, 108, 109 Second, while most investigations have found that hsa-miR-
184 is downregulated in tumor tissues, Chen et al.106 found that tongue squamous cell 
carcinoma had upregulated levels of hsa-miR-184 compared to corresponding non-
tumorous tissue and that upregulation of hsa-miR-184 may promote tongue squamous 
cell carcinoma migration and metastasis. Therefore, since sEVs are a mode of 
microenvironmental communication and are known to be involved in tumor 
microenvironment progression and metastasis, it is possible that hsa-miR-184, a potential 
promoter of cell migration and metastasis, may be released into the microenvironment 
where it could serve to promote disease spread.  Lastly, the variety of types and stages of 
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ovarian cancer involved in this study may influence hsa-miR-184 expression. For 
instance, late stage (III/IV) epithelial ovarian cancer tissues have demonstrated lower hsa-
miR-184 expression,105 which may skew the differential expression results if samples are 
not more specifically categorized for analysis. While the intracellular mechanisms of hsa-
miR-184 require further investigation, especially for therapeutic applications, hsa-miR-
184 differential expression and its known involvement in ovarian cancer mechanisms 
may prove to be a useful biomarker for diagnostic or disease progression monitoring 
applications. It is hoped that more insight into this possible biomarker and the discovery 
of others may be realized during an ongoing Phase II patient study that focuses on 
patients who have identified BRCA1 mutations.  
Frequently denoted as BRCA1 “positive,” a mutation in the BRCA1 tumor 
suppressor gene is associated with a much higher risk of developing ovarian, breast, 
fallopian tube, peritoneal, and pancreatic cancer.110 As a result of a BRCA1 mutation, the 
homologous recombination system responsible for repairing double strand DNA breaks 
may fail and cell cycle arrest may be impaired with consequence of a higher risk of tumor 
development.111 For women with a BRCA1 mutation, the lifetime risk of developing OC 
is 40% and late stage OC discovery survival rates remain low.110 In the currently ongoing 
study, cervical mucus samples from patients undergoing prophylactic surgery as well as 
those with tumors, both cancerous and non-cancerous, will be processed for EV isolation 
for subsequent characterization via RNA sequencing and proteomics. The resulting 
miRNA expression and protein data from these samples will be used to identify novel 
protein biomarkers for early stage OC. Moreover, machine learning algorithms are being 
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constructed that will be used to correlate miRNA and protein expression data to uncover 
specific biological pathways involved in tumor initiation and progression. In this manner, 
intermediary proteins may be identified that may prove to be diagnostically useful 
biomarkers or potential cancer therapy targets.  
Sample source selection and OC sEV diagnostic potential  
These investigations have compared the resultant sEV morphology and miRNA 
profiles for different sEV separation methodologies and sample sources (urine and 
cervical mucus). The apparent distinctions between urine and CM-derived sEVs, 
particularly concerning miRNA expression, highlight the need to consider sample source 
when selecting sEV separation method, downstream analysis, and biomarker discovery. 
Both urine- and CM-based diagnostic approaches have great potential and are worthy of 
consideration for downstream sEV analysis. However, for these investigations, CM was 
chosen based on proximity to the cancer origin and preliminary results. Resulting sEV 
miRNA data suggests that CM-derived sEV miRNA sequencing can be used to construct 
a panel of OC diagnostic biomarkers. With the correct sEV isolation methods, CM-
derived sEV miRNA may deliver a simple test that could be seamlessly integrated into 
routine gynecological examinations. Such a test would greatly increase the number of 
early-stage OC diagnoses and potentially increase the average 5-year survival rate of OC 
patients. While the lofty aims of this assay are still far from accomplished, future 
investigations are being designed to address the diagnostic accuracy of specific 
biomarkers. These investigations should include more CM-derived sEV miRNA 
sequencing and analysis, CM-derived sEV proteomics analysis, CM-derived sEV C-CP 
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film-based separation, and colorimetric assay development. Continued development of C-
CP film-based sEV isolation could benefit from even sample application and increased 
wicking capacity using sample and absorption pads (similar to standard lateral flow 
assays, e.g. pregnancy test strips). Uniform sample application and wicking would 
improve the consistency of C-CP film-based sEV separation and elucidate the prospects 
of the sEV isolation strategy for use in diagnostics.   Further transcriptomics and 
proteomics investigations should focus on clustering patients based on carcinoma subtype 
or underlying pathophysiology and analyzing data using bioinformatic machine learning 
algorithms to reveal expression patterns. These expression patterns may then be used to 
develop a panel of diagnostic biomarkers to predict OC occurrence. Paired with the 
appropriate sEV isolation, predictive OC biomarkers could lead to more accurate, easier 
to perform, and inexpensive OC detection assays. Clinical translation of this technology 
has the potential to reach clinical or home settings and would truly revolutionize early 
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The primary goal of these studies is to ultimately create a “liquid biopsy” system 
for exosome-based diagnosis of ovarian cancer. Exosomes are an excellent “liquid 
biopsy” candidate species as they are found in a variety of body fluids, making invasive 
or surgical diagnostic procedures unnecessary. In addition, they are inherently more 
stable than other liquid biopsy targets, such as free DNA, RNA, and proteins. While 
promising, exosome applications have been limited by inconsistent, expensive and time-
consuming isolation techniques. To alleviate this problem, we have developed a PET C-
CP fiber-based EV isolation method that is quick and inexpensive and have compared it 
to standard EV isolation protocols.  
For ovarian cancer diagnostics to be possible using this new isolation platform, 
we must devise methods of selective EV isolation based on specific EV-associated 
ovarian cancer biomarkers. These efforts will require the use of model sEVs derived from 
normal and malignant ovarian cells. To this end, we have engineered a model system 
consisting of two ovarian cell lines, one normal and one cancerous, to produce green and 
red fluorescent sEVs, respectively, that may be employed in the testing and optimization 
of the PET C-CP EV isolation platform for specific sEV capture. The model sEVs can be 
easily visualized via fluorescence microscopy and provide a simple, cost-effective, 
consistent system to verify specificity and sensitivity of antibodies to OC biomarker 
proteins grafted to the PET C-CP fiber surfaces for use in lateral flow-based diagnostics 
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for OC. In order to ensure selective capture potential and imaging compatibility, the 
model EVs were generically captured on the PET C-CP fibers and selectively captured on 
nitrocellulose using ovarian cancer marker-specific antibodies.  
With future experiments in mind, we demonstrated that urine or cervical mucus 
can be used as a sample source for EV isolation and for EV miRNA differential 
expression analysis. The miRNA data collected during these investigations and in 
ongoing proteomics investigation will be used to identify novel ovarian cancer EV 
biomarkers. Additionally, a new clinical investigation of BRCA1 mutation patients with 
or without ovarian cancer of varying stages will continue to bolster biomarker discovery. 
Newly discovered ovarian cancer biomarkers will be incorporated into the new PET C-
CP platform selective EV capture method to improve early ovarian cancer detection. To 
support clinical translation of the PET C-CP fiber technology, a PET C-CP fiber-based 
film is being refined to capture and detect ovarian cancer EVs as a colorimetric lateral 
flow assay, similar to a pregnancy test. With a new EV isolation method, model sEVs 
designed to test it, a protocol for ovarian cancer biomarker identification and 
incorporation, we have a clear path toward clinical translation. Future work will focus on 
the development of a prototype for a quick, inexpensive, and easy-to-use colorimetric 









EXTRACELLULAR VESICLE CHARACTERIZATION IN BUFFERS 
 
Materials and Methods 
Extracellular Vesicles (EV) isolation 
 Caov-3 cells were grown to 80% confluency, refreshed with new media, and 
incubated for 3 days. Conditioned media was then aspirated from the culture flask and 
processed using an ultracentrifugation protocol. Briefly, conditioned culture media was 
centrifuged at 700 x g for 5 minutes at 22˚C using an Eppendorf Centrifuge 5430R 
(Eppendorf, Hamburg, Germany). The resulting supernatant was centrifuged at 2,000 x g 
for 10 minutes at 22˚C using an Eppendorf Centrifuge 5430R (Eppendorf, Hamburg, 
Germany). Again, the resultant supernatant was centrifuged at 10,000 x g for 30 minutes 
at 4˚C using a Beckman Coulter Avanti J-26S XPI Centrifuge with a JA-25.50 rotor 
(Beckman Coulter, Brea, CA). Lastly, the supernatant resulting after centrifugation at 
10,000 x g was centrifuged at 120,000 x g for 60 minutes at 4˚C using a Beckman 
Coulter Optima XPN-80 Ultracentrifuge and a Type 45 Ti rotor (Beckman Coulter, Brea, 





EV buffer characterization 
Caov-3 ultracentrifugation EV samples in PBS were mixed with several buffers at 
a ratio of 1:1. Mixing buffer working concentrstions included 1X PBS, 5%,10%, 20%, 
and 30% glycerol, 25 mM trehalose, 20% acetonitrile, mixed 20% acetonitrile and 25 
mM trehalose,, 1 M ammonium sulfate, and mixed 1 M ammonium sulfate and 20% 
acetonitrile diluted in PBS. EVs were mixed with each buffer and stored briefly on ice 
prior to fixation and staining for transmission electron microscopy (TEM) imaging. 
Sample preparation for transmission electron microscopycaov-3 EVs isolated by UC 
were fixed in 4% paraformaldehyde for 30 minutes on ice. All grid adhesion and staining 
steps were performed by pipetting drops of sample, stain, or wash onto parafilm and 
moving 200 mesh copper formvar coated grids (Electron Microscopy Sciences, Hatfield, 
PA) from one drop to the next. After sample fixation, grids were placed coated side down 
on 5 µL drops of each sample for 5 minutes. Grids were washed 3 times with DI water 
for 4 minutes each, stained with 2% uranyl acetate for 5 minutes, and then washed 3 
times with DI water for 4 minutes each. Grids were air dried in a low-humidity 





 Caov-3 small EVs (sEVs) isolated by UC were subjected to a various buffers and 
imaged using TEM to assess morphological structure and damage. Caov-3 sEVs in PBS 
(see Figure A1b) demonstrated sEV characteristics under this staining methodology. 
Caov-3 sEVs in PBS maintain a “dimpled” structure with a slight shadow surrounding 
the vesicle and are within 30-150 nm in diameter as compared to the negative control. 
Caov-3 sEVs diluted in 5%, 10%, 20%, and 30% glycerol (see Figure A1c-f) 
demonstrated similar morphology to Caov-3 sEVs in PBS and displayed no evidence of 
structural damage. Glycerol samples demonstrated significant non-vesicular imaging 
artifacts compared to the positive and negative controls. Next, Caov-3 sEVs diluted in 25 
mM trehalose (see Figure A1g) demonstrated morphology similar to Caov-3 sEVs in 
PBS, but appeared in a smaller size range and stained much darker. Samples diluted in 25 
mM trehalose also displayed significant non-vesicular imaging artifacts compared to the 
positive and negative controls. Caov-3 sEVs diluted in 20% acetonitrile (see Figure A1h) 
demonstrated very little morphological similarities to Caov-3 sEVs in PBS and contained 
large amounts of organic debris while Caov-3 sEVs diluted in 20% acetonitrile with 
addition of 25 mM trehalose (see Figure A1i) saw some retention of sEV morphological 
structure in addition to altered staining and organic debris. Addition of 1M ammonium 
sulfate to Caov-3 UC samples (see Figure A1j) resulted in morphological change and 
possible crenation of vesicles as well as altered staining and non-vesicular artifacts. 
Finally, addition of 1M ammonium sulfate and 20% acetonitrile to Caov-3 UC samples 




Figure A1. Scanning electron microscopy of Caov-3 small extracellular 
vesicles isolated by UC and diluted in various buffers. PBS negative control 
containing a) no sEVs and Caov-3 sEVs diluted in b) PBS, c) 5% glycerol, d) 
10% glycerol, e) 20% glycerol, f) 30% glycerol, g) 25 mM trehalose, h) 20% 
acetonitrile, i) 20% acetonitrile and 25 mM trehalose, j) 1 M ammonium sulfate, 
and k) 1 M ammonium sulfate and 20% acetonitrile. 
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staining, and non-vesicular imaging artifacts, similar to Caov-3 vesicles subjected to 1M 
ammonium sulfate alone. 
Discussion 
As the parameters surrounding binding affinity of sEVs to poly(ethylene 
terephthalate) capillary-channeled polymer (C-CP) fibers are being further investigated, it 
is important to determine which media components may work best for eventual elution 
and separation of sEVs from the PET C-CP fibers. Ideally, all reagents used during the 
separation process should be compatible with the technical aspects of the 
chromatography process, while also retaining the morphology, structure, and informatic 
components of the sEVs. Damage to the vesicles could result in misinterpretation of 
downstream results. Therefore, TEM imaging was used to look at morphology and 
potential damage to vesicles in various buffers. As discussed before, intact sEVs 
observed under TEM tend to flatten out slightly, showing a circular structure with a 
“dimpled” interior.1, 2 Additionally, vesicles in this format tend to show a darker ring or 
shadow around the circular structure due to the uranyl acetate employed while staining.3 
Of note, observed differences in the intensity of staining may be due in part to slight 
variation within the staining process. Any significant structural variation or lack thereof 
may indicate significant damage to or lysing of the vesicles. 
Caov-3 sEVs collected via UC and diluted in 5%, 10%, 20%, and 30% glycerol 
(see Figure A1c-f) appeared to maintain normal sEV morphology within this description 
when compared to Caov-3 sEVs diluted in PBS. Glycerol, frequently used as a cryo-
protectant in biological laboratories4, is an organic osmolyte that helps maintain cell 
integrity and protein structure through reduction of intracellular non-organic ions.5-7 
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Furthermore, because it is a highly polar protic solvent, glycerol has been used as a 
solvent in hydrophobic interaction chromatography.8, 9 Dilution of sEVs in 5-30% 
glycerol revealed conserved sEV morphology under TEM (see Figure A1c-f). Small EV 
protectant and organic solvent properties make glycerol an ideal candidate for further 
biological liquid chromatography investigations.  
Caov-3 sEVs diluted in 25 mM trehalose showed limited damage based on 
morphology but appeared in much lower concentrations and smaller vesicle diameters, 
suggesting that damage or vesicle lysing may be occurring (see Figure A1g). Small EVs 
in 20% acetonitrile alone appeared to be severely damaged, lysed, and fragmented (see 
Figure A1h). While addition of 25 mM trehalose to 20% acetonitrile appeared to protect 
sEVs from some of the effects of 20% acetonitrile, there remained significant changes in 
vesicle staining and morphology among most vesicles (see Figure A1i). Addition of 25 
mM trehalose to storage buffers has been shown to prevent aggregation and cryodamage 
in exosomes while narrowing the size distribution of the vesicles.10 In this study, sEVs 
diluted in or supplemented with 25 mM trehalose demonstrated conserved morphology 
and structure (see Figure A1g,i). Therefore, 25 mM trehalose may be worth further 
investigation as a stabilizing agent for downstream sEV analysis and sEVs undergoing 
liquid chromatography separation. 
As sEVs are comprised of a semi-permeable phospholipid bilayer, they are 
susceptible to disruption with organic solvents and small changes to osmotic pressure. 
Acetonitrile is a polar aprotic organic solvent that is particularly useful for 
chromatographic separations. However, its organic dissolution properties may severely 
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disrupt the phospholipid bilayer of sEVs, even in low concentrations.11 This is clearly 
demonstrated in Figure A1h, where only organic fragments remain after application of 
20% acetonitrile to sEVs and in Figure A1i where the vesicles are disfigured. Dilution of 
Caov-3 sEVs in 1 M ammonium sulfate demonstrated significant changes in vesicle 
shape and staining, but did not fragment the vesicles to the same degree as 20% 
acetonitrile (see Figure A1j). Finally, sEVs diluted in a solution of 20% acetonitrile and 1 
M ammonium sulfate demonstrated significant changes in vesicle shape and staining, but, 
again, did not fragment the vesicles to the same degree as 20% acetonitrile alone (see 
Figure A1k). Ammonium sulfate is an inorganic salt commonly used in chromatographic 
separations that reduces protein solubility without denaturing the proteins.12, 13 However, 
semipermeable phospholipid bilayers are highly susceptible to variations in salt 
concentrations in solution. For example, human osmoregulation maintains NaCl in the 
blood at 0.9 % w/v and any variations can lead to changes in osmotic pressure and 
crenation or lysing of cells.14 Ammonium sulfate, while not frequently tested with living 
cells due to toxicity concerns, has demonstrated inhibitory effects toward C. Albicans 
with a concentration greater than 0.3 g/L.15 In perspective, 1 M ammonium sulfate is 
equivalent to 132.14 g/L and, for these reasons, will likely affect the stability of the 
phospholipid bilayer of sEVs. 
 Together, these results indicate that glycerol in moderate concentrations ranging 
from 5-30% may help protect sEV morphology if used as a diluting reagent. Furthermore, 
addition of 25 mM trehalose, while results are not as conclusive, may help retain EV 
morphology as well. However, 20% acetonitrile and 1 M ammonium sulfate, when 
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applied separately and in conjunction may severely alter sEV structure and would likely 
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EXOSOME UPTAKE EXPERIMENT 
 
Materials and Methods 
 
Passage of Dictyostelium discoideum 
Dictyostelium discoideum AX2 cell culture flasks were passaged when cells 
reached at least 70-90% confluency. Media from the old 25 cm2 flask was replaced with 7 
mL of fresh HL5 (Recipe on DictyBase.org) and the flask was vigorously beaten against 
the palm 5-7 times to detach the amoeba in solution. Next, 7 mL of fresh HL5 was added 
to each new culture flask and supplemented with 7 µL of 1000X Ampicillin (or 
appropriate selection). Finally, 0.1- 0.3 mL of the cell culture media from the old flask 
was added to any new flasks. Passage of cells into 75 cm2 culture flasks follows the same 
protocol with exception of using 15 mL of fresh HL5 and 15 µL of 1000x Ampicillin (or 
appropriate selection) instead. 
Exosome isolation 
All centrifugation steps performed below 12,000Xg were performed using an 
Eppendorf Centrifuge 5430R (Eppendorf, Hamburg, Germany). Centrifugations of 
12,000Xg or more were performed using a Beckman Coulter Avanti J-26S XPI 
Centrifuge with a JA-25.50 rotor (Beckman Coulter, Brea, CA). The first centrifugation 
step was performed at 700Xg (5 min., 22˚C) in a full 50 mL conical centrifuge tube. 
After centrifugation, 45 mL of the supernatant was transferred to a new 50 mL conical 
centrifuge tube for further centrifugation, with the remaining 5 mL of supernatant saved 
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for exosome isolation via the C-CP HIC method. The second centrifugation was 
performed at 2,000Xg (10 min., 22oC.) The final centrifugation step was performed at 
12,000Xg (30 min., 4oC.) The supernatant was carefully removed and the final pellet was 
re-suspended in 400 µL of PBS and stored at 4oC.  
GFP-Vacuolin-β AX2 transfection  
 Escherichia coli containing GFP-Vacuolin-β plasmid were obtained from Dr. 
Marcus Maniak, University of Kassel, Germany. GFP-Vacuolin-β presence in E. coli was 
verified via Polymerase Chain Reaction (PCR) with primers matching the GFP-Vacuolin- 
β nucleotide sequence. A Plasmid Maxi Kit (QIAGEN, Hilden, Germany) was used to 
isolate the GFP-Vacuolin-β plasmid followed by gel electrophoresis and PCR to verify 
the presence of the plasmid. AX2 Dictyostelium discoideum cells were transfected with 
the GFP-Vacuolin- β plasmid by electroporation. D. discoideum cells were centrifuged 
for 5 minutes at 500Xg and 4˚C, washed in 1 mL of H50 solution (Recipe on 
DictyBase.org) twice and resuspended to a concentration of 2x107 cells/mL. After 
washing, 100µl of the cells in H50 were added to a pre-chilled 1 mm gap cuvette. Next, 2 
µg of GFP-Vacuolin-β plasmid DNA was added to the cuvette and allowed to incubate 
on ice for 5 minutes. The cuvette underwent two consecutive pulses of 0.85 kV and 
capacitance 25 µF with 5 seconds recovery between pulses. Electroporated cells sat on 
ice for 5 minutes before being transferred to culture flasks with 7 mL of HL5 media. 
G418 selection was added to the culture flask the next day. Upon sufficient growth, GFP-
Vacuolin-β AX2 cells were sorted using a BIORAD S3e cell sorter to obtain a higher 
percentage of high intensity fluorescent cells. 
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Exosome uptake experiment 
GFP-Vacuolin- β AX2 cells were centrifuged for 5 minutes at 500Xg and 22˚C 
and then resuspended in HL5 media to a concentration of 1x106 cells/mL. Next, 400 µL 
of the cell solution was added to live cell imaging well plates and cells attached to the 
dish for 1 hour. Exosomes isolated from normal AX2 cells were stained for 90 minutes at 
37 ˚C using Cell Mask Orange (Thermo Fisher Scientific Inc, Waltham, MA) at a 
concentration of 5 µg/mL. Following staining, exosomes were filtered using a 30 kDa 
cutoff (Amicon Ultra-0.5 Centrifugal Filter unit, MilliporeSigma, Burlington, MA) to 
remove excess stain following manufacturer instructions. Prior to imaging, GFP-
Vacuolin-β AX2 cell nuclei were stained with Hoechst 33342 at a concentration of 5 
µg/mL for 5 minutes followed by washing and covering cells with PBS. Stained AX2 
exosomes were added to the GFP-Vacuolin-β AX2 cell wells (5, 10, or 20 µL) and 
imaged every 60 seconds for 30 minutes. 
Imaging conditions 
Confocal fluorescent images were captured using a Leica SP8 confocal 
microscope with Hyvolution super-resolution (Leica, Wetzlar, Germany). All images 
were captured using an HC PL APO CS2 63x/1.40 oil immersion objective. Hoechst 
images were obtained using 405 nm excitation (15% power; gain=50), and a HyD 
detector (411-449 nm detection;). GFP images were obtained using 488 nm excitation 
(15% power; gain=100), and a HyD detector (512-564 nm detection).  RFP images were 
obtained using 558 nm excitation (25% power; gain=300), and a HyD detector (575-650 







Figure B1. Exosome uptake experiment. GFP-Vacuolin Dictyostelium discoideum 
cells (Green) with Hoechst stain (cyan) exposed to cellMask Orange stained D. 
discoideum exosomes (Red) time lapse, Leica SP8 confocal microscope 63x 




 The purpose of this experiment was to investigate exosome uptake mechanisms 
within a recipient cell using fluorescence microscopy. With little knowledge of the 
uptake and dissemination mechanisms surrounding exosomes in recipient cells, further 
investigation is required. Knowledge of these mechanisms will be particularly important 
for future exosome drug delivery investigations. The recipient cells used during the 
uptake experiment were engineered to express a GFP tag on Vacuolin-β, a protein 
expressed within the endocytic pathway of D. discoideum. Any overlap of fluorescent 
exosomes and GFP-Vacuolin-β expression may suggest that exosome dissemination is 
occurring throughout the endocytic pathway. Although this experiment likely needs 
refinement to obtain clearer results, exosomes (red, Figure B1) were observed entering 
the GFP-Vacuolin-β AX2 cells (green, Figure B1). Further investigation may be required 
to determine if the cellMask orange stain is remaining adhered to the exosome surface 
and whether the exosome lipid bilayer is mixing with the cell plasma membrane.  It is 
unclear why the GFP expression disappeared around 8-12 minutes during exosome 
incubation. Furthermore, Hoechst staining of the GFP-Vacuolin-β AX2 cell was 
inconsistent likely due to D. discoideum tendency to expel foreign stains. Although this 
experiment produced very interesting images, it should be performed again with adjusted 
staining and uptake parameters. Investigators revisiting this experiment may look to 
adjust the live/dead cell imaging choice, resolution of the microscope used, stain 
concentrations, Hoechst and cellMask Orange stain choices, incubation time, cell 
concentrations, or exosome isolation technique. Alternatively, a similar experiment can 
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be performed using the IHOE-CD81-GFP or SKOV-3-CD9-RFP cells developed in 




EXTRACELLULAR VESICLE DRUG DELIVERY PROPOSAL 
 
Hypothesis and Specific Aims 
 Exosomes are a class of extracellular vesicles, typically 30-100 nm in diameter, 
that facilitate cell-to-cell communication via paracrine and autocrine signal transduction.1, 
2 Exosome research has quickly developed into a flourishing research topic over the last 
15 years and we are only now discovering the numerous roles of exosomes within regular 
homeostasis and the metastasis of cancers. To date, the scientific community has 
envisioned multitudes of exosome applications from cancer diagnosis to treatment of 
neurodegenerative diseases, some of which are coming to fruition.3-5 
Exosomes are emerging as a potential Drug Delivery System (DDS) due to their 
size, encapsulating ability, natural biocompatibility, and potential for membranous 
marker manipulation.6-8 Specifically, exosomes have been shown to cross the blood-brain 
barrier (BBB), which may allow for drug delivery to specific portions of the brain, a 
significant advantage over many other DDSs.9 Our long term goal is to continue 
examining the potential for an exosome DDS that will deliver pharmaceutical or gene 
modifying agents past the BBB to specific regions of the brain for treatment of 
neurodegenerative diseases. 
However, as exosome research is still in its early stages, there is a significant 
problem with isolating exosomes quickly, efficiently, and with sufficient purity in order 
to implement effective down-stream analysis and applications.10 In previous research, our 
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cohort has developed a method of exosome isolation via Capillary-Channeled Polymer 
(C-CP) fibers using Hydrophobic Interaction Chromatography (HIC) for small-scale 
disease diagnostic purposes.11-20 We plan to convert to and test this method of exosome 
isolation on a larger scale using batches of allogeneic cells grown in a bioreactor and 
modified to contain specific targeting moieties.  
Specifically, our research group has imagined mass-producing exosomes to be 
used for drug delivery of catalase as a treatment for Parkinson’s disease. We hypothesize 
that exosomes isolated via Capillary-Channeled Polymer fibers using Hydrophobic 
Interaction Chromatography, modified to express a rabies virus glycoprotein (RVG)-
targeting peptide, and loaded with catalase will decrease brain inflammation in 
Parkinson’s disease model mice. In order to assess this hypothesis, we will investigate 






Investigate the capability of Capillary-Channeled Polymer fibers using 
Hydrophobic Interaction Chromatography to isolate exosomes from mammalian cell 
culture grown on large scales. 
Aim 2: 
Genetically modify mammalian cells to include modified exosomal membrane 
protein RVG-targeting peptides and investigate the loading capacity of catalase into 
RVG-targeted exosomes.  
Aim 3: 
Evaluate the effects of RVG-targeted and catalase loaded exosomes on cell 







Parkinson’s disease (PD) is among the most common neurodegenerative disease 
affecting adults worldwide. In the United States, 680,000 adults of over the age of 45 
have developed this physically and mentally debilitating disorder and an increasingly 
older population and increased lifespan will likely escalate the number of 
neurodegenerative cases seen every year.21 PD is characterized by degeneration of the 
dopaminergic neurons of the substantia nigra region of the brain. The degeneration of 
these neurons leads to decreased downstream production of dopamine, a neurotransmitter 
involved in significant pathways controlling reward-motivated behavior and motor 
function. As a result, patients with PD exhibit symptoms including loss or disruption of 
motor control and mental cognition.22, 23 Most clinical treatments for PD still focus on 
replacement of the missing dopamine by administering pharmaceutical precursors that 
can be converted into dopamine. For example, levodopa is a precursor to dopamine that 
can cross the BBB, where it is converted to dopamine by DOPA decarboxylase.24 Despite 
the alleviation of symptoms, dopamine replacement therapies do not significantly slow 
the degeneration of dopaminergic neurons or the development of PD.25 
The pathology and development of PD is still a topic that is poorly understood, 
but evidence suggests that a variety of pathways may lead to a final common pathway of 
neuronal cell death. Altered mitochondrial activity, inflammatory changes, proteolysis 
modifications, and the formation of reactive oxygen species (ROS) have all been 
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implicated in the pathogenesis of neuronal cell death. Specifically, oxidative stress due to 
the formation of ROS is considered a cornerstone of the ideas surrounding dopaminergic 
cell death and has been implicated to contribute to a variety of neurodegenerative 
diseases. As such, PD has been associated with a reduction of redox enzymes including 
catalase, glutathione, superoxide dismutase, and others.23, 26 Therefore, replacement or 
supplementation of redox enzymes has been theorized to slow the pathogenesis of 
dopaminergic cell death.27 Furthermore, catalase, a powerful antioxidant capable of 
eliminating 1 million ROS per second per molecule, has been implicated as a potential 
treatment for PD.6  
Unfortunately, 98% of drugs suspected to remedy various disease states of the 
central nervous system (CNS) cannot cross the BBB efficiently, catalase included.6 
Therefore, a DDS capable of crossing the BBB may be required to deliver catalase to the 
CNS for treatment of PD. Exosomes, a class of extracellular vesicles involved in cell-to-
cell communication, have demonstrated drug delivery capabilities with increased 
biocompatibility and are able to cross the BBB.6-9 Furthermore, Haney et al.6 have 
specifically demonstrated the ability of exosomes to deliver catalase to the CNS. Taken a 
step further, to improve the capacity of exosomes targeting the CNS, several research 
groups have engineered cell cultures to secrete exosomes that express RVG peptide on 
their surface.8, 28, 29 RVG peptide targeting has shown to improve CNS drug uptake and 
delivery across many DDSs, including exosomes.30 
Previously, we have developed a method of exosome isolation using C-CP fibers 
and HIC that is quicker, more efficient, and cheaper than conventional methods. 
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Furthermore, HIC can be scaled up to process much larger volumes of cell culture media 
that may prove ideal for downstream analysis.14 The major goals of this proposal are to 
investigate the ability of C-CP fibers and HIC to isolate exosomes on a large scale and 
investigate the ability of RVG-peptide expressing exosomes loaded with catalase to target 
the CNS and affect brain inflammation in Parkinson’s disease model mice. We believe 
that this proposed research is significant because it will help develop a promising 
exosome isolation method capable for use in clinical settings and investigate the 
capability of exosomes as a DDS and the ability of catalase to treat Parkinson’s disease. 
A1) Our proposal investigates a method of exosome isolation via C-CP fibers and 
HIC on large scales:  We have shown previously that C-CP fibers and HIC can be used to 
isolate exosomes on small scales for diagnostic purposes. Conventional methods of 
exosome isolation, ultracentrifugation, ultrafiltration, and others, have been proven to 
isolate exosomes, but with high inefficiency, cost, and time requirements. Furthermore, 
current methods of exosome isolation do not always produce high purity exosomes that 
are viable and consistent enough for clinical use.10, 31, 32 Our technology, which we 
believe is capable of processing large volumes of media, provides a faster, cheaper, and 
more efficient method of isolating exosomes in clinical settings. 
A2) Our proposal aims to create an allogeneic dendritic cell line engineered to 
express RVG-peptide targeted exosomes:  A considerable hurdle to employing 
engineered exosomes in a clinic is the need to use autologous cells. Exosomes must be 
isolated after autologous cells are harvested, engineered, and grown from each individual 
patient. Exosomes derived from autologous sources are likely to produce a smaller 
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immune reaction. However, evidence suggests that allogeneic exosomes may avoid 
significant detection by the innate and adaptive immune systems due to the size of the 
vesicles.33-36 An allogeneic exosome source could allow for pre-production, 
concentration, and lyophilization of exosomes for faster clinical application and more 
consistent drug development. 
A3) Our proposal investigates the ability of catalase to treat Parkinson’s disease 
with an enhanced RVG-peptide targeted exosome DDS:  The absence or reduction of 
redox enzymes in PD is a potential target point for drug therapeutics. Catalase, a 
powerful antioxidant, could potentially mitigate or slow down the effects that ROS have 
on degeneration of dopaminergic neurons and reduce inflammation in the brain.6 An 
RVG-targeted exosome DDS could allow for enhanced delivery of catalase across the 
BBB into the central and peripheral nervous systems for treatment and prevention of 
various neurodegenerative disorders.8, 29, 30, 37 
 
B) Innovation 
B1) Our method of exosome isolation is unique and may contribute to 
translational exosome research:  Standard methods of exosome isolation lack the qualities 
to be consistently used in small clinical settings and on large scales for drug 
development. Ultracentrifugation, perhaps the most common method of exosome 
isolation, is too costly, time consuming, and difficult for most translational applications.4, 
10, 32, 38-40 Our method of exosome isolation using C-CP fibers and HIC is extremely cost 
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effective, quick, and easy to use. These C-CP fibers, developed by the Marcus research 
group at Clemson University, has been previously used to isolate other small molecules 
and proteins from solution.13-16 Our exosome isolation method has the potential to 
transform exosome translational applications and galvanize clinical exosome research. 
B2) Allogeneic, engineered exosomes will allow for more consistency and quality 
control in drug development:  Consistency and quality control in regards to DDS 
development and drug treatment are essential for pharmaceutical approval and 
advancement to clinical trials. Autologous exosomes have been used in clinical trials due 
to identical DNA expression and histocompatibility.7, 41, 42 However, allogeneic 
exosomes, if shown to be hypo-immunogenic or engineered to have reduced 
immunogenicity, could allow for greater, more specific manipulation and mass-
production for pharmaceutical DDS development. We will engineer and modify a cell 
line that produces biocompatible allogeneic exosomes ideal for immune system 
avoidance and eventual clinical approval. 
B3) Our methodology integrates an innovative exosome isolation technique with a 
unique targeted DDS to realize a translational treatment:  We have partnered with experts 
in high performance liquid chromatography and bioengineering to implement techniques 
suitable for our goals including HIC, mass-production of cell lines in bioreactors, and 
DDS development. A multidisciplinary approach encompassing innovative strategies and 
complementary experts will allow us to investigate the feasibility of our technology and 





Our cohort has previously demonstrated the capability of C-CP fibers and HIC to 
isolate exosomes on small scales for diagnostic purposes (Figure C1). As it has been done 
previously with protein isolation, we believe that we can scale up our exosome isolation 
procedure using C-CP fibers and HIC to separate exosomes from larger volumes of 
milieu. Furthermore, based on previous experiments performed by other research 
groups43-45, we believe we can engineer a cell line appropriate for allogeneic exosome 
separation and subsequently develop an exosome DDS for alleviation of Parkinson’s 
disease degeneration and symptoms. Specifically, we hope to: (Aim 1) evaluate the 
ability of C-CP fibers and HIC to isolate exosomes from large volumes of human induced 
pluripotent stem cell (HiPSC)-derived dendritic cell (DC) culture milieu; (Aim 2) 
engineer and modify HiPSC-derived DCs to release RVG-peptide targeted exosomes and 
investigate the loading capacity of catalase into RVG-targeted exosomes; (Aim 3) 
investigate the effects of RVG-peptide targeted exosomes loaded with catalase on 
Parkinson’s disease brain inflammation. 
C1) Introduction 
 Exosomes are extracellular vesicles, approximately 30-100 nm in diameter, 
involved in various methods of autocrine and paracrine cell communication. Fortuitously, 
the messages carried by exosomes can potentially be traced back to the originating cell, 
allowing for many biomedical applications, such as disease diagnostics. Furthermore, the 
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ability of exosomes to load and pass cargo to many portions of the body, including the 
central nervous system, has led to investigation into exosome drug delivery applications.1, 
4, 10, 32, 46, 47 With so many potential applications and encouraging studies, exosome 
research has exploded onto the scene and has become a hot topic over the past 5 years. As 
a result, early progress has made toward developing exosomes as potential disease 
diagnostic biomarkers. Ideally, by identifying either the internal or external makeup of 
patient exosomes, clinicians may be able to provide a cancer diagnosis without the need 
to perform an invasive biopsy. Investigation into exosome origins has revealed several 
proteins and steps involved in the biogenesis of exosomes, but exosome uptake 
mechanisms, despite several investigations, still remain elusive.1, 47, 48 Remarkably, 
Alvarez et al.8 have demonstrated the ability of exosomes to perform as an efficient DDS 
for neurodegenerative diseases using modified RVG peptide exosomes, which may 
further the development of a translatable exosome DDS.  
However, despite the promising advancements, the methods with which most 
investigators isolate exosomes are inefficient, time consuming, and costly. The “gold-
standard” of exosome isolation, ultracentrifugation, is a proven method, but is expensive, 
time-consuming, results in low purity samples, and most importantly, is not easily 
translatable to the clinic.31, 32, 38, 49, 50 With greater development of these exosome 
applications comes a greater need to improve exosome isolation methods. Using HIC in 
conjunction with C-CP fibers provides a promising alternative to standard exosome 
isolation procedures. Hydrophobic interaction chromatography and packed C-CP 
columns use innate hydrophobicity properties to isolate exosomes from the surrounding 
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environment. Particles of varying hydrophobicity will attach to and elute from the 
column at different salt concentrations, allowing for easy separation. This technique, 
especially when using solid phase extraction spin down columns, is extremely quick, 
cheap, easy, and suitable for clinical translation. Modification and scaling of this 
procedure could potentially result in a process that could mass-produce exosomes for 
other down-stream applications, including drug delivery. 
Several clinical trials have used exosomes derived from dendritic cells for 
immunostimulatory purposes to prime the host immune system to target cancer cells 
producing neoantigens.36 Down the line, dendritic-derived exosomes could be loaded 
with cancer therapeutics and be used to stimulate the immune system to target cancer 
cells and, in conjunction, deliver cancer drugs to the desired target.  However, most 
exosome trials involve exosomes derived from autologous sources, which limits the 
replicability and quality control of the biological treatment.41, 42 Allogeneic-derived 
exosomes have demonstrated hypo-immunogenic properties and could increase the 
quality, consistency, and replicability of an exosome biological treatment.34, 51 
Development of exosomes from an allogeneic dendritic cell line could result in a DDS 
that can be used to treat any number of cancers and neurological disorders and stimulate 
the immune system for enhanced outcomes. 
Specifically, PD, which results in dopaminergic neurodegeneration in the 
subtantia nigra, has been pinned as a potential target for an exosome DDS. Although the 
pathology of PD is poorly understood, several factors, including excess ROS, have been 
implicated in the disease development. Therefore, treatment with powerful antioxidants 
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may help remediate or slow down the neurodegeneration associated with PD.22, 23 
Specifically, catalase, a powerful antioxidant, has shown promise in alleviation of PD, 
but, like most drugs, cannot cross the BBB.6 An exosome DDS, capable of crossing the 
BBB and targeting the CNS, may allow for specific delivery of catalase to the CNS. 
Furthermore, exosomes engineered to contain an RVG-peptide targeting system may 
allow for increased efficiency and efficacy of delivery to the CNS. 
C2) Preliminary Studies 
 Previously, Marcus et al.52 have demonstrated the potential for fast protein 
separation using C-CP fibers. Using C-CP fibers developed by the Marcus lab, we have 
used hydrophobic interaction chromatography to separate cell culture media components 
from dictyostelium Discoideum and Caov-3 cell lines. Specifically, we have demonstrated 
the ability to separate extracellular vesicles from cell culture after cells have been 
removed by either centrifugation or filtration. Nanoparticle Tracking Analysis (NTA) 
Figure C1. Average exosome concentration and particle size 
distribution measured by NTA.  Exosomes isolated sequentially by 




allows for characterization of nanoparticle size distributions and concentrations using 
light scattering and Brownian motion properties. Using NTA (Figure C1), we have shown 
that the separation technique we have developed isolates extracellular vesicles of 
approximately 100-200 nm. Furthermore, we have demonstrated that the extracellular 
vesicles are adhering to the solid-phase component of the HIC method via scanning 
electron microscopy (SEM) and fluorescent microscopy (Figure C2).  
C3) Research Plan 
Aim 1: Investigate the capability of Capillary-Channeled Polymer fibers using 
Hydrophobic Interaction Chromatography to isolate exosomes from mammalian cell 
culture grown on large scales. The goal of this aim is to determine whether scaled up C-
CP fiber columns using HIC can isolate exosomes of high purity, quality, and quantity. 
To do this we will perform a number of chemical and physical verification steps to ensure 
effective total quality management of the separation method. 
Figure C2. SEM and Fluorescent images of extracellular vesicles adhered 
to C-CP fiber surfaces. (a) SEM image of Caov-3 ultracentrifuge derived 
extracellular vesicles and (b) fluorescent image of Caov-3 cellMask orange 
stained ultracentrifuge derived extracellular vesicles. 
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Aim 1.1: Verify the presence of exosome-associated markers in the C-CP fiber 
and HIC elution. Rationale: Although there is no “gold standard” to characterize 
exosomes, according to the International Society of Extracellular Vesicles, extracellular 
vesicles must be characterized by both protein composition and physical traits.53 Samples 
must be characterized not only to determine the presence of exosomes, but also to 
determine the quality, quantity, and purity of the exosome samples. Our method of 
exosome isolation has demonstrated the ability to isolate well-characterized exosomes for 
diagnostic purposes. Therefore, we hypothesize that large-scale exosome isolation via C-
CP fibers and HIC will produce high purity exosome samples with typical exosome-
enriched proteins.  
Experimental Design: In order to investigate the protein composition of C-CP 
fiber and HIC isolated exosomes, we will perform standard protein Bradford assays and 
western blots of exosome-enriched proteins. Specifically, using a western blot, we will 
look for the presence of CD9, CD81, CD63, TSG101, calnexin, and Grp94 to 
characterize the presence and purity of exosomes. 
Expected Outcomes: As there are many types of extracellular vesicles, exosomes 
included, it is important for us to be able to first, verify the presence of extracellular 
vesicles and then second, verify that the sample is exosome-enriched. Since extracellular 
vesicles are derived from the phospholipid bilayer membrane of cells, transmembrane 
proteins are typically used to characterize their presence. Therefore, we would expect 
samples to contain the transmembrane proteins CD9, CD81, and CD63, all of which are 
typically used to characterize extracellular vesicles. Furthermore, cytosolic proteins that 
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are involved in extracellular vesicle biogenesis can be used to identify exosomes. In this 
instance, we will use TSG101, which is involved in the development of multivesicular 
bodies that generate exosomes, as a positive marker. A positive appearance of TSG101 
further verifies the existence of extracellular vesicles and further suggests that the sample 
may be exosome-enriched. Additionally, to further characterize our samples as exosome-
enriched, we will look for microvesicle markers calnexin and Grp94. These two markers 
are typically found enriched in the endoplasmic reticulum, a common place of origin for 
microvesicles. Therefore, we would expect our isolated exosome samples to contain little 
to no amounts of calnexin and Grp94. Lower amounts of calnexin and Grp94 would 
indicate that our exosome samples do not contain other types of extracellular vesicles 
including microvesicles, ectosomes, and apoptotic bodies.53 If we can detect at least one 
transmembrane protein marker, one cytosolic protein marker and minimize the amount of 
negative exosome marker detected for each sample, we will have found chemical 
evidence that our sample contains exosomes and not another type of extracellular vesicle. 
Furthermore, we would expect a Bradford assay to find higher amounts of protein in each 
sample as compared to our previous research of exosome isolation on a small scale. 
Potential Pitfalls and Alternatives: We do not expect to encounter significant difficulties 
with the western blot process as it is a very well developed technology and commonplace 
procedure in our lab. Furthermore, we have previously found that C-CP fiber and HIC 
exosome isolation produces samples with exosome-enriched markers, so we would 
anticipate to find these markers again. However, upon scaling up the procedure and using 
larger chromatography columns we may not encounter exosome isolation using the same 
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properties and framework. Mass isolation of exosomes may shift the expected adsorption 
and elution values of the columns due to oversaturation or vesicle aggregation. Although, 
with some adjustment and saturation analysis we should be able to overcome any 
alteration to the HIC procedure. Additionally, with a larger column, we might expect the 
concentration of exosomes isolated to scale linearly based on the size of the column or 
the amount of media injected through the column. We will test many column sizes and 
injection volumes to find the most efficient and effective procedure for producing pure, 
high concentration exosomes for down-stream analysis. 
 It is well known that western blot analysis is not a terribly quick procedure and 
performing protein analysis with this method on many samples may require a significant 
amount of resources and time. Furthermore, western blot analysis only detects the 
proteins of interest and ignores the presence of any other potentially important proteins. 
Therefore, we may consider using protein mass-spectrometry to identify the entire protein 
spectrum of each sample. Complete protein analysis would allow us to further analyze 
each sample and potentially differentiate between different types of exosomes for down-
stream application. 
Aim 1.2: Further characterize the presence, quality, and quantity of exosomes in 
the C-CP and HIC elution by physical properties. Rationale: As mentioned in aim 1.1, 
although there is no perfect process, exosomes can be reasonably characterized and 
identified using both protein composition and physical traits. Physical trait analysis can 
be used to further investigate the quality, quantity, and purity of the samples. Therefore, 
we hypothesize that large-scale exosome isolation via C-CP fibers and HIC will produce 
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exosomes with uniform size and density, high and consistent concentration, and sufficient 
purity. 
Experimental Design: In order to investigate this aim we will inject cellular milieu 
samples into the scaled up C-CP fiber columns, perform HIC, and analyze the elution 
using nanoparticle tracking analysis (NTA), scanning electron microscope (SEM) 
imaging, transmission electron microscope (TEM) imaging and fluorescent imaging. 
Performing each of these techniques will allow us to verify the presence, quality, purity, 
and concentration of exosomes in each eluted sample. Furthermore, these techniques will 
also allow us to analyze the solid-phase surface interactions of the exosomes and C-CP 
fibers. 
Expected Outcomes: By using several techniques to characterize the physical 
traits of our samples, we would expect a complete and replicated profile for each sample. 
Each of these procedures unveils information about the sample from a slightly different 
perspective. Specifically, from NTA, we would expect a size distribution similar to our 
previous research with the highest concentration of nanoparticles at approximately 100 
nm. As we will be working with much larger volumes of media, we would also expect a 
nanoparticle concentration much higher than our previous research and on par with other 
standard exosome isolation methods. SEM imaging of the vesicles attached to the C-CP 
fibers pre- and post-elution will reveal information about the surface interactions between 
the vesicles and solid-phase C-CP fibers. We would expect similar images as compared 
to our previous research (Figure C2). Specifically, vesicles should be evenly distributed 
across the surface of the fiber with little aggregation, should be free of any visible 
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damage or deformity, and should no longer be present after elution from the fiber. TEM 
imaging will be used to further characterize the general shape, size, and structure of the 
eluted vesicles post-elution. We would expect TEM imaging to display highly 
concentrated vesicles of approximately 30-100 nm in diameter with the highly 
characteristic ‘dimple’ or ‘cupped’ appearance of exosomes. We would not expect to see 
broken, damaged, or deformed vesicles with TEM imaging due to the moderate nature of 
our exosome isolation. Finally, fluorescent imaging will be used to further verify vesicle 
and C-CP fiber interaction. Cellular stains CellMask and CellTracker will be used to 
fluorescently stain exosome samples prior to incubation with C-CP fibers and imaging. 
Similar to SEM, we would expect fluorescent images obtained using Leica SP8 with 
HyVolution, a super resolution software enhancement, to show vesicles evenly 
distributed across the fiber with little aggregation and the absence of vesicles post-
elution. 
Potential Pitfalls and Alternatives: As we have performed all of these techniques 
in previous research with C-CP fibers, we would expect fewer hurdles in collecting this 
information. NTA is commonly used to quantitatively and qualitatively assess exosome 
properties, but admittedly is not a perfect method. Many articles have addressed this 
issue54, 55, but few better quantitative methods have emerged. Alternatively, to quantify 
exosome samples, we could use dynamic light scattering (DLS) or a newer technique 
such as tunable resistive pulse sensing (TRPS). Both DLS and TRPS have advantages 
and disadvantages, but the main point is that there is no perfect single method to analyze 
exosome properties. Therefore, it is best to assess the quality and quantity of our samples 
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using several techniques. SEM and TEM are very robust and informative techniques that 
will help assess the size and deformity of vesicles, but are limited to single vesicle 
analysis and do not incorporate the entire sample. As SEM and TEM imaging quality is 
almost entirely dependent on sample preparation, poor fixation and staining protocols 
may need to be adjusted based on the needs of the sample. If required, we may consider 
using cryogenic electron microscopy if TEM and SEM imaging do not produce adequate 
or quality results. Fluorescent imaging using Leica SP8 with HyVolution has a limit a 
resolution of approximately 140 nm, which is larger than the diameter of exosomes. 
Therefore, collecting images of individual vesicles via this method is very difficult, but 
possible when observing juxtaposed or collections of vesicles. Alternatively, as our lab is 
highly ingrained in the light microscopy community, we could send fiber and elution 
samples for super resolution imaging with a lower limit of resolution.  
Aim 2: Genetically modify mammalian cells to include modified exosomal 
membrane protein RVG-targeting peptides and investigate the loading capacity of 
catalase into RVG-targeted exosomes. The goal of this aim is to generate a modified 
HiPSC-derived dendritic cell line to further investigate exosomes as a DDS. Specifically, 
we will modify the targeting moiety of the exosomes and investigate the loading capacity 
of catalase into exosomes. 
Aim 2.1: Manipulate HiPSCs to differentiate into dendritic cells. Rationale: Production of 
an allogeneic cell line will allow for down-stream production of allogeneic exosomes. 
Presently, several clinical exosome studies have used exosomes derived from autologous 
dendritic cells, but allogeneic exosomes have demonstrated hypo-immunogenic 
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properties.34, 41, 42, 51 Therefore, we are aiming to develop an allogeneic dendritic cell line 
for exosome production. We hypothesize that HiPSC expression manipulation will result 
in fully functional allogeneic dendritic cells capable of producing allogeneic exosomes. 
Experimental Design: Specifically, we will follow previously well-developed 
protocols to differentiate HiPSCs into DCs similar to the CD141+ subtype.45 Doing so 
involves a number of additions and removals of specific growth factors at certain time 
points. Formation of embryoid bodies (EBs) through differentiation of HiPSCs, as a first 
step toward differentiation of HiPSCs into DCs, has been demonstrated using several 
types of bioreactors with reduced mixing.56 In this instance, we will use structured and 
scheduled treatments of HiPSCs with pre-determined growth and differentiation factors 
using a high throughput bioreactor to initiate and complete the differentiation process of 
HiPSCs into DCs. Specifically, cells will be cultured over a 30 day period with gradual 
removal of growth factors including Bone Morphogenetic Protein 4 (BMP4), Vascular 
Endothelial Growth Factor (VEGF),  Stem Cell Factor (SCF), and Granulocyte 
Macrophage Colony-Stimulating Factor (GM-CSF). Finally, the culture will be 
supplemented with Interleukin 4 to support final differentiation.45 
Expected Outcomes: Forced differentiation is a highly controlled and structured 
process that is more easily accomplished using a high throughput bioreactor. Several well 
developed published protocols have demonstrated the expected outcomes of each 
differentiation step during the process that we will follow. We would expect to observe a 
step-wise transformation of HiPSCs into hematopoietic stem cells, common myeloid 
progenitors, DC precursors, immature DCs, and finally mature DCs. Quality management 
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along each step of the differentiation process will be critical to achieve the expected 
outcomes. The final outcome should be a variety of DCs presenting qualities similar to 
the CD141+ subtype as detailed in published protocols.43, 45, 57   
Potential Pitfalls and Alternatives: Forcing differentiation of stem cells is a very 
structured and difficult process and meticulous monitoring will be required to complete 
an accurate differentiation into DCs. Therefore, there may be certain difficulties in 
finding the exact environmental variables, growth factors, and timing for the process. We 
would expect that if the initial HiPSCs are slightly different than in previous studies that 
the differentiation process may vary slightly. By using a high throughput bioreactor we 
will be able monitor the environmental variables and test several cell culture preparations 
at one time to ensure an adequate final product of suitable quality and expression. If the 
differentiation procedure from HiPSCs to DCs is not fully accomplished with satisfactory 
expression and quality we could consider completing the remaining goals using 
allogeneic HiPSCs. As exosomes have demonstrated hypo-immunogenic properties, a 
different source of allogeneic exosomes may be worth investigating. Furthermore, since 
even allogeneic cells may contain epigenetic variation depending on the source, we could 
investigate the epigenetic expression of the cells and the impact of epigenetic expression 
on exosome variation. 
Aim 2.2: Engineer HiPSC-derived dendritic cells to display RVG-targeting 
peptide on exosome surface membranes. Rationale: Exosomes are capable of crossing the 
BBB, but are not specifically targeted to remain in the brain and could disperse 
throughout the remaining blood. Ideally, exosomes engineered to target the brain 
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specifically will increase the fraction of injected exosomes in the central nervous system 
and are more likely to meet the designed target. We aim to create a DDS that is more 
accurate for drugs being delivered to the central nervous system via exosome transport. 
Therefore, we hypothesize that HiPSC-derived dendritic cell exosomes can be engineered 
to display RVG-targeting peptides on the outside phospholipid bilayer surface. 
Experimental Design: RVG-peptide targeted exosomes have been engineered 
from murine cells, but have yet to be developed in human cells.8 We will clone the RVG 
peptide into the human Lamp2b gene, an exosome-enriched transmembrane protein, 
using plasmid cDNA. Specifically, Lamp2b plasmid cDNA will be isolated from storage 
Escherichia coli and engineered to contain the RVG codon sequence using DNA 
fragments, restriction sites, and restriction and ligation enzymes. The resulting RVG-
Lamp2b plasmid will be transformed into E. coli for plasmid verification and storage. 
After isolating the engineered plasmid from E. coli, RVG-Lamp2b cDNA will be 
transfected into HiPSC-derived DCs and cultured using the Lipofectamine 3000 
transfection kit. Subsequently, we will verify the presence of RVG-peptide in both the 
DCs and DC exosomes via anti-RVG western blot. 
Expected Outcomes: The HiPSC-derived cell line that we are developing will be 
stably transfected with a human cDNA plasmid. As part of cloning procedure, we will 
verify that RVG is inserted into the Lamp2b cDNA in the correct location using selection 
agents. After isolation of the cDNA and transfection into HiPSC-derived DCs, we would 
expect successfully transfected cells to express the positive selection trait (gaining 
resistance to a drug) inserted into the plasmid cDNA. An anti-RVG western blot of the 
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transfected DCs and subsequent exosomes will further verify the expression of RVG-
Lamp2b in the transfected cells and exosomes. 
Potential Pitfalls and Alternatives: Stable plasmid cDNA transfection in 
mammalian cells is not a terribly efficient process and as such, we may run into 
difficulties while performing the transfection. Furthermore, transfection with RVG-
Lamp2b cDNA is no guarantee that the transfected DC exosomes will contain RVG-
Lamp2b protein. Transient plasmid transfection is much more efficient and easier than 
stable transfection and has previously been used for mass production of proteins in 
mammalian cells.58 Thus, as an alternative, we could transiently transfect the DCs to 
express RVG-Lamp2b and then isolate the exosomes within 24-48 hours post-
transfection. Furthermore, as there are many transmembrane proteins typically enriched 
on the surface of exosomes, we could use other peptides such as CD9, CD81, or CD63 to 
develop an RVG-targeted exosome. 
Aim 2.3: Investigate loading capacity of catalase into various modified exosomes. 
Rationale: Catalase is a powerful antioxidant that may help mitigate neuronal degradation 
in PD and other neurodegenerative diseases by limiting ROS. Like many drugs, catalase 
cannot cross the BBB and requires transport to reach the central nervous system.6 We 
believe that exosomes can be used as an efficient DDS for catalase due to their natural 
ability to cross the BBB and hypo-immunogenicity.7, 9 Therefore, we hypothesize that 
catalase can be loaded into RVG-targeted and normal exosomes with high efficiency for 
downstream drug delivery. 
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Experimental Design: There are a number of different approaches to loading 
enzymes, RNAs, and other pharmaceuticals into exosomes, yet no one technique has 
emerged as the standard option.59 Therefore, we will investigate several exosome loading 
techniques with our specific cell line and exosomes. Specifically, we will investigate the 
loading efficiency of electroporation, sonication, saponin permeabilization, and room 
temperature incubation of exosomes with catalase. NTA, DLS, and TEM will be used to 
examine the physical structure and integrity of the vesicles after loading. To effectively 
measure the amount of catalase or antioxidant in a sample, we will measure the rate at 
which hydrogen peroxide decomposes. Hydrogen peroxide decomposes at a very slow 
rate when no antioxidants are present. This hydrogen peroxide decomposition assay and 
western blot will be used to demonstrate the loading capacity and stability of exosomes 
loaded with catalase. 
Expected Outcomes: Exosome properties can vary based on cell type origin, 
environmental factors, and biochemical purpose. As such, we would expect exosomes 
derived from HiPSC-derived DCs to have different size, integrity, loading capacity, 
proteins, makeup, and internal content than any exosomes studied previously. Therefore, 
it is difficult to predict which method of exosome loading will ultimately demonstrate the 
most efficient loading. Electroporation, sonication, saponin permeabilization, and room 
temperature incubation have all demonstrated loading capability in exosomes from 
multiple sources.6, 8, 59, 60 However, sonication has demonstrated high loading efficiency 
and sustained release with exosome and catalase formulations, so we would expect the 
highest efficiency with sonication.6 Each loading procedure applies very different 
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physical stresses to the exosomes and therefore, will likely cause disruption, collapse, or 
deformation of the vesicles in varying amounts. NTA, DLS, and TEM will clarify the 
physical exosome disturbances of each loading technique. Furthermore, we would expect 
the hydrogen peroxide decomposition assay and western blot to reveal a high loading 
capacity and retention time for each of the techniques with room temperature incubation 
likely having the lowest efficiency.  
Potential Pitfalls and Alternatives: Since each of the exosome loading techniques 
can potentially damage or deform the exosome membrane, we may run into problems 
with catalase loaded exosome downstream applications. To help mitigate these potential 
problems we will assess the physical quality, loading capacity, and retention time of each 
of the loading techniques. With the most promising loading techniques, we can further 
assess the uptake and delivery of the exosome-catalase formulations in cell culture. If 
none of the proposed techniques offer an appropriate efficiency we could also investigate 
exosome extrusion, freeze/thaw, and optically reversible protein-protein interactions as 
potential alternative methods for loading. 
Aim 3: Evaluate the effects of RVG-targeted and catalase loaded exosomes on 
cell cytotoxicity and brain inflammation in Parkinson’s disease model mice using 
Intravenous injection. The goal of this aim is to measure brain inflammation in 
Parkinson’s disease model mice after treatment with catalase loaded and RVG-targeted 
exosomes. We will use various histological techniques and fluorescent techniques to 
evaluate the level of inflammation in the mice brain samples. 
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Aim 3.1: Evaluate the cytotoxicity of RVG-targeted exosomes loaded with 
catalase using cell cytotoxicity and proliferation assays. Rationale: Exosomes have not 
typically been found to have cytotoxic properties, but any material introduced into a cell 
environment, especially with engineered modifications, could potentially introduce some 
form of toxicity. Therefore, especially with RVG modification, it is important to assess 
the cytotoxicity and proliferation of cell lines in vitro prior to performing any animal 
studies. We hypothesize that RVG-targeted exosomes from HiPSC-derived DCs will not 
be toxic to or alter the proliferation of in vitro cell cultures. 
Experimental Design: Using Neuro2a (murine neuronal cells) and C2C12 (murine 
muscle cells) cell lines, we will perform a Trypan Blue exclusion viability assay and an 
MTT cell toxicity and proliferation assay to determine the cytotoxicity of catalase alone 
and RVG-targeted and normal exosomes loaded with catalase. Furthermore, we will use 
the same two cell lines to perform a mixed lymphocyte reaction using CD3+ T cell 
proliferation to determine the immunogenicity of catalase alone and the RVG-targeted 
and normal exosomes loaded with catalase. 
Expected Outcomes: As previously mentioned, exosomes have demonstrated 
hypo-immunogenic qualities and specifically, RVG-targeted exosomes have shown low 
immunogenicity in mice.8, 51 Specifically, Trypan Blue exclusion can be used to 
determine cell viability and an MTT assay measures the level of cell metabolic activity, 
which can be used to quantify cell viability and proliferation. From these two assays, we 
would expect high viability and proliferation of cells treated with RVG-targeted 
exosomes loaded with catalase. Furthermore, to assess the immunogenicity of the 
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produced catalase loaded exosomes, we will use a mixed lymphocyte reaction using 
CD3+ T cell proliferation. After treatment with RVG-targeted exosomes loaded with 
catalase, we would expect low T cell proliferation, indicating low immunogenicity. 
Potential Pitfalls and Alternatives: Cell viability, proliferation, and 
immunogenicity assays are standard and custom procedures for any substance being 
introduced as a novel drug or pharmaceutical agent. An exosome DDS, as an engineered 
pharmaceutical component, will require cell viability, proliferation, and immunogenicity 
assessment. We would not expect significant difficulties performing the assays, as they 
are very standard practice and well developed. However, if we find that any assay does 
not produce appropriate or sufficient results, we will perform subsequent additional 
experiments such as colorimetric tetrazolium assays, luminogenic ATP assays, or DNA 
synthesis assays. If we find that RVG-targeted exosomes loaded with catalase generate 
unacceptable levels of cell viability, proliferation, or immunogenicity, we will readdress 
the engineering and source of the exosomes. We could potentially engineer the exosomes 
to be less immunogenic by disrupting beta-2-microglobulin and C2TA genes, which have 
been shown to affect MHC-I and MHC-II generation and immunogenicity, using 
CRISPR/cas9.57 Cells modified to not express MHC-I and MHC-II molecules will in turn 
release exosomes without MHC-I and MHC-II molecules. Both MHC-I and MHC-II are 
involved in histocompatibility and immune response of foreign materials. If the MHC 
molecule does not match the unique MHC molecules of the host, then an immune 
response will be triggered. Removal of the MHC molecules will help increase 
histocompatibility and decrease immune response in the host.  
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Aim 3.2: Use histology and fluorescence techniques to stain and quantify 
inflammation and evaluate biodistribution in Parkinson’s disease model mice brain 
sections treated with RVG-targeted exosomes loaded with catalase. Rationale: 
Parkinson’s disease and other neurodegenerative diseases are often associated with brain 
inflammation in addition to physical and cognitive degeneration.22, 23 Histological and 
fluorescent imaging techniques can be used to quantify the amount of inflammation in 
brain sections and help determine the level of neurodegeneration in the affected subject. 
Treatment with RVG-targeted exosomes loaded with catalase, which aims to eliminate or 
reduce ROS in the central nervous system, could reduce the downstream effects of 
Parkinson’s disease, including inflammation. Therefore, we hypothesize that RVG-
targeted exosomes loaded with catalase will reduce inflammation in Parkinson’s disease 
model mice.  
Experimental Design: We will use both intranasal (i.n.) and intravenous (i.v.) 
injection to assess the effects of RVG-targeted exosomes loaded with catalase on 
Parkinson’s disease model mice. All exosome samples will be stained with fluorescent 
dye prior to injection to help assess biodistribution using fluorescent microscopy. After 
injection with either RVG-targeted catalase exosomes, normal catalase exosomes, 
unloaded exosomes, or catalase alone, mice will be sacrificed and perfused at several 
time points ranging from 4 to 48 hours. After fixation, mice brains will be sectioned and 
prepared for staining. To assess the general cell composition and level of inflammation 
we will stain the sections with hematoxylin and eosin (H&E) and observe the tissue using 
standard wide-field light microscopy. Additionally, we will perform anti-CD11b 
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immunohistochemistry (IHC) to further assess the level of inflammation in the brain 
sections. 
Expected Outcomes: Given that catalase has previously been shown to reduce 
brain inflammation when loaded into exosomes, we would expect the RVG-targeted 
exosomes loaded with catalase to achieve similar or better reduction in inflammation and 
targeting.6 With H&E staining, we would expect to observe an array of neuronal and 
microglial cells in addition to other immune cells. In general, higher concentrations of 
immune cells in the tissue indicate greater levels of inflammation. Various amounts of 
neutrophils, basophils, eosinophils, monocytes, lymphocytes, or macrophages could help 
determine the stage of inflammation, type of inflammation, or other potential causes of 
inflammation. For instance, a high level of eosinophils and basophils is typically 
associated with anaphylactic reaction.61 CD11b antibody is typically used as a marker for 
microglial cells, macrophages, and other granulocytes within nervous tissue.6 We would 
expect Immunohistochemistry using CD11b to show moderate, but reduced 
concentrations of immune cells and activated microglial cells in mice brain sections with 
RVG-targeted catalase exosomes as compared to normal catalase exosomes and untreated 
mice.  
Potential Pitfalls and Alternatives: H&E and IHC are very common and 
established staining techniques, so we don’t expect any significant hurdles. Furthermore, 
we work with cell staining and imaging experts that will help improve and expedite the 
process. With both imaging techniques, we would expect to see inflammation in the brain 
sections. Furthermore, we would expect to see targeted biodistribution of exosomes. 
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However, the inflammation may vary depending on the region of the brain that is imaged. 
We must be careful to identify and document each region of the brain and compare and 
contrast the inflammation. As Parkinson’s disease develops in the substantia nigra, we 
may expect higher levels of inflammation in the areas surrounding the substantia nigra. If 
H&E or IHC fail to produce accurate or consistent images, then we may consider 
immunophenotyping spleen tissue derived from the subject mice to get a sense of the 
overall immune reaction to the treatments. 
Conclusion 
We believe that with further development of exosome isolation via C-CP fibers and HIC 
we will be able to create a clinically translatable technique that can be applied to any 
number of exosome applications. Further development of this technique, coupled with 
development of an allogeneic cell line for exosome isolation, could have a large impact 
on the development of an exosome DDS. Many ailments, including cancers and 
neurodegenerative diseases, could benefit from more specific and capable drug delivery 
system. With the methods we have outlined here, we hope to achieve our goal of 
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The animals and protocols used in this study will be approved by the Clemson University 
Institutional Animal Care and Use Committee (IACUC). Clemson University follows 
strict guidelines to maintain adherence to the protocols and procedures laid out by the 
IACUC. Specific designated areas within the Godley-Snell Research Center will be used 
to maintain and treat the mice used in this proposal. 
This study will require the use of mice in Aim 3. Both Parkinson’s disease model mice 
(Nrf2-) and wild type mice (C57BL) will be used to assess the effects of the developed 
DDS. A total of 160 Nrf2- and 160 C57LB mice will be required for completion of this 
portion of the study. 
 
Aim 3: Evaluate the effects of RVG-targeted and catalase loaded exosomes on cell 
cytotoxicity and brain inflammation in Parkinson’s disease model mice using Intravenous 
injection. 
Aim 3.2: Use histology and fluorescence techniques to stain and quantify 
inflammation and evaluate biodistribution in Parkinson’s disease model mice brain 
sections treated with RVG-targeted exosomes loaded with catalase 
80 Nrf2- mice for dose inflammation quantification = 5 mice per group x 4 groups 
(PBS injection, no treatment, RVG-exosome dose, and RVG-exosome w/ catalase 
dose) x 4 dosages. 
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80 C57LB mice for dose inflammation quantification = 5 mice per group x 4 
groups (PBS injection, no treatment, RVG-exosome dose, and RVG-exosome w/ 
catalase dose) x 4 dosages. 
80 Nrf2- mice for time point inflammation quantification = 5 mice per group x 4 
groups (PBS injection, no treatment, RVG-exosome dose, and RVG-exosome w/ 
catalase dose) x 4 time points. 
80 C57LB mice for time point inflammation quantification = 5 mice per group x 4 
groups (PBS injection, no treatment, RVG-exosome dose, and RVG-exosome w/ 
catalase dose) x 4 time points. 
Use of a mouse model in exosome research is essential prior to human clinical 
trials due to the young age of the potential therapies. Particularly, testing treatment of 
RVG-exosomes loaded with catalase will require investigation in a mouse model. Nrf2- 
mice are useful for studying oxidative stress in the pathogenesis of Parkinson’s disease.  
All mice will be housed at the Godley-Snell Research Center and handled and cared for 
by experienced technicians and veterinarians. 
All procedures and experiments on mice will be performed in a manner such as to 
minimize discomfort, distress, pain, and injury. All mice exhibiting excessive pain or 






Engineered or innate exosomes are not known to be infections to humans or 
animals. Direct exposure or ingestion of exosome samples may cause mild cellular level 
inflammation. All experiments will be performed in a laboratory meeting the biosafety 






Resources and Environment 
All fluorescent microscopy equipment and BSL2 lab space will be provided by 
the Clemson Light Imaging Facility. Procedures requiring the use of bioreactors and 
BSL2 lab space is available through the Clemson department of Bioengineering. The 
Clemson Electron Microscopy facility will assist in the staining and gathering of SEM 
and TEM images. Finally, all procedures requiring the use of mice will be performed at 
the Godley Snell Research Center, which is a Clemson University approved location for 
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